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Abstract 
Background: Aortic valve stenosis is the most common degenerative valve 
disease affecting the Western elderly population. Medical therapy is ineffective at 
treating the mechanical obstruction of blood flow. Surgical Aortic Valve 
Replacement (SAVR) is the current recommended treatment for symptomatic 
severe AS but often high risk patients are declined for this. Transcatheter Aortic 
Valve Implantation (TAVI) allows the percutaneous delivery of the prosthetic valve 
but this novel approach is associated with complications. 
Aims: This thesis aims to focus on the effects of TAVI and contemporary SAVR on 
patients’ quality of life, neurocognitive function and the left ventricular reverse 
remodelling. 
Methods: High risk patients with symptomatic aortic stenosis were studied at 
baseline, 30 days, 6 month and 12 months after intervention. Cerebral MRI with 
diffusion weighted imaging for micro-embolism was conducted before and after 
intervention and again at 6 months. Cardiac MR was conducted at baseline and 6 
months. Health related quality of life and a comprehensive battery of neurocognitive 
functional assessments were also conducted across 3 and 4 time points 
respectively.  
Results: The incidence (54(77%) vs. 17(43%), p=0.001) and number (3.4±4.9 vs. 
1.2±1.8, p=0.001) of new micro-infarcts was greater after TAVI compared to SAVR. 
Physical component scores (PCS) in TAVI increased after 30 days (32.1±6.6 vs. 
38.9±7.0, p<0.0001) and 6m (40.4±9.3, p<0.0001); the improvement occurred later 
in SAVR (baseline: 34.910.6, 30d: 35.910.2, 6m: 42.811.2, p<0.001). 
At 12 months, the majority of neurocognitive function tests did not show a 
significant change in the proportion of patients categorised as having impaired NCF 
compared to baseline in the TAVI or SAVR groups. 
- iii - 
After 6 months, there were significant improvements in indexed end-diastolic 
volumes (TAVI: 10025mls vs. 8726mls, p<0.001; SAVR 9128mls vs. 8217mls, 
p<0.05) 
Extracellular volumes were similar for both groups at baseline (range 22.8 to 
24.6%). There was no significant change in ECV after 6 months (TAVI, 24.09% vs. 
29.311%, SAVR, 23.87 vs. 23.59, p= 0.76). 
Conclusions: TAVI patients experience higher numbers of cerebral micro-infarcts 
than contemporary SAVR patients, but this appears to have no effect on HRQoL; 
TAVI patients experienced earlier improvements in quality of life than SAVR 
patients. There was also no evidence of neurocognitive functional decline after 
TAVI using a battery of very sensitive neurocognitive function tests.  
Both TAVI and SAVR improved cardiac imaging parameters with evidence of 
reverse LV remodelling but no change in diffuse myocardial fibrosis after 6 months. 
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1  Introduction 
This thesis shall focus on adults with severe calcific aortic valve stenosis and 
the effect of the treatment of aortic valve stenosis by conventional surgical 
aortic valve replacement. The important cardiovascular and neurocognitive 
differences will be compared to the novel percutaneous technique of 
transcatheter aortic valve implantation. This section will cover the important 
and unique features of the aortic valve and how various disease processes 
can impact on its effective function.  
1.1 Aortic Valve Anatomy and Function 
The aortic and pulmonary valves are also known as the semi-lunar valves as 
they are formed at junction of the truncus and conus from mesenchymal 
cushions. A septum forms between the common outflow tracts thus forming 
the left and right ventricular outflow tracts along with further anti-clock wise 
rotation to take up their final anatomical positions (Teal et al., 1986).  
The aortic valve is located between the left ventricular outflow tract and the 
proximal ascending aorta and normally has three cusps which are thin 
(<1mm) and mobile. The cusps are described according to the relationship 
with the coronary ostia: the left cusp near the left coronary artery ostium, the 
right cusp near the right coronary artery ostium and the non-coronary cusp 
which is posterior. The cusps have four histological layers; endothelium, 
fibrosa, spongiosa and ventricularis (Freeman and Otto, 2005). The cusps 
attach on to the aortic annulus which itself is composed of dense collagen 
that becomes part of the aortic root. Congenital variations include bicuspid, 
quadricuspid and unicuspid valves. In a series 932 adults undergoing valve 
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surgery for non-rheumatic valve disease, 54% had a congenitally malformed 
valve, of which 90% were bicuspid, 9% unicuspid (Roberts and Ko, 2005). 
The function of the aortic valve like all valves is to maintain unidirectional 
blood flow and thus prevent regurgitation of the stroke volume back in to the 
left ventricular cavity and therefore prevent volume overloading of the 
ventricle. Without this mechanism the left ventricle (LV) becomes volume 
overloaded and persistence of this would lead to ventricular inefficiency and 
heart failure. The aortic valve experiences the maximal mechanical forces 
when closed and these forces are obligatorily transmitted to the annulus and 
aortic root (Thubrikar et al., 1986).  
1.2 Calcific Aortic Stenosis 
There are several disease processes that can affect the function of the aortic 
valve causing changes in the valve tips, cusps and annulus. The processes 
include infection, inflammation and degeneration (Otto et al., 1994). The 
pathological processes lead onto failure of the valve to function efficiently 
and this can progress to complications. For example, sub-acute endocarditis 
of the aortic valve can be caused by bacterial infiltration of the aortic valve. 
In this situation the valve can lose the ability to close causing regurgitation of 
blood into the left ventricle and subsequent myocardial dysfunction.  
A more gradual process occurs in degenerative aortic valve disease which is 
the focus of this thesis. Recent evidence has shown that calcific aortic valve 
is not just a process of mechanical wear but involves active inflammation of 
the valve and proximal structures. The initial event involves endothelial injury 
allowing pro-inflammatory cells and lipids to enter the valve, which are 
followed by macrophages and oxidation of the lipids, mainly low-density 
- 4 - 
lipoprotein (LDL) (Freeman and Otto, 2005). This cascade of events 
continues promoting the proliferation of fibroblasts and myofibroblasts. The 
abnormal dense collagen depositions lead to progressive fibrosis mediated 
by matrix metalloproteinases (MMP) and tissue inhibitors of 
metalloproteinases (TIMP). The valvular fibrosis has evidence of 
angiogenesis, lipid cores and significant cellular inflammatory infiltration. 
This unopposed insult persists, leading to osteoblast recruitment and 
eventual calcification of the valve. (Rajamannan et al., 2003) The 
calcification is mediated by osteocalcin, bone morphogenic protein (BMP-2) 
and alkaline phosphatase (Kaden et al., 2004). 
The combination of inflammation, fibrosis and calcification leads to 
thickening of the valve leaflets and progressive stiffness which effects cusp 
separation and leads to leaflet restriction. This culminates in the calcification 
of the valve tips and leaflets causing a narrowing of the valve orifice known 
as aortic stenosis.  
1.3 Severe Aortic Stenosis 
1.3.1 Clinical Presentation of Aortic Stenosis 
The clinical presentation of aortic stenosis can be with exertional 
breathlessness (dyspnoea) during activities of daily living, chest pain or 
syncope or acute LV failure requiring emergency hospital treatment. This 
level of functional impairment can be graded according to the New York 
Heart Association (NYHA) classification between I to IV (1964). Class I 
patients have cardiac disease but without resulting limitations of physical 
activity where as in class IV there is an inability to carry on with any physical 
activity and symptoms can occur at rest. However, often patients can be 
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asymptomatic and can be diagnosed incidentally, such as routine pre-
operative assessment or screening physical examination.  
A general and cardiovascular system examination should be performed in all 
patients suspected to have aortic valve disease. A physical examination may 
reveal a slow rising brachial or carotid arterial pulse, a palpable thrill across 
the praecordium and attenuation of the second heart sound and the 
presence of an aortic ejection systolic murmur (systolic crescendo-
decrescendo). The murmur is caused by the increased velocity of blood flow 
through the narrowed valve orifice and subsequent turbulence. The murmur 
may radiate towards the carotid artery and in the elderly may even be 
audible at the apical area. In addition there may be reverse splitting of the 
second heart sound and early signs of peripheral and pulmonary 
oedema(Ross and Braunwald, 1968). The intensity of the murmur does not 
correlate with the severity of the gradient (Munt et al., 1999). 
1.3.2 Diagnosing Severe Aortic Stenosis 
The severity of aortic valve stenosis is graded on: the peak and mean 
pressure differences (gradients) between the LV cavity and aorta, and the 
valve area. All of the measurements are performed using transthoracic 
echocardiography which uses M-mode, 2D, continuous and pulsed wave 
Doppler analysis.  
Invasive measurement can be performed during X-ray left heart 
catheterisation by crossing the aortic valve and measuring LV systolic and 
end-diastolic pressure as well as measuring pressure during a pullback 
across the valve. The pressure difference here is a ‘peak to peak’ 
measurement and the values obtained are similar to gradients obtained by  
- 6 - 
the mean pressure gradient measured by Doppler in echocardiography. The 
invasive measurement, although crude does provide interventional 
cardiologists with immediate assessment before and after implantation of a 
percutaneous valve. 
Severe aortic stenosis is defined by an effective orifice area (EOA) of <1cm2, 
Peak velocity of more than 4ms-1, Peak gradient greater than 65mmHg or a 
mean greater than 40mmHg and associated with early mortality and heart 
failure (Vahanian et al., 2012). Although all valve diseases increase with 
age, aortic stenosis has a higher prevalence in the elderly population. 
Nkomo et al reported sex-adjusted odds ratio of 2.5 (CI 2.02-3.12) with every 
10 year increase in age (Nkomo et al., 2006). There was a higher incidence 
of aortic stenosis in men than in women even after adjusting for age. The 
EuroHeart survey had also found a substantial burden of valvular disease in 
Europe due to degenerative disease, older age and increasing life 
expectancy (Iung et al., 2003). 
1.3.3 Natural History of Aortic Stenosis 
The progression of aortic stenosis is slow and hence can take many years to 
become significant enough to cause symptoms in the patient. An 
observational echocardiographic study of 2131 patients with aortic valve 
thickening reported that 15.9% developed aortic stenosis with 2.5% 
progressing to severe aortic stenosis (Cosmi et al., 2002). The factors that 
determined progression in this study were age, left ventricular hypertrophy 
and mitral annular calcification. The predictors of progression in established 
aortic stenosis are age, coronary artery disease, left ventricular dysfunction, 
left ventricular wall thickness, valvular calcification and the presence of mitral 
regurgitation (Faggiano et al., 1996). The majority of these factors are 
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related to the early changes seen in a pressure overloaded left ventricle and 
represent the abnormal remodelling that occurs.  
Most asymptomatic patients are followed up in a cardiology clinic every one 
or two years. The average annual change in mean pressure gradient is 
7mmHg with a reduction in valve area on 0.1 cm2 (Palta et al., 2000). 
Currently, it is difficult to accurately predict the future progression in 
individual patients. However, a study in 123 patients with asymptomatic 
aortic stenosis; the major predictor of death or aortic valve replacement by 
surgery was peak velocity on echocardiography (Otto et al., 1997). At 5 
years, 74% of the patients had either died or undergone surgical aortic valve 
replacement (SAVR).  
The onset of symptoms is associated with adverse outcomes and indicates 
valve disease progression. Severe symptomatic aortic stenosis in the elderly 
patient has the worst prognosis with reported mortality of 51% in those that 
were managed without any form of valve replacement (Leon et al., 2010a). 
Although age and severity of aortic stenosis carry very poor prognosis, it is 
important to consider other co-morbidities that can co- exist, such as 
ischaemic heart disease, diabetes, chronic obstructive pulmonary disease 
(COPD) and renal dysfunction in an elderly population. 
1.3.4 Risk Evaluation in Aortic Stenosis 
The evaluation of risk is important when discussing treatment strategies with 
patients. This involves comprehensive clinical assessment of disease 
severity through a combination of invasive and non-invasive testing, as well 
as the individual patients’ co morbidities. In addition to this there are two risk 
scoring tools available: European System for Cardiac Operative Risk 
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Evaluation (EuroSCORE) and the Society of Thoracic Surgeons score STS 
score (Nashef et al., 1999, Wendt et al., 2009).  
The logistic EuroSCORE (www.euroscore.org) predicts operative mortality in 
patients undergoing cardiac surgery and was developed through evaluation 
over 20,000 patients across Europe (Roques et al., 2003). This identified the 
key factors that influenced outcome which were: age, gender, Chronic 
Obstructive Pulmonary Disease (COPD), extra cardiac arteriopathy, 
neurological dysfunction, previous cardiac surgery, renal failure (creatinine 
>200µmolL-1), the presence of endocarditis, critical preoperative state, 
unstable angina, LV dysfunction, recent MI and pulmonary hypertension. 
The operative factors were: emergency surgery, type of surgery and post MI 
septal rupture. The logistic EuroSCORE is most commonly used but can 
over estimate risk in certain patients. As a consequence EuroSCORE II has 
been developed but has yet to be validated in a larger contemporary 
population (Nashef et al., 2012). 
The STS score risk calculator is more complicated and requires the input of 
several variables: the procedure, patient demographics, risk factors, 
previous cardiovascular interventions, preoperative cardiac status, 
echocardiographic and cardiac catheter findings. The online calculator 
(www.riskcalc.sts.org) provides the mortality, morbidity, length of stay and 
risk of stroke, renal failure, infection and re-operation.  
1.3.5 Frailty and Activities of Daily Living (ADL) 
The definition and measurement of frailty is difficult and has been studied in 
gerontology (Fried et al., 2004). Frailty is a syndrome with various factors 
that have to be considered which are biological, psychological and social. 
- 9 - 
Overall there is a loss of patient reserves encompassing energy levels, 
physical ability, cognition and health (Hogan et al., 2003). Other workers 
have focussed on symptoms and signs, such as unintentional weight loss, 
feeling exhausted, poor grip strength and slow walking speeds, as well as 
overall reduced physical activity (Fried et al., 2001). There is also evidence 
to suggest clinical judgement by physicians of frailty based on history taking 
and clinical examination can be useful to predict outcomes (Jones et al., 
2004). A good example is the Clinical Frailty Scale derived from the 
Canadian Study of Health and Ageing (CSHA), which is on a 7 point 
measure (very fit=1, severely frail=7) (Rockwood et al., 2005). 
1.4 Treatment of Aortic Stenosis 
The treatment of aortic stenosis is driven by severity of symptoms and the 
gold standard for the treatment of severe symptomatic aortic stenosis being 
surgical aortic valve replacement (SAVR) (Nishimura et al., 2014). Current 
guidelines recommend SAVR in symptomatic patients with aortic velocity of 
greater than 4 metres per second and a mean pressure gradient of greater 
than 40 mmHg. The symptoms covered are dyspnoea, angina and syncope 
as well as symptoms on exercise testing. The consensus document 
attributes Class I recommendation and this is supported by a level of 
evidence: B (Nishimura et al., 2014). There is no specific drug therapy for 
aortic stenosis but general medical therapy is discussed below. Patients are 
usually identified in primary care and referred to secondary care for 
assessment and surveillance by a consultant cardiologist.  
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1.5 Medical Drug Therapy 
1.5.1 Diuretics 
Diuretics are drugs that act on the kidney to increase excretion of sodium 
chloride and water. The renin-angiotensin-aldosterone system usually 
regulates overall fluid and electrolyte balance. Diuretics are classed 
according to the site of action, such as thiazides which act on the distal 
tubule and loop diuretics which act on the thick ascending loop of Henle.  
In the emergency situation, a patient can present in acute pulmonary 
oedema and respiratory failure. Intravenous loop diuretics (Furosemide) 
have a role in reducing the degree of alveolar oedema and can be used as 
maintenance oral therapy. Diuretics reduce the preload to the LV so have to 
be used with caution and the patients renal function should be monitored 
(Carabello and Paulus, 2009). The adverse metabolic effects are 
hypokalaemia, hypomagnesemia, hyperglycaemia and hyperuricaemia. 
Aldosterone antagonist have been used in aortic stenosis with a reduced risk 
of hypokalaemia, however a randomised control trial did not show any 
benefit of delaying systolic dysfunction, LV mass regression or delay 
progression of valve stenosis (Stewart et al., 2008). 
1.5.2 Beta-blockers and Vasodilators 
Beta adrenoceptor blockers act on β1 and β2 receptors and reduce the heart 
rate, myocardial contractility and have anti-arrhythmic properties (Class II or 
III). Generally beta blockers should be avoided in severe symptomatic aortic 
stenosis as the reduction in myocardial contractility may cause acute 
decompensation in a pressure overloaded left ventricle. In addition 
vasodilators, such as nitrates and hydralazine, reduce systemic blood 
pressure and reduce coronary blood flow and therefore have an adverse 
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effect in patients with severe fixed outflow obstruction (Carabello and 
Paulus, 2009).  
ACE inhibitors block the conversion of angiotensin I to angiotensin II, the 
latter is a potent vasoconstrictor and also stimulates aldosterone release. 
Overall their effectiveness of ACE inhibition has been demonstrated in IHD 
and heart failure with improvement in symptoms and major adverse 
cardiovascular events (AIRE(1993)). However, they should be used with 
extreme caution in aortic stenosis as the vasodilatory properties can 
increase the aortic valve gradient and precipitate angina and syncope. 
Nevertheless, recent studies have demonstrated safety of ACE inhibitors in 
severe aortic stenosis (Dalsgaard et al., 2014, Bull et al., 2015). In a study of 
44 patients given trandolapril, there was a reduction in LV end-systolic 
volume and decrease in pro-brain natriuretic peptide, and there was no 
adverse effects, such as severe hypotension (Dalsgaard et al., 2014). The 
Ramipril in Aortic Stenosis (RIAS) trial was a prospective double blinded 
randomised trial against placebo. The was a reduction in LV mass on 
cardiovascular MR imaging for the Ramipril 10mg group at 6 months and 12 
months (Bull et al., 2015). More importantly there were no adverse events. 
Therefore, there may be a role for supervised use of ACE inhibitors in the 
management of patients in the early stages of disease.  
1.5.3 Statins 
The role of statins (3-hydroxy-3-methylglutaryl-CoA reductase inhibitors) in 
aortic stenosis has been controversial because of conflicting evidence of the 
effect on progression of calcific AS. Retrospective and prospective studies 
have shown that patients receiving statins had a slower progression of 
stenosis than individuals that did not (Novaro et al., 2001, Moura et al., 
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2007). However, randomised controlled trial of 165 patients receiving 
Atorvastatin 80mg did not show a difference in the rate of stenosis after 25 
months (Cowell et al., 2005). Overall, statins are used in patients with 
hyperlipidaemia and coronary heart disease, which often co-exists with 
aortic stenosis. With the above evidence the current guidelines do not 
recommend statin therapy for the prevention of haemodynamic progression 
in aortic stenosis (Nishimura et al., 2014). 
In clinical practice, medical therapy is used cautiously in patients with aortic 
stenosis and the focus is treating the co-existing hypertension, IHD or heart 
failure. Overall there is a very limited role for medical drug therapy but it 
does provide relief of some of the symptoms, however the obstructive nature 
of aortic stenosis warrants relief in order to offer the best long term result.  
1.6 Surgical Aortic Valve Replacement 
1.6.1 History 
The first ever valve replacement was performed in the aortic position by 
Harken et al in 1962 using a “caged ball” and this was followed later by 
mitral valve replacement by Starr (Harken et al., 1962, Starr and Edwards, 
1961). Prior to this valve surgery was limited to performing blind 
commissurotomies, however this dramatically changed following the advent 
of cardio-pulmonary bypass and eventual cardioplegia. Early experience 
was obstructed with complications related to bleeding, infection and 
embolism which lead to death and prolonged hospital stay. As experience in 
the procedure and peri-operative care and post-operative intensive care 
units developed, the associated complications also decreased.  
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1.6.2 Indications 
Current guidelines recommend surgical aortic valve replacement in patients 
with severe aortic stenosis and symptoms or in the presence of early LV 
systolic dysfunction or a rapid change in gradient (Vahanian et al., 2012). 
The evaluation of the patient is performed by the cardiologist and clinical 
visits can occur between 6 and 12 months. The LV function assessed by 
transthoracic echocardiography can prompt surgery if the ejection fraction is 
<50%. In a proportion of patients the reported symptoms may not be clear 
and therefore an exercise treadmill test can be conducted. Generally a 
contraindication of exercise testing is known severe aortic stenosis, however 
there is evidence that the test is effective at identifying patients that may 
benefit from surgery. (Das et al., 2005) During exercise testing a positive test 
is denoted by new symptoms of: syncope or angina, ECG changes of ST 
depression, ventricular arrhythmia or a greater than 20mmHg fall in blood 
pressure (Amato et al., 2001). In a study of 66 asymptomatic patients, 66.7% 
had a positive ETT and 6% experienced sudden cardiac death, all of which 
also had a positive ETT (Amato et al., 2001). This implies that the response 
to exercise may have important prognostic implications.  
Earlier studies showed that SAVR in aortic stenosis dramatically reduced 
mortality when compared to medical therapy alone, with 3 year survival of 
87% compared to only 21% in the medical group (Schwarz et al., 1982). 
Over the last 50 years standards and techniques have improved making 
SAVR very safe and effective. The Society of Cardiothoracic surgery of 
Great Britain and Ireland quote an in-hospital mortality of 1.85% and 5 year 
survival of over 80% for the index aortic valve replacement (Bridgewater, 
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2010). German registry data of 11,000 patients found the mortality to be 3% 
in all comers across 80 sites (Gummert et al., 2011). 
1.6.3 Operative Method 
Conventional SAVR is performed under a general anaesthesia and through 
a full median sternotomy, however minimally invasive options include mini-
sternotomy can be achieved (Salenger et al., 2015). After full heparinisation 
the patient is placed on cardiopulmonary bypass via arterial and venous 
cannulae. Once stable the aorta is clamped and cardioplegia is achieved. 
The aorta is opened and the calcified valve cusps are excised. The surgeon 
uses a sizer to select the appropriate diameter of the prosthesis. Pledgets 
are sutured to the aortic annulus and brought through the prosthetic sewing 
ring. The new valve is lowered in to position and all sutures are tied. The 
aorta is sutured closed and the cross clamp is released. The heart is de-
aired and cardioplegia is reversed and the patient is weaned off bypass. 
Often patient require temporary epicardial pacing and inotropic support to 
facilitate coming off bypass. The whole operation can take between 2 to 3 
hours and patients are subsequently managed on cardiac intensive care 
units. Once the patient has been extubated from the respirator and has good 
analgesia, they are monitored for a further 24 to 48 hours and are 
transferred to a cardiac surgical ward. Epicardial wires remain in-situ in the 
event of bradycardia or evidence of damage to the native conduction 
system. AV conduction delays are frequent after cardiac surgery and 
currently the pacemaker implantation rates are between 1 to 2%, but this 
significantly increases with age, pre-existing conduction disease and post-
operative MI (Del Rizzo et al., 1996). 
- 15 - 
1.6.4 Surgical Aortic Valve Prostheses 
There are varieties of modern biological (xenograft) or mechanical 
prostheses available to the surgeon. Registry data from Europe and USA 
shows an increase in the implantation of bioprostheses over time (Brown et 
al., 2009) (Bridgewater et al., 2011). In the proportion of patients aged 61 to 
70 years undergoing isolated SAVR there has been an increase from 49.2% 
to 73.1% of bioprostheses over a 5 year period (Bridgewater et al., 2011).  
Mechanical valves are durable and require lifelong oral anticoagulation with 
warfarin, which may not be feasible or suitable for certain patients, such as 
those at high risk of bleeding. The novel oral anticoagulants (NOAC) are 
contraindicated as there is a risk of valve thrombosis, especially in the mitral 
valve position.  These valves can be tilting discs, bi-leaflet or rarely ball and 
cage types. The Veteran Affair trial in 394 patients receiving a mechanical 
(Bjork-Shiley) spherical disc prosthesis or a bioprosthesis (Hancock porcine) 
had a 15 year follow up period (Hammermeister et al., 2000). This showed a 
reduction in mortality and primary valve failure as well as a low incidence of 
re-operation.  
The bioprosthetic valves can be stented or stentless and can be made from 
porcine, bovine, equine or pericardial tissues. In addition homografts and 
pulmonary autografts can be used in the aortic position. Stentless 
bioprostheses do increase the EOA and reduce the transvalvular velocities, 
but do not show an improvement in clinical outcomes(Perez de Arenaza et 
al., 2005). Bioprosthetic valves do not require long term anticoagulation but 
have a higher incidence of reoperation due to degeneration. Therefore 
bioprosthetic valves are preferred in the elderly patient with high  long term 
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bleeding risk and a lower likelihood of requiring re-operation in their 
remaining life time (Vahanian et al., 2012).  
1.7 Transcatheter Aortic Valve Implantation 
1.7.1 History of TAVI 
Transcatheter aortic valve implantation is a percutaneous method of treating 
aortic stenosis in the higher risk patient group who cannot have conventional 
open cardiac surgery. The technique has evolved from balloon aortic 
valvuloplasty (BAV), which was initially used for the treatment of congenital 
severe aortic stenosis as a bridge to surgery. Cribier et al performed BAV in 
the 1980s as a possible therapy for calcific aortic stenosis (Cribier et al., 
1986). However, this proved to provide short term symptomatic 
improvement, as there was a higher proportion of recurrence of stenosis and 
therefore BAV was performed less often and became a palliative procedure. 
(Lieberman et al., 1995). In 1992 Andersen et al performed the first TAVI in 
the porcine model with a self-made stainless steel stent and a porcine valve 
sewn on to this stent (Andersen et al., 1992). This used the retrograde 
transaortic method and the valve was balloon expandable as opposed to the 
antegrade approach that Cribier used. Early results showed minimal para-
valvular regurgitation, but coronary flow was obstructed in 33% as the stent 
struts lay close to the ostium of the left main coronary artery. Cribier et al 
performed the first human percutaneous implantation in 2002 but used a 
transvenous antegrade approach which is technically demanding (Cribier et 
al., 2002). The transaortic retrograde approach was optimised by Webb et al 
in 2005 and uses the femoral artery as the access site and is currently the 
favoured approach (Webb et al., 2006).  
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1.7.2 Evidence for TAVI 
Over 200,000 TAVI procedures have been performed worldwide and the 
number is likely to increase as AS becomes more prevalent (Sinning et al., 
2012). The seminal paper was the Placement of Aortic Transcatheter Valve 
Trial (PARTNER) which randomised 358 patients who were not suitable for 
SAVR to either standard therapy (including BAV) or transfemoral 
transcatheter implantation of a balloon-expandable valve (Leon et al., 
2010a). This was a highly selected patient group with a 30 day mortality risk 
>50% (PARTNER cohort B). In the standard arm 84% had BAV performed 
but mortality was significantly lower in the TAVI arm (30.7% vs. 50.7%). The 
incidence of major stroke (5.0% vs. 1.1%) and major vascular complications 
(16.2% vs. 1.1%) were higher. At 1 year the NYHA class was lower in the 
TAVI arm and prosthetic function had not deteriorated. The overall benefits 
continued after two year follow up and included improvement in all cause 
mortality, cardiovascular mortality and repeat hospitalisation (Makkar et al., 
2012a). 
The second group, (PARTNER cohort A) were considered to have high 
surgical risk with a predicted 30 day mortality of 15% and/or a STS score 
>10 and were randomised to SAVR or TAVI (Smith et al., 2011a). This trial 
showed a non-inferiority to SAVR with similar 30 day mortality and stroke 
events, however major vascular complications were significantly more 
frequent in the TAVI group, although the SAVR group had higher bleeding 
complications. At two years there was no difference in mortality rates but the 
presence of para-prosthetic regurgitation was associated with increased 
mortality (Kodali et al., 2012a).  
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The patients in the PARTNER trials received 1st generation Edwards-
SAPIEN prosthesis which required large femoral sheaths (22F-24F) and 
surgical cutdowns to the artery. This may have contributed to the increased 
bleeding and vascular complication rates.  
The UK TAVI registry database reported on 870 patients from all 25 sites 
(Moat et al., 2011). Two major types of prostheses were used: CoreValve 
(52%) and Edward-Sapien (48%) with the majority of procedures being 
performed trans-femorally. The mortality rates across 3 time points were: 
7.1% at 30 days, 21.4% at 1 year and 26% at 2 years.  
1.7.3 Vascular Access Site for TAVI 
The femoral, subclavian, transapical, direct aortic and carotid approaches 
have been performed for TAVI (Webb et al., 2006, Grube et al., 2007, 
Lichtenstein et al., 2006, Latsios et al., 2010, Modine et al., 2012). The 
favoured arterial access route is the common femoral artery (CFA) which 
has to have a vessel diameter larger than 6mm on imaging usually by CT 
aortography. The CFA is punctured at the level of the femoral head thus 
aiming to avoid the bifurcation of the artery in to the deep and superficial 
branches. Fluroscopic guidance is recommended to locate the femoral head 
and some centres use ultrasound for vascular access (Garrett et al., 2005). 
The vessel is assessed for calcification, atheroma and tortuosity which all 
play a role in success and complications. Earlier TAVI prostheses required 
larger sheaths necessitating surgical cut down, however current sheaths are 
smaller and allow for percutaneous access site closure using suture based 
closing devices (e.g. ProStar XL or PerClose Proglide (Abbott Vascular 
Devices)). For example, two Proglide devices can be placed once femoral 
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access is achieved and the guide wire can be reintroduced to allow for the 
larger sheath insertion.  
Transapical access is indicated in patients with severe peripheral vascular 
disease and requires surgical antero-lateral mini-thoracotomy at the level of 
the fifth/sixth intercostal space (Lichtenstein et al., 2006). A pericardiotomy is 
performed to allow direct myocardial puncture and subsequent dilatation to 
allow access of the delivery sheath. The myocardium is closed with purse 
string sutures and the chest wall is closed by standard surgical techniques. 
Currently, balloon expandable prostheses are only used as self expanding 
CoreValves are not used.  
The subclavian approach also requires surgical cut down with the advantage 
of not requiring ventriculotomy as is in the apical approach (Petronio et al., 
2013). This approach is used for patients with severe peripheral vascular 
disease and is as effective as the transfemoral approach although a direct 
comparison is awaited (Petronio et al., 2010). Additional caution has to be 
taken with patient with history of CABG with left internal mammary artery 
graft as this can be compromised during sheath and device manipulation. 
The direct aortic approach is novel but involves a small mid-clavicular or 
right parasternal incision to expose the ascending aorta (Latsios et al., 
2010). This allows for direct puncturing for sheath insertion and device 
delivery but larger studies of efficacy are awaited. The carotid approach has 
many advantages but experience is limited to a few centres but is feasible 
and tolerated in patient without significant complications such as stroke 
(Modine et al., 2012). Recent UK TAVI registry data comparing survival 
between transapical, subclavian, direct aortic and transfemoral showed that 
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TA, DA and SC had similar high EuroSCOREs but poorer survival outcomes 
(Frohlich et al., 2015). TF reported 86.4% one year survival whereas DA and 
TA had lower survival at 75.2% and 74.7% respectively.  
1.7.4 TAVI Device  
Since the inception of TAVI several prostheses have achieved safety 
approval. The most prevalently used prostheses are described here. 
1.7.4.1 CoreValve TAVI 
The CoreValve TAVI (Medtronic inc, Minneapolis, Minnesota, USA) is a self 
expanding prosthesis made from nickel-titanium alloy (Nitinol) which anchors 
its self in the supra annular position. The prosthesis is crimped down into a 
delivery sheath and when released in position expands with a prominent 
radial force. (Grube et al., 2006) Cold temperatures are used during crimping 
of the valve and after deployment expansion will continue at body 
temperatures. Currently there are four 3rd generation valves available for 
annular sizes between 18 to 29 mm (23mm, 26mm, 29mm, and 31mm). The 
CoreValve is retrogradely delivered from the femoral or subclavian approach 
and can be post dilated but not repositioned by recompression once fully 
deployed.  
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Figure  1-1 CoreValve prostheses (Medtronic Inc, USA) 
 
1.7.4.2 Edward Sapien TAVI 
The Edward Sapien (Edwards Life Science, Irvine, USA) valve is a balloon-
expandable system that is made from cobalt chromium (Webb et al., 2006). 
This can be inserted from the femoral, subclavian or transapical approach; 
there are 4 sizes 20, 23 mm, 26mm and 29 mm. The Edwards Sapien XT 
has a tubular slotted frame with thinner struts but preserved radial strength. 
The valve leaflets are bovine pericardium which has been treated with anti-
calcification reagent similar to technology used on surgical valves (Webb et 
al., 2009). The lower frame has a fabric covering to provide an improved 
seal to the aortic annulus and thus prevent further para-valvular 
regurgitation. Once positioned the valve is implanted with balloon inflation 
and can be post dilated.  
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Figure  1-2 Edward Sapien XT prostheses (Edwards Lifesciences, USA) 
 
1.7.5 General Procedure for TAVI 
There are several stages during TAVI which requires meticulous planning 
and a multi-disciplinary approach involving interventional cardiologists, 
cardiac surgeons, imaging cardiologists, cardiac anaesthetists, catheter lab 
nurses, and cardiac technicians. The patient undergoes general anaesthesia 
and arterial lines and central venous catheters are inserted for monitoring. A 
temporary transvenous pacing wire is placed in the RV to facilitate rapid 
ventricular pacing during valve intervention. Transesophageal 
echocardiography (TOE) is also performed to map the aortic valve, LV 
function and mitral valve. Vascular access is obtained depending on the 
approach as agreed by the MDT. The large sheath is inserted following 
serial dilatation over a stiff wire. The aortic valve is crossed with a straight 
0.035 wire using a Judkins right catheter or Amplatz 1 or 2. A long exchange 
length J-tipped wire is then used to swap the standard catheter for a pigtail 
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catheter. A stiff pre-coiled wire is inserted via the pigtail into the LV cavity. 
Initially a balloon valvuloplasty is performed under X-ray fluoroscopy and 
TOE guidance while the RV is rapidly paced at 180 to 190 beats per minute 
to minimise cardiac motion. The delivery catheter is taken close to the 
ballooned valve and the prostheses in positioned and deployed again using 
rapid RV pacing. If there is significant aortic regurgitation detected by 
contrast aortography and TOE then further balloon dilatation can be 
performed. The vascular access site is closed and the patient is returned to 
the coronary care unit for monitoring and recovery from the general 
anaesthesia.  
This technique is continually developing and evidence is merging for 
procedure to be performed under local anaesthesia with conscious sedation. 
Studies have shown this to be safe and effective in various centres. This 
also means that transoesophageal echocardiography is no longer obligatory. 
Patients are monitored in a high dependency environment for minimum 24 
hours after which venous sheaths for temporary pacing and central venous 
catheters and arterial lines can be removed. The patients are reviewed daily 
by the interventional cardiologist and assessed for complications. The aim 
usually is encouraging early mobilisation of the patient on the ward and safe 
discharge back to the community.  
1.7.6 TAVI Complications 
TAVI is performed in a high-risk group of patients which predisposes them to 
procedure related complications which may be peri-procedural, early prior to 
discharge or late. The risks of complications are on balance less than 
various risk associated with conventional aortic valve surgery. Surgical risk 
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is potentiated by the problems related to prolonged general anaesthesia and 
the stressor of cardiopulmonary bypass.  
The specific complications of TAVI are discussed below focusing on 
vascular injury, device induced trauma, embolic phenomena and conduction 
tissue disturbance.  
1.7.7 Vascular Access Complications 
The femoral artery is the preferred vascular access route to insert delivery 
sheaths, however the sheaths have a large diameter ranging from 12 to 18F 
gauge. During vascular access the possible complications include 
dissection, haematoma and haemorrhage which may progress to a 
retroperitoneal bleed (Leon et al., 2011). However, the incidence of vascular 
complications has decreased as delivery sheaths have become smaller and 
with the wider use of percutaneous suture based closure devices (Barbanti 
et al., 2015). Nevertheless, in a study comparing Proglide and Prostar 
devices, there was a high incidence of vascular complication (17.3%) and 
significant number of patients requiring further peripheral percutaneous 
intervention (Barbanti et al., 2015). In addition, CT assessment of ileo-
femoral arteries for suitability for access has reduced complications (Wuest 
et al., 2012). Major predictors of vascular injury are vessel tortuosity and 
calcification and prior peripheral vascular surgery. Major vascular 
complications can be treated with peripheral intervention with stents or by 
open vascular surgical repair. In a study comparing access by the surgical or 
percutaneous method, bleeding complications were significantly higher in 
the percutaneous approach but overall complications were no different 
(Spitzer et al., 2015). 
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1.7.8 Intra-procedural complications 
There are several stages of valve implantation that can develop into a 
serious complication. Cerebral embolism may occur during device delivery 
up an atheromatous aorta, which will be discussed later (Fairbairn et al., 
2012a). There is a risk of myocardial perforation with guide wires and 
temporary pacing leads which lead on to a haemorrhagic pericardial effusion 
and tamponade (Katsanos et al., 2015). This effusion must be treated with 
emergency pericardiocentesis to prevent cardiovascular collapse and 
cardiac arrest (Lange et al., 2011). Other potential risks are aortic rupture 
more likely to be seen in patients with a severely calcified aorta called 
porcelain aorta. The rupture could be in the ascending aorta or at the aortic 
and mitral valve junction. Both scenarios are catastrophic and patients are 
unlikely to survive despite emergency conversion to open surgery 
(Eggebrecht et al., 2014). In a registry of balloon expandable valves 
(Edwards Sapien), the conversion to emergency cardiac surgery was low at 
1.2% but the associated 30-day mortality was 52% (Eggebrecht et al., 2014, 
Thomas et al., 2011). During implantation across the native diseased valve, 
calcified atheroma can embolise again causing stroke or travel down the 
coronary arteries resulting in myocardial ischaemia and infarction. As the 
prostheses is deployed there may be abrupt displacement of the device or 
the coronary ostia may become occluded which will both require immediate 
percutaneous coronary intervention (Ribeiro et al., 2013). Occasionally, 
when there is higher risk of coronary obstruction, some operators may either 
perform preventive coronary angioplasty such as treating a left main 
coronary artery stenosis or may place a guide catheter with an angioplasty 
wire within the coronaries and therefore if a bailout coronary intervention is 
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necessary then this can be performed swiftly. In a large multi-centre study, 
coronary obstruction was rare (<1%) and was associated with severe 
hypotension and electrocardiographic changes. The left coronary artery was 
involved and associated predictors were low coronary height, prior aortic 
bioprosthesis and a shallow sinus of Valsalva (Ribeiro et al., 2013). 
1.7.8.1 Paravalvular Aortic Regurgitation 
The ideal goal is to implant the bioprosthetic valve in the aortic position 
which is functional without valve incompetence also called regurgitation. The 
prosthesis may not have complete deployment or expansion of its metal 
frame resulting in a space between the outer frame of the TAVI device and 
the native valve. This space allows blood that has been ejected from the left 
ventricle into the aorta to return into the ventricle. The resulting para-valvular 
regurgitation is a poor prognostic factor which is a known factor associated 
with death (Kodali et al., 2012a). If the TAVI device is not appropriately 
anchored to the aortic wall then there is a risk of device embolisation in to 
the LV cavity or aorta. This is evident during the procedure but can occur in 
the first 24 hours leading to cardiac arrest and death (Makkar et al., 2013). 
During deployment of the valve if rapid pacing does not decrease the aortic 
pressure, then the TAVI device will be ejected into the aorta. If there is 
significant regurgitation with the first device, then a second TAVI device may 
be required to be placed inside the initial prosthesis; this is known as “Valve 
in Valve”. The use of “valve in valve” and/or the event of valve embolisation 
is associated with mortality at 1 year (Makkar et al., 2013). Another cause of 
post procedure aortic regurgitation is a valve leaflet that is adherent to the 
device frame: a “stuck leaflet”, but this is a rare event.  
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1.7.9 Pacemakers 
The AV node is in close proximity to the aortic annulus and therefore 
complete heart block may be seen and require permanent therapy with a 
pacemaker. (Pereira et al., 2013)  The need for pacemakers following aortic 
valve surgery is established and is caused by surgical injury during excision 
of the native valve (Dawkins et al., 2008). In long term surgical follow up, 
over two-thirds of patients that required post-operative pacing were 
dependent on pacing at one year (Merin et al., 2009). 
For TAVI the predictors for permanent pacing are pre-existing conduction 
disease, especially left bundle branch block and also, self-expanding valves 
(Medtronic CoreValve) have a higher pacing rate compared to balloon 
expandable (Edwards Sapien) (Jilaihawi et al., 2009, Urena et al., 2012). 
This observation is primarily related to the difference in valve design. 
1.7.10 Other Complications 
Acute Kidney Injury (AKI) is defined by a sudden reduction in glomerular 
filtration rate and is reflected in an increase in serum creatinine (>26µmol/L) 
or a decrease in urine output (<0.5ml/kg/hour) over a 6 hour period and can 
be graded on severity (AKI stage 1 to 3) dependent on the urine output and 
need for dialysis (Bellomo et al., 2004). The mechanisms of kidney injury 
can be from a variety of sources. Significant haemorrhage can lead to 
hypovolaemia resulting in pre-renal AKI. Others include, contrast induced 
nephropathy, renal ischaemia, embolism from calcific or athero-thrombo-
embolism (Aregger et al., 2009). In a study of 213 TAVI patients, 11.7% 
developed acute kidney injury with 1.4% requiring renal replacement therapy 
(Bagur et al., 2010). 
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The rates of infection and early and late endocarditis  are low in patients 
treated with TAVI (Leon et al., 2010a). Nevertheless, all patients receive 
prophylactic antibiotics prior to procedure.  
1.7.11 Stroke 
Stroke is defined as an acute onset of a focal neurological deficit that last 
longer than 24 hours otherwise the episode is categorised as a transient 
ischaemic attack. TAVI has a higher stroke rate in comparison to SAVR 
which has a poor effect on long term quality of life and prognosis. The major 
problem is micro-embolisation during deployment which can be observed 
during transoesophageal echocardiography (TOE) and transcranial Doppler 
(Kahlert et al., 2012). The reported ranges of strokes are between 2.9 to 10 
% (Leon et al., 2010a, Grube et al., 2007). There is a concern that silent 
embolic cerebral infarcts can affect future cognitive function (Vermeer et al., 
2007). The episodes of micro-embolisation can occur during other 
procedures such as percutaneous coronary intervention (PCI), balloon aortic 
valvuloplasty (BAV) and atrial fibrillation ablation. Although silent infarcts 
lack the clinically overt stroke-like symptoms, there has been evidence to 
show this may contribute to physical and cognitive decline which may be 
detected by serial neurocognitive assessment (Vermeer et al., 2003).  
1.8 Role of MRI in the Assessment of Aortic Stenosis 
Magnetic Resonance imaging (MRI) uses the properties of a high field 
strength electromagnet and radiofrequency impulses to generate images 
from various tissues. The field strengths used in clinical practice are 1.5 to 3 
Tesla. One Tesla is equivalent to approximately 20,000 times the strength of 
the earth’s magnetic field. (Balaban, 2010) By placing a subject in the bore 
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of a magnet all the protons align in the direction of the field, then a 
radiofrequency impulse is delivered to shift them from equilibrium and as the 
protons recover they emit energy which is detected as a signal. The 
detected signal is used and post processed to produce an image.  
1.8.1 Basic Principles 
The human body contains hydrogen atoms in all its parts which is 
particularly useful for nuclear magnetic resonance imaging. The hydrogen 
nucleus exhibits a magnetic dipole and a property of spin which is a 
characteristic of all atoms. Nuclear magnetic resonance refers to the 
observation where nuclei that have a net magnetic moment can absorb and 
release electromagnetic energy at specific resonant frequencies.  
A magnetic field is a region where particles that are charged will experience 
an electromagnetic force. Hence if a hydrogen atom is placed in a strong 
magnetic field then it will align in the direction of the field. However, 
hydrogen atoms possess their own angular momentum and therefore 
‘precess’ around the direction of the externally applied field. Very soon 
equilibrium is achieved and there is a net magnetisation in the direction of B0 
and is termed M0. 
1.8.2 MR system 
In an MR system there are three electromagnetic parts: the main magnet 
coils, three gradient coils, and a radiofrequency transmitter coil. The main 
magnet applies the constant strong magnetic field and is denoted by B0, and 
clinical systems are generally 1.5 Tesla or 3 Tesla. Conventionally, x, y and 
z orthogonal planes are used to identify the directions of the magnetic fields; 
the z direction refers to B0. The three gradient coils can generate a varying 
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magnetic field in the direction of B0 as they can be turned off and on very 
rapidly. Therefore an object within the bore of the scanner will experience 
varying forces depending on the location. The units of measure for the 
gradient field strength are millitesla per metre (mT/m). 
The radiofrequency transmitter coils have an important role in signal 
generation as they produce a radiofrequency magnetic field. The frequency 
is within the megahertz range which is determined by the main magnet (1.5T 
or 3T) and the radiofrequency field is conventionally referred to as B1. 
1.8.3 The MR Signal 
The combination of a strong static magnetic field and radiofrequency 
generated fields produce an unique MR signal that can be detected by 
radiofrequency receiver coils and used to produce the image. The 
radiofrequency transmitter coil generates a magnetic field to deliver energy 
to the aligned protons. This is performed at a unique frequency known as the 
Larmor frequency or the resonance frequency. The Larmor frequency (0) is 
defined by the Larmor equation:  
 0 =  
Where  is the gyromagnetic ratio (for the proton=42.6MHz/Tesla). Therefore 
at 1.5T the Larmor frequency is 64MHz. This radiofrequency field is applied 
as a short time and is known as the rf pulse. 
At equilibrium, the net magnetisation is M0 in the line with B0, but when a rf 
pulse is generated the net magnetisation moves away from M0. This 
promotes a rotational motion about M0, known a precession, which occurs at 
Larmor frequency. The flip angle refers to the angle between the net 
magnetic vector and the transverse plane, Mxy after the application of a rf 
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pulse. The oscillating magnetic field can induce a current in the receiver coil 
thus generating the MR signal. As discussed above, the longitudinal 
component of magnetisation is strong as it aligns with B0, therefore the MR 
signal is measured in the transverse (x,y) plane in order to be able to detect 
changes as a result of the rf pulse.  
1.8.4 Radiofrequency pulses 
There are several types of radiofrequency pulses used in MR imaging and 
they are sub-divided by their flip angle and subsequent effect. A saturation 
pulse, has a 90o flip angle, which means that the energy is delivered to move  
protons from the position of equilibrium towards the transverse (x,y) axis. 
Therefore, the net magnetisation is highest in the x,y plane and least in the 
z-axis and therefore is the largest transverse magnetisation and largest MR 
signal. The saturation pulse is an example of an excitation pulse and forms 
the basis for spin-echo imaging. 
When a radiofrequency pulse is applied with an angle that is less than 90o 
then the net magnetisation is shared between the x,y plane and z plane, 
therefore the transverse magnetisation signal has lower energy as opposed 
to the higher levels seen in the saturation pulse earlier. The low flip angle 
impulses can be repeated with shorter delays as there will be available 
protons magnetised in the z plane as they would not have been fully excited. 
The low flip angle pulses are used in gradient echo imaging. 
For 180o flip angles, the net magnetisation can be aligned to the z axis but 
after the pulse, there is no signal in the transverse plane (x,y) and thus no 
detectable signal. This 180o pulse is known as an inversion pulse and used 
in inversion recovery sequences such as black blood imaging. Also, this 
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inversion pulse can be used to restore coherence that may be lost in certain 
sequences or attributable to magnetic field inhomogeneity.  
1.8.5 Characteristics of the MR signal 
There are several types of MR signals that are used in clinical practice to 
show normal anatomy and detect pathologies. A key event after the 
radiofrequency pulse is the process of relaxation, which occurs as the 
excited protons return to a state of equilibrium or rest. Relaxation effects net 
magnetisation in two planes; the longitudinal (z) and transverse(x,y) planes.  
T1 relaxation 
The longitudinal relaxation time, is referred to as T1 and is the time taken for 
the z component of magnetisation to return to the equilibrium (63% of its 
value at equilibrium). The process is exponential and can be described by 
the following equation: 
 Mz(t)= M0 (1–e
–t/T1) 
The magnetisation, Mz recovers to an equilibrium value (M0), ‘t’ refers to time 
and T1 is the longitudinal relaxation time decay constant. So initially, 
recovery is rapid and then the net magnetisation plateaus as equilibrium is 
approached. The shorter the T1 time constant the faster the relaxation 
process and return to equilibrium. With T1 relaxation there is a transfer of 
energy from spinning protons to the surrounding tissues in the form of heat 
and can also be described as spin-lattice relaxation. As an example, free 
water has a long T1, however water bound in tissues has a shorter T1 as 
this can transfer the energy to the surrounding area (lattice).  
T2 relaxation 
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The transverse relaxation process refers to the decrease of net 
magnetisation in the xy plane as protons rotate about the z axis. This 
process is longer than longitudinal relaxation. Similarly the magnetisation 
decay can be defined by the following equation where T2 is the transverse 
relaxation time decay constant: 
 Mxy(t)=Mxy(0)e
–t/T2 
Initially there is coherence of spin and net magnetisation in the xy plane, 
however, as the protons spin about the z axis and gradually change the 
phase angles, this results in a net loss of magnetisation in the transverse 
plane. In a receiver coil this is detected as an oscillating magnetic field that 
is weakening and is known as Free Induction Decay (FID). There are two 
relaxation times that are important in the transverse xy plane; T2 and T2*. 
Both of these detectable signals are a measure of loss of coherence in the 
spin of protons. T2 relaxation is also known as a spin-spin interaction where 
a spinning proton transfers energy to another spinning proton. This transient 
interaction alters the phase angle and thus the Larmor frequency.  
The other cause of a loss in coherence of protons is caused by the 
variations in the applied magnetic field (B0). These distortions or localised 
inhomogeneities are inherent to a specific magnet and induced by a 
body(subject) place in the field itself. T2* relaxation is a combination of T2 
relaxation and the effect of variations in the magnetic field.  
1.8.6 MR Echoes 
There are two major types of echo used in MR imaging that will be 
discussed here. The first is gradient echo (GE) and the second is spin echo 
(SE). 
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Gradient Echo 
Gradient echoes are produced by the application on two separate magnetic 
field gradients. The initiation of the first gradient alters the strength in the 
magnetic field and spinning protons lose their coherence as they are now 
precessing at differing phases. The effect in the transverse direction (xy) of 
magnetisation is that the signal drops to zero. A second magnetic field 
gradient is applied in the opposite direction to restore phasing of the protons 
and the free induction decay (FID) signal reappears. This signal generated is 
known as a gradient echo. The echo time denoted by TE and is the duration 
between the origin of the radiofrequency pulse, application of the gradient 
fields and to the maximal amplitude obtained by the gradient echo; this is 
also the “best” time to sample a signal. The echo time is measured in 
milliseconds and is unique to the pulse sequence selected by the MR 
operator. 
Spin Echo 
The spin echo is generated by first applying an excitation rf pulse at 90o 
followed by a ‘refocussing’ 180o rf pulse at half the echo time. After the first 
pulse the protons will alter their spin phase due to T2 relaxation and as an 
effect of magnetic field inhomogeneity; the first type of dephasing is 
irreversible but the second is reversible. The application of the second 180o 
rf pulse switches positive relative phase changes to a negative; the opposite 
applies to relative phase changes that were negative. The spins come back 
into phase which increases the amplitude of the free induction decay signal; 
the signal that is readout is the spin echo. 
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1.8.7 Making the image 
Slice selection 
A slice of tissue will experience the static field (B0) of the main magnet but if 
the gradient coils also generate another field (gradient field) then there will 
be a net field effect across the slice. We recall that the Larmor frequency of 
protons will vary and depend on the strength of the local magnetic field. 
Thus the frequency will vary along the applied gradient field (Gs: slice 
selection gradient). A specific slice can therefore be excited by transmitting a 
rf pulse with the frequencies within that slice. The rf pulse contains a range 
of frequencies referred to as a bandwidth. Therefore tissue outside these 
frequencies will not resonate as they have different Larmor frequencies, and 
so this gives us slice specificity for a location. In addition the thickness of a 
slice is determined by the range of the bandwidth, such that a thin slice will 
have a narrower frequency bandwidth.  The slice thickness is also 
dependent of the strength of the gradient field as this does effect the 
frequencies of the tissues at a slice. 
Phase and frequency encoding 
A phase encoding gradient is applied which causes the protons to spin at 
varying frequencies according to the location along the gradient. Thus the 
protons in the stronger part of the gradient will spin at a higher frequency 
than those located at a lower field gradient. When the gradient (Gp) is turned 
off, this leaves the protons in relatively different phases dependent on where 
they were located along the gradient. The direction of the applied gradient in 
this situation is known as the phase encoding direction.  
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The frequency encoding gradient (GF) is applied after the phase encoding 
gradient and is at 900 to this. The protons rotate at differing frequencies 
dependent on the location to the applied gradient, similar to that seen with 
phase encoding gradients. The unique feature of the frequency encoding 
gradient is that it is applied for a long period of time and coincides with the 
signal readout period. The signal is composed of a collection of frequencies 
(bandwidth) which depends much on the location along the applied gradient. 
Additional gradients are applied sequentially following the imaging gradients 
in order to counteract the dephasing of protons that occurs which effects the 
MR signal. The dephasing gradients are applied after the imaging gradients 
but with opposite slopes. 
Image reconstruction 
The process of image reconstruction is complex and involves several 
mathematical stages. The data from the MR signal are complicated and 
have to be broken down into individual components. A mathematical process 
known as Fourier transformation is used where signal or waveform in time 
can be expressed by its various frequency components. Therefore the 
frequency encoded MR signal can be converted to a series of frequency 
components. However, Fourier transformation can only be performed on 
signals that are time dependent therefore the variation from phase encoding 
frequencies requires additional steps. The MR signal generation steps are 
repeated with identical gradients except for the phase encoding gradient, for 
which the strength of the applied gradient is increased in stages. The time 
between intervals is known as the repetition time (TR). 
What is k space? 
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K space is a data point that represents a component of spatial frequency for 
an image. A point in the MR signal contains information about parts of the 
whole image. There is an inverse relationship between image space and k 
space. The lines of k space are typically filled in a parallel manner known as 
Cartesian acquisition. The central region of k space contains the most 
information regarding image contrast and the peripheral regions contain 
higher frequencies that provide details of spatial resolution.  
 
1.8.8 Pulse sequences and image contrast 
The ability to define normal and abnormal tissue in imaging has to be 
determined by the quality of the visible differences between tissues. The 
unique features of MRI are that excellent contrast that can be achieved 
between blood, muscle and fat to define pathology. We know from earlier 
that different tissues have individual T1 and T2 relaxation times. In spin echo 
the varying of TR and TE can impact on the tissues relaxation times on the 
MR signal. Where as in gradient echo the flip angle, TR and TE alterations 
can influence the tissues signal. 
T1 weighted spin echo 
A short TR and TE are used in T1 weighted spin echo imaging to give fat a 
high signal and appear bright whereas fluid has a lower intensity. T1 
weighted imaging is ideal for cardiac anatomical imaging. 
T2 weighted spin echo 
T2 weighted spin echo utilises a long TR and long TE. The pre-dominant 
contrast occurs between muscle and fluid which have a short and longer T2 
relaxation time respectively. T2 weighted imaging is used to determine fluid 
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filled areas and depicts myocardial oedema very clearly. Overall spin echo 
sequences give the “black blood” appearance which provides excellent 
contrast between tissue and blood. The signal void appears because blood 
is fast moving through the selected slice and therefore moves thorough after 
the first rf pulse without being refocused by the second rf pulse. 
Spoiled Gradient Echo contrast 
Spoiled gradient echo imaging uses a short TR and therefore allows for 
faster imaging. However, after the first read out the dephasing or a spoiler 
gradient has to be applied to prevent the initial signal from interfering on the 
next signal generation. 
T1 weighted gradient echo imaging uses a short TR and TE with a low flip 
angle and provides good cardiac cine imaging.  T2* weighted imaging on the 
other hand uses longer TE and TR to achieve contrast. This form of imaging 
is used in iron loaded studies or myocardial haemorrhage.  
Balanced Steady state free precession 
Balanced steady state free precession gradient echo sequences are used 
widely to assess ventricular function. The transverse magnetisation is not 
spoiled but instead re-phased after each readout and successively 
contributes to a steady state signal. The increased signal in SSFP compared 
to a spoiled gradient echo signal means a higher receiver bandwidth can be 
used with short TR and TE. However, this sequence is prone to banding 
artefacts caused by field in-homogeneities. 
1.8.9 Contrast Agents 
Gadolinium based contrast agents are used in MR imaging which are 
chelated to prevent toxicity. The agent remains extracellular after 
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intravenous administration and is excreted renally and  is contra-indicated in 
patients with severe kidney disease and lower glomerular filtration rates. 
This is because of a disease process called nephrogenic systemic fibrosis 
(NSF) which occurred in patients with severe renal disease who received 
linear gadolinium based contrasts. The gadolinium from these early agents 
displaced in to organs and tissues resulting in subcutaneous fibrosis. Biopsy 
of tissues confirmed deposition of gadolinium and thus safety concerns were 
raised. However, modern agents have cyclical chelation and therefore have 
a reduced risk of displacement of the ion and hence a low risk of NSF. There 
have been no reports of NSF in recent years and never in patients with 
normal renal function.   
The Gadolinium contrast agent shortens T1 relaxation times and so 
increases the signal intensity in T1 weighted imaging. The agent is usually 
administered according to body weight 0.1 to 0.2 mmol/kg.  
 
1.9 Cerebral Magnetic Resonance Imaging 
Cerebral MRI is established in acute stroke management and neurovascular 
disease. The cerebral infarcts appear as focal areas with the same intensity 
as cerebral spinal fluid. MRI can use diffusion weighted imaging (DWI) to 
confirm micro-infarcts that have reduced diffusion areas. This helps detect 
multiple embolic events easily. Other information such as evidence of 
cerebral atrophy and small vessel ischaemia can be commented upon. 
T1 and T2 weighted cerebral imaging 
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T1 weighted images are used to detect gross anatomical abnormalities and 
aid detection of older cerebral areas of infarction. On T1 weighted images 
they can appear hypo-intense and iso-intense in the acute phase. T2 
weighted imaging in the early phase of cerebral infarction give a very bright 
hyper-intense signal and can also detect peri-infarct oedema. 
1.9.1 Diffusion weighted imaging 
The MR signal is sensitive to random motion of molecules, the latter being 
known as “self-diffusion”. Therefore when diffusion is obstructed by physical 
barriers then this can be detected as a signal if diffusion weighted imaging is 
used. A pulsed gradient spin echo (PGSE) is used by applying a 90º and 
180º rf pulse along with variable gradients, which allows control and 
variability on the degree of weighting (b-factor). In general in diffusion 
weighted imaging a low signal is seen in tissue with normal function and a 
high signal is detected in disrupted tissues. An apparent diffusion coefficient 
(ADC) can be calculated from two or more diffusion weighted images (by 
varying b-factor). The diffusion coefficient is measured in units of mm2s-1. 
1.10 Cardiovascular MRI 
Cardiovascular MR imaging has become established as a modality which 
allows multi-parametric assessment in cardiac disease. CMR uses ECG 
gating to acquire images over several heart beats and breath holds to 
reconstruct cine and static images. There are various pulse sequences that 
allow optimal image acquisition and help to measure disease burden. 
1.10.1 LV Function 
The gold standard for volumetric analysis is CMR and this is superior to 
echo and Myocardial perfusion scintigraphy (MPS) and also has the added 
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benefit of excellent intra and inter-observer reproducibility (Alfakih et al., 
2003, Messroghli et al., 2005, Bellenger et al., 2000a).  The cine pulse 
sequence is typically Steady State Free Precession (SSFP) using gated 
ECG to acquire multiple phases. This uses typical TR 3ms, TE 1.5ms and 
temporal resolution of 20 to 50ms. This achieves a high signal-to-noise ratio 
and improved contrast between myocardium and the blood pool. From 
acquired images the end diastolic phase can be identified and the 
endocardial border can be contoured using quantitative software (QMass 
7.2, Medis, Netherlands). This process is repeated for all LV slices to 
calculate an End-diastolic volume by the summation of discs method 
(excluding the papillary muscles). The contouring can be repeated to the 
end-systolic phase to similarly calculate the end-systolic volume. These 
measures can be used to calculate the stroke volume (SV), ejection fraction 
(EF). The mass can be quantified by contouring the epicardial contour and 
including the papillary muscles.  
1.10.2 Late Gadolinium Enhancement 
Late Gadolinium Enhancement (LGE) imaging uses an inversion recovery 
(IR) gradient echo sequence. The Look-Locker method is used after the 
administration of Gadolinium contrast agent to find the optimal inversion time 
(TI) to null the myocardium. This allows areas of hyperenhancement to be 
very well visualised.  LGE is described according to distribution within the 
myocardium and typical patterns include; sub-endocardial 
hyperenhancement consistent with MI; patchy fibrosis for cardiomyopathy 
along with mid-wall fibrosis (Kim et al., 1999). Focal areas of 
hyperenhancement have been reported to vary in patients with severe aortic 
stenosis and be associated with poor outcome after SAVR (Weidemann et 
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al., 2009). In this study, cardiac biopsies were analysed along with LGE 
images, overall there was an improvement in EF but, at 9 months there was 
no change in the degree of enhancement which suggested AVR did not 
have an impact of focal fibrosis and this type of fibrosis was permanent.  
LGE imaging does not detect diffuse interstitial fibrosis as this relies on 
comparing the signal intensity between nulled ‘normal’ myocardium to a 
relatively hyper-enhanced fibrotic area. This makes accurate quantification 
difficult as post processing software requires an arbitrary set threshold to 
differentiate between normal and diseased areas.  
1.10.3 Diffuse Fibrosis and T1 mapping 
Abnormal left ventricular hypertrophy as seen in aortic stenosis can lead to a 
diffuse fibrosis developing prior to the severe focal areas. Diffuse fibrosis 
leads to expansion of the extracellular matrix and volume (ECV) which is 
mediated by myofibroblasts (Krayenbuehl et al., 1989). New methods of 
imaging this extracellular space have been developed using T1 mapping.  
T1 is the longitudinal relaxation time for the z-component of magnetisation of 
protons after a radiofrequency pulse; where fat has a shorter T1 time than 
muscle and fluid has the longest. The T1 time represents 63% of the tissues 
value at equilibrium.  Each tissue contains varying amounts of water 
molecules which aids differentiation but also pathological processes like 
fibrosis, oedema and inflammation play a role (Mewton et al., 2011). 
1.10.4 Modified Look-Locker Inversion Recovery 
T1 mapping techniques have been developed to acquire high spatial 
resolution images with single breath holding at both 1.5T and 3T field 
strengths. This allows signal quantification in milliseconds for each 
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myocardial voxel and therefore does not use an arbitrary scale as in LGE 
imaging.  Messroghli et al developed the technique and validated the 
method on volunteers and patients with disease (Messroghli et al., 2004). 
This is performed using the modified Look-Locker Inversion recovery 
(MOLLI). For each slice, there are 3 successive Look- Locker acquisitions 
(LL1, LL2 and LL3) with 3 (TI=100ms), 3 (TI=200ms) and 5 (TI=350ms) single 
shot readouts respectively. For each of the LL acquisitions the first read out 
occurs at the TI after a non-slice selective adiabatic 180o pulse and at a 
delay time (TD) after the previous R wave. Subsequent images are acquired 
at time TD after the R wave until the required number of images are 
obtained. A total of 11(3, 3, 5) images are obtained. The images are then 
post processed using dedicated software (e.g. MR Maps) which sorts the 
images in order of TI and applies a three-parameter non-linear curve fitting 
using a Levenberg-Marquardt algorithm (Messroghli et al., 2007) (Messroghli 
et al., 2010). This produces a T1 map which can be analysed by drawing 
regions of interest, therefore it is possible to obtain pre-contrast and post-
contrast T1 values. The changes in T1 can help differentiate between 
healthy and diseased myocardium. At 1.5T the healthy normal myocardial 
pre-contrast T1 is 977±63ms and post contrast T1 is 483±20ms (Messroghli 
et al., 2006). In comparison, infarct regions have a longer pre-contrast time 
but the post contrast time is shorter due to retention of Gadolinium. 
The studies in this thesis used MOLLI for T1 mapping as this was available 
on our 1.5T Philips scanner and had been previously validated and several 
studies had been published using this method. There are several other T1 
mapping methods, however, the techniques were not available to our centre 
as some sequences are vendor dependent, i.e. only available and validated 
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on Siemens scanners. T1 mapping has been validated using 1.5T and 
therefore we did not use 3T for the studies in the thesis. An additional 
restriction was that the TAVI valves had not been declared 3T compatible. 
1.10.5 Shortened Modified Look Locker Inversion Recovery 
(ShMOLLI) and Equilibrium contrast CMR 
Other methods of T1 mapping include; Shortened Modified Look Locker 
Inversion Recovery (ShMOLLI) and Equilibrium contrast CMR. (Piechnik et 
al., 2010) (Flett et al., 2010)  
ShMOLLI acquires 7 (5+1+1) images and therefore shortens the breath hold 
time and has been shown to correlate with MOLLI, however, does 
underestimate T1 by 4% and is more prone to noise artefacts (Piechnik et 
al., 2010). 
Equilibrium contrast CMR aims to calculate the volume of distribution of 
gadolinium in the myocardium and estimate the amount of diffuse fibrosis 
(Flett et al., 2010). The method involves giving a bolus of gadolinium 
followed by a dilute infusion over 30 to 60 minutes to achieve contrast 
equilibrium. The pre-and post-contrast T1 maps are acquired using standard 
LGE imaging parameters (spoiled gradient echo inversion recovery). The 
haematocrit is obtained to give the blood volume of distribution and the 
following equation is used to calculate myocardial volume of distribution (Vd) 
or extra cellular volume (ECV): 
𝑉𝑑 = (1 − ℎ𝑐𝑡) × (
(
1
𝑇1𝑚𝑦𝑜 𝑝𝑜𝑠𝑡 −
1
𝑇1 𝑚𝑦𝑜 𝑝𝑟𝑒)
(
1
𝑇1𝑏𝑙𝑜𝑜𝑑 𝑝𝑜𝑠𝑡 −
1
𝑇1 𝑏𝑙𝑜𝑜𝑑 𝑝𝑟𝑒)
) 
Flett et al were able correlate their method with myocardial biopsies in 18 
patients and therefore quantify the diffuse myocardial fibrosis (Flett et al., 
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2010).  This method was also used in patients with aortic stenosis before 
and after SAVR, where there was no significant regression of fibrosis, 
although there was a reduction in LV hypertrophy that was attributed to 
changes in cell volume (Flett et al., 2012). 
Clinical utility of T1 mapping is still in early developmental stages. There 
have been case reports and short series of T1 mapping to aid diagnoses. 
Cardiac amyloidosis presenting with heart failure often has cardiac MR 
assessment and LGE imaging does not allow nulling of the myocardium. 
Here T1 mapping has been shown to provide diagnostic yield with high T1 
values. An inverse effect on would be shortening as seen in Fabry’s disease. 
1.10.6 Extracellular Volume (ECV) 
The ECV can also be measured using MOLLI to obtain the myocardial and 
blood pool T1 values. Ugander et al showed a difference in patients with MI 
and atypical LGE patterns, also that ECV changed with age (Ugander et al., 
2012). Kellman et al have shown that motion correction and co-registration 
of the images is important in obtaining accurate ECV values (Kellman et al., 
2012). The normal ECV is been reported to be between 20 to 30% (Kellman 
et al., 2012, Ugander et al., 2012). 
Overall, CMR would be able to provide insight into the TAVI and 
contemporary SAVR patient group.  The accurate LV measurement, diffuse 
fibrosis and late gadolinium patterns may help predict patient outcomes.  
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1.11 Health Related Quality of Life 
Health related quality of life (HRQoL) is a multi-dimensional idea that 
includes various areas of life known as domains. This concept of HRQoL 
covers variety of components which are important to the patients’ wellbeing 
and provides a great holistic view of the patients’ status. The quality of life 
notion extends beyond quantitative measures of outcome such as survival 
after an intervention, a patient’s life expectancy or even adverse events due 
to complications. HRQoL covers domains of physical health, emotional well-
being, mental and social functioning. The physical measures refer to what 
the patient can do or how much pain they are in whereas the mental 
components refer to the symptoms of low mood and depression or concerns 
about their future resulting in anxiety.  
1.11.1 Measuring Health Related Quality of life 
Although absolute measures of outcome are useful when assessing the 
effect of treatment on a particular disease being able to measure HRQoL 
can also be valuable. The problem with any measurement is to define the 
standards that the investigator will use which can be difficult when trying to 
measure a multi-domain area like HRQoL (Guyatt et al., 1993). In order to 
achieve accurate measurements several HRQoL scales have been 
developed and well established examples of these are the Short form 36 
item Health survey questionnaire (SF-36) and EurQoL (McHorney et al., 
1994). The advantages of an established scale are that the instrument is 
reliable and validated. Using the SF-36 as an example, this is a patient 
reported outcome (PRO) which covers 36 items and questions are 
addressed to cover a variety of aspects. There are 8 domains covering 
subjective health: physical functioning, role limitations due to physical 
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problems, role limitations due to emotional problems, social functioning, 
mental health, energy/vitality, pain and general health perceptions. The 
reliability of the SF-36 has been shown to be consistent and the validity has 
been proven across patients with differing health states.  
1.11.2 Health Related Quality of Life in Aortic Stenosis 
Several studies conducted for valvular disease have shown patient reported 
outcomes to improve on medical and surgical therapy. Earlier surgical valve 
replacement research did not record specific HRQoL outcomes perhaps as 
not all scales had been validated. However, recent randomised control 
studies do include HRQoL outcomes and have shown significant 
improvement although emphasis is usually put on survival outcomes and 
improvement in valvular dynamics. The PARTNER trials for TAVI have 
recorded HRQoL outcomes and shown an improvement in both arms. 
Reynolds et al evaluated 628 patients with severe aortic stenosis that were 
in the high surgical risk arm that were treated with either TAVI or SAVR, 
known as cohort A (Reynolds et al., 2012). They used the SF-12 which was 
an abridged version of the SF-36 along with the Kansas City 
Cardiomyopathy questionnaires and EuroQoL (EQ-5D). Quality of life and 
health status were measured at baseline, 1 month, 6 months and 1 year. 
They reported almost 10-point improvement in health status in those treated 
with TAVI via the femoral route compared to SAVR. There was a significant 
improvement (>5 points) in SF-12 physical and mental scores at follow up 
time points in the TAVI arm. However, the surgically treated arm did have 
significant improvements in the physical score too but with a small point shift 
(~2 points).  
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Fairbairn et al showed serial improvement in many domains in patients 
undergoing TAVI over 12 month period. (Fairbairn et al., 2012b) There were 
positive changes seen early as 30 days in SF 12 Physical scores and the 
improved well-being continued up to 12 months. Predictors of improvement 
in HRQoL scores included male sex and operator experience. (Fairbairn et 
al., 2012b) 
Health related quality of life may be seen as a global indicator of general 
health. This is an important issue for patients and carers who live with 
various disease conditions and therefore a key part of medical practice. 
There are several external factors that can influence HRQoL, such as the 
procedure patients receive or any consequence related to the procedure. 
We know micro embolism and stroke are complications of both TAVI and 
SAVR. Therefore, an important evidence free area is whether stroke and 
cerebral micro-embolism affect general health status and quality of life.  
1.12   Neurocognitive Assessment 
Neurocognitive testing allows objective assessment of patients who may 
have a subclinical change in cognitive function as a consequence of brain 
injury; classically traumatic brain injury.  Multiple tests have been developed 
and validated in brain injury for cognitive assessment and in stroke patients. 
The recent VARC criteria also set out key areas that neurocognitive 
functional assessment should address when appraising TAVI and key 
assessment points; baseline, 30 days, 6 months and 12 months. Due to the 
nature of TAVI and embolic load, various concerns have been raised with 
respect to the effect of these silent cerebral infarctions (Fairbairn et al., 
2012a, Kahlert et al., 2012). Neurocognitive assessment is used in clinical 
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practice by Clinical Psychologists to grade degrees of cognitive impairment 
and assess response to treatment and rehabilitation. Various studies have 
reported on reliability and validity of these tests. 
1.12.1 Neurocognitive assessment in Coronary artery 
bypass grafting (CABG) 
Previously patients having CABG have shown changes in their 
neuropsychological function after surgery (Zamvar et al., 2002). Possible 
mechanisms include; cardiopulmonary bypass causing a systemic 
inflammatory response and micro-embolisation from aortic and cardiac 
manipulation (Pugsley et al., 1994, Borger et al., 2001). There was some 
suggestion that off-pump CABG results in less neurocognitive impairment 
(Zamvar et al., 2002).  Another study comparing biological AVR with CABG 
found that post-operatively there was a reduction in cognitive function, but 
the CABG group improved at 4 months, however the biological AVR did not 
(Zimpfer et al., 2002).  
Patients undergoing surgery can face a double cerebral insult. There first 
would be related to cardiopulmonary bypass, cardioplegia and subsequent 
restoration. The second would be the risk of thromboembolic stroke. 
Therefore the neuronal cells would experience ischaemia, systemic 
inflammation and possible infarction. All of which will influence cerebral 
activity and may have long term health consequences. 
Various areas of cerebral function are assessed including executive function, 
verbal fluency, semantic fluency, immediate and delayed recall, manual 
dexterity, ability to complete task, evidence of depression or anxiety. What is 
unknown is the consequences on the micro-infarcts following TAVI, although 
there are concerns that the events may contribute to vascular dementia.  
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1.12.2 Neurocognitive function in TAVI 
There are limited studies of neurocognitive function in the TAVI patient 
group. A study in 27 transapical TAVI patients with a 3 month follow up 
period did not show any decline in 5 cognitive domains (short term memory, 
working memory, verbal learning, delayed recognition and verbal fluency) 
(Knipp et al., 2013). However, they did not conduct any paper pencil tests 
such as, trail making A and B in the TAVI group because of their poor 
general condition.  
A comprehensive assessment neurocognitive assessment will provide 
information on the significance of the cerebral lesions detected on MRI as 
TAVI is being considered in the intermediate to high risk groups.  
 
1.13  Aims and Objectives  
The aim of the study was to recruit a minimum of 25 patients who were 
being treated by Transcatheter aortic valve implantation (TAVI) or surgical 
aortic valve replacement (SAVR) and perform a cerebral MRI and cardiac 
MRI scan at baseline. After intervention a cerebral MRI prior to discharge 
and at 6 months follow up cardiac MRI were necessary. Also a 
comprehensive neurocognitive assessment at 4 time points: baseline, 30 
days, 6 months and 12 months was conducted.  
The primary outcomes are:  
1. To assess the relationship of cerebral infarction and the effect on 
health-related quality of life over 6 months. 
2. To assess the relationship of cerebral infarction and the effect on 
neurocognitive function over 12 months 
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3. To describe the changes in cardiac reverse remodelling after 
intervention on aortic stenosis specifically to assess the change in 
diffuse and focal myocardial fibrosis after TAVI and SAVR. 
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2 Chapter 2 Methods 
The following chapter describes the general methods used during the period 
of study and further details including ethics are described in the individual 
study chapters. 
2.1 Patient Recruitment 
Patients with severe aortic stenosis were prospectively recruited between 
March 2012 and April 2013. Severe AS was defined by echocardiography 
with an aortic valve area <0.8cm2 or a peak velocity of >4ms-1 through the 
aortic valve using continuous wave Doppler. A multidisciplinary team 
including Cardiac surgeons, Cardiologists and anaesthetists would assess 
the patients’ suitability for TAVI or SAVR. The TAVI patient group are 
generally >65 years old, with a higher EuroSCORE and/or significant co-
morbidities that would prevent safe conventional surgery. Exclusion criteria 
were: permanent pacemakers, claustrophobia, or being unable to lie in the 
scanner for 60 minutes.  
Patients accepted for TAVI or SAVR were sent a patient information sheet 
(PIS) by post then a follow up telephone call to discuss any questions. Once 
verbal consent was obtained an appointment was booked for the baseline 
visit at which time formal written consent was taken. Baseline visit consisted 
of: cerebral and cardiac MRI and neurocognitive testing before the TAVI or 
SAVR. After the procedure the patient would have the second cerebral MRI 
before discharge from the hospital. Patients who required a permanent 
pacemaker would no longer continue with the MRI component but would be 
invited back for neurocognitive assessment at 30 days, 6 months and 12 
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months. Although MR safe/compatible pacemakers and leads are available, 
these were not included in the studies. The cerebral scans would have been 
unaffected, but the cardiac component would have been affected by 
artefacts. Patients were contacted by telephone to have a follow up cerebral 
and cardiac MRI at 6 months.  
2.2 Patient Risk Factors and Demographics 
All patient characteristics were recorded on a study clinical record form 
(appendix) and transferred to a secure password protected database. The 
following were recorded: age, sex, height, weight, significant co-morbidities 
(Hypertension, IHD, MI, DM, Hyperlipidaemia, AF, Stroke/TIA, PVD, and 
COPD). The EuroSCORE and EuroSCORE II were calculated along with the 
STS score. 
2.3 TAVI procedure 
TAVI was performed under general anaesthesia in a dedicated cardiac 
catheter laboratory. The 18 French third generation CoreValve™ prosthesis 
(Medtronic, Minneapolis, USA) was used at the Leeds General infirmary. 
The femoral or subclavian artery was accessed with a valved sheath. The 
native valve was crossed with a guidewire under x-ray fluoroscopy. A 
temporary pacing wire was placed in the RV apex for rapid pacing during 
intervention. Balloon aortic valvuloplasty was performed with rapid pacing. 
The CoreValve was delivered gradually to maintain satisfactory positioning. 
The patients were fully heparinised during TAVI and the activated clotting 
time of >200sec. Patients were on Aspirin 75mg once a day and on day 3 
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clopidogrel 75mg once a day was initiated for a period of 6 months if there 
were no bleeding complications. 
2.4 SAVR general method 
All surgical patients were operated at the Leeds General Infirmary. A midline 
sternotomy was performed and TOE was used intra-operatively. Following 
standard heparinisation the aorta was cross clamped and cardiopulmonary 
bypass was initiated with mild hypothermia. The type and size of the surgical 
prosthesis was determined by annular size, patient characteristics, surgical 
and patient preference. Some patients required coronary artery bypass 
grafting.  
2.5 Cerebral Diffusion Weighted Imaging (DWI) for Cerebral 
Infarction 
Before (pre) and after (post) TAVI or SAVR cerebral imaging was performed 
on the 1.5 Tesla scanner (Intera, Philips Healthcare, Best, Netherlands or 
Avanto, Siemens Medical Systems, Erlangen, Germany). The patient had to 
be able to lie supine within a specific head coil for approximately 5 to 10 
minutes for the duration of the scan.  
Cerebral Protocol: 22 slices, 5 mm thickness, 1 mm gap. The typical field of 
view (FOV) was 350 and relative FOV 100.  
i. Survey 
ii. T2 weighted Fast Field Echo (FFE) 
iii. Turbo Field echo (TFE) 
iv. Diffusion Weighted imaging (DWI) 
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The images were transferred as DICOM files for analysis. Two experienced 
Neuroradiologist independently reported the images and were blinded to the 
clinical data. The numbers of cerebral infarcts were recorded along with the 
arterial distribution and the infarction volume was quantified using planimetry 
technique in QMass post-processing software (version 7.2, Medis, 
Netherlands). 
2.6 Cardiovascular MRI protocol 
The study was performed on the 1.5 Tesla (Intera, Phillips Healthcare, Best, 
Netherlands or Avanto, Siemens Medical Systems, Erlangen, Germany) for 
all visits (Baseline, 6 months) using the same imaging protocol. 
Protocol: 
i. Survey 
ii. Localisers: Using cine steady state free precession (SSFP), the 
vertical long axis (VLA) view and Horizontal long axis (HLA) view 
are identified. (1 slice, 8mm thickness with 24 phases; FOV 400, 
RFOV 100.) 
iii. Black blood T1 trans-axial acquisition: 24 slices with a thickness of 
8mm using 24 phases. (FOV 340, RFOV 80) 
iv. LV volumes: These are planned using the VLA and HLA views to 
identify the short axis of the LV and cine slices are then acquired. 
Typically 10 to 12 contiguous slices are acquired covering from 
the mitral valve plane to beyond the apex. (Thickness: 10mm, 0 
mm gap, 30 phases. FOV 340, RFOV 100) 
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v. Left ventricular outflow tract (LVOT): The sagittal/oblique view is 
acquired first by planning from the LV stack, and then the image 
plane is rotated 90 degrees to obtain the coronal view. The cine 
images consist of 3 to 5 slices. (Thickness: 6mm, 0 mm gap, 30 
phases, FOV 380, RFOV 100) 
vi. AV phase encoded velocity mapping. A through plane scan is 
planned from the two previously acquired LVOT views at the sino-
tubular junction. The initial VENC is set higher at 400cm/s for the 
baseline scan and assess for aliasing, if present the VENC was 
increased by 50 cm/s. For follow up studies the VENC was set at 
250cm/s and adjusted accordingly. The acquired phase contrast 
image should be check for aliasing and if present then the VENC 
should be increased by 50cm/s. Both breath held and non-breath 
held images are acquired with 40 phases.  (1 slice, 10 mm 
thickness, FOV 350, RFOV 85) 
vii. Aortic arch views. SSFP cines are to include the whole arch and 
are planned through the ascending, transverse and descending 
aorta. (7 slices, 6mm thickness, 0 gap, 24 phases, FOV 320, 
RFOV 100) 
viii. Aortic Distensibility. Performed using high temporal resolution cine 
imaging with the imaging plane is perpendicular to the ascending 
and descending aorta at the level of the bifurcation of the 
pulmonary artery.  (1 slice, 8 mm thickness with 0 mm gap, 50 
phases, FOV 320, RFOV 100) 
- 57 - 
ix. Aortic Pulse Wave Velocity (PWV). A through plane phase 
encoded velocity mapped image is acquired in the same 
geometric plane as the distensibility cines. The VENC is set at 
250cm/s and increased if there are aliasing pixels seen. Again 
both breath held (FOV 350 RFOV 85) and non-breath held (FOV 
400 RFOV 70) images are acquired. (1 slice, 10 mm thickness, 40 
phases) 
x. ‘3 of 5’. The 3 slices will reflect the basal, mid ventricular and 
apical views in the SA of the left ventricle. The 3 slices are 
planned from 5 slices with the ventricle in systole using the VLA 
and 4Ch images. (10 mm thickness, 24 phases, FOV 400, RFOV 
100) 
xi. Myocardial Tagging. Complementary spatial modulation of 
magnetization (CSPAMM) pulse sequence is used to generate 
tags on the apical, mid and basal ventricular slices, using the ‘3 of 
5’ technique. (10mm thickness, 18 phases, 2 stacks, FOV 300, 
RFOV 75) 
xii. T1 mapping: This is performed using the modified Look-Locker 
Inversion recovery (MOLLI) as described by Messroghli 
(Messroghli et al., 2004).  This was selected as it was available on 
the scanner and had been previously developed and validated, 
along with 3 clinical studies in aortic regurgitation and ischaemic 
heart disease. The other t1 mapping techniques were not 
available during the study period. For each slice, there are 3 
successive Look- Locker acquisitions (LL1, LL2 and LL3) with 3 
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(TI=100ms), 3 (TI=200ms) and 5 (TI=350ms) single shot readouts 
respectively. A total of 11(3, 3, 5) images are obtained. (3 slices, 3 
of 5 technique, 8 mm thickness, FOV 380, RFOV 340). The 
process is performed pre-contrast, then 5 and 15 minutes after 
contrast.  
xiii. Look-Locker inversion time scout. A single mid ventricular slice to 
obtain the inversion time (TI) at which the myocardium is nulled. 
(10mm thickness, FOV 390, RFOV 95) 
xiv. Late Gadolinium Enhancement. A T1-weighted segmented 
inversion-recovery gradient echo pulse sequence is used with the 
inversion time being adjusted according to the LL scan. Each slice 
is acquired with one breath hold. (12 SA, 3 VLA, 3 HLA slices, 
10mm thickness, 0 gap, FOV 350, RFOV 100) 
 
2.7 Neuropsychological Assessment 
The neuropsychological assessment was conducted by trained doctors and 
trained research nurses. The neuropsychological assessment training was 
performed by an academic clinical psychologist, who also checked for data 
quality and consistency of assessment. The assessment was undertaken in 
a quiet room at a table with chairs for the assessor and patient. The baseline 
and 6 month visits were conducted before the MRI examination; 30 day and 
12 month assessments were conducted at home or hospital. The 
handedness and years of education for each patient were recorded.  
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2.7.1 National Adult Reading Test (NART)  
This is a quick method to estimate premorbid verbal IQ by testing the correct 
pronunciation of irregular English words (Nelson and O'Connell, 1978). The 
number of errors is recorded. 
2.7.2 Mini Mental State Examination (MMSE)  
This is a screening test for dementia and decline in cognition which is 
commonly used in clinical practice (Folstein et al., 1975). The MMSE has 11 
items that assess orientation, short term memory, attention and visual spatial 
skills. The total score indicates levels of cognitive impairment: 21-24 is mild, 
10-20 is moderate, <10 are severe. 
2.7.3 Hopkins Verbal Learning Test (HVLT)  
This assesses verbal memory thorough simple list learning, multiple 
reminder trials and delayed recognition and recall (Brandt, 1991). A list 12 
items (semantically grouped) are slowly read out and the patient has to 
recall them (3 trials). Recognition memory is assessed thorough an 
additional list with 12 distractor items (6 related and 6 unrelated). After 30 
minutes an attempt at recalling the original list should be made for delayed 
recall score. The immediate recall, total recall and a delayed recall scores 
are collected. In addition the numbers of related and unrelated errors are 
recorded.  
2.7.4 Rey-Osterrieth Complex Figure test (ROCF)  
This assesses the visio-constructive skills of the patient (Rey, 1941). The 
patient is asked to copy a complicated geometric figure with a HB pencil.  
Once the patient has completed the drawing, the figures are removed and 
the patient is asked to redraw the image from memory. After a delay of 30 
minutes the patient is asked to redraw the figure from memory. All 3 
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drawings are scored according to how the lines are placed (poorly placed vs. 
Properly placed) and whether they are correct or distorted/incomplete or 
absent/not recognisable. 
2.7.5 Trail making A and B  
This is a test of psychomotor speed which has been validated (Lezak, 2004). 
The patient is timed with a digital stopwatch and asked to draw lines with a 
pencil between the circled numbers (TMT-A) in ascending order as fast as 
they can. For TMT-B the patient has to alternate between a number and a 
letter maintaining numerical and alphabetical order. TMT-A includes 1 to 25 
digits, TMT-B consists of digits and letters (1-A-2B-3C...-L13). Both times 
are recorded in seconds.  
2.7.6 Controlled oral word association test (COWAT)  
This is a test of higher executive function using a verbal and semantic 
fluency tasks (Tombaugh et al., 1999).  
a. FAS The patient is asked to say words beginning with, F, A, 
and S within one minute for each letter. The total number of 
words for all three letters is recorded along with number of 
errors. 
b. Semantic fluency Patient is asked to say words that are within 
a semantic category within one minute. The total number of 
words and the number of errors are recorded. The categories 
for each visit are: animals (baseline and 12 month), clothing 
(30 days), and foods (6 month). 
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c. Switching fluency. Patient is asked to say words that 
alternate between two categories. The total number of pairs 
and errors are recorded.  
2.7.7 Letter Number sequencing (LNS)  
This is taken from the Wechsler Adult Intelligence Scale-III (WAIS-III) 
(Wechsler, 1997). The patient hears a sequence of random letters and 
numbers and is asked to repeat the numbers and letters back to the 
assessor but should give the numbers first followed by the letter. Both have 
to be in numerical and alphabetical order. The sequence increase in length 
until the patient fails three times. The number of correct responses is 
recorded. 
2.7.8 Digit-symbol substitution test (DSST)  
This is taken from the Wechsler Adult Intelligence scale-R (WAIS-R) 
(Wechsler, 1981).This measures attention, perceptual speed, motor speed, 
visual scanning and memory. The patient is given a form with 9 symbols 
corresponding with 9 digits. Below there are rows of digits with empty boxes 
below. The patient has 2 minutes to fill in as many corresponding symbols 
as possible. The total number of correct associations is collected.  
2.7.9 Grooved Pegboard testing 
The grooved pegboard test is a manipulative dexterity test that consisted of 
25 holes into which a grooved peg must be placed (Grooved Pegboard, 
model 32025, Lafayette Instrument, IN, USA. www.lafayetteinstrument.com) 
(Lezak, 1995). All the pegs are identical. All patients are given the same 
instructions:  
“This is a pegboard and these are the pegs. All pegs are the same. They 
have a groove, that is a round side and a square side and so do the holes in 
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the boards. What you must do is match the groove of the peg with the 
groove of the board and put these pegs into the holes like this (The 
examiner demonstrates). When I say go, begin here and put the pegs into 
the board as fast as you can using only your dominant hand. Fill the top row 
then move on to the next row, ready go”.  
The time to complete the test using the dominant hand is recorded in 
seconds using a standard stopwatch. The number of dropped pegs is 
recorded. The pegs are then removed by the examiner and the participant is 
asked to repeat the test using the non-dominant hand (Instruments, 2003).  
The grooved pegboard test has been part of other neuropsychological 
assessment batteries such as the Repeatable Cognitive-Perceptual-Motor 
battery (Lewis and Kupke, 1992).  
 
Figure  2-1 Grooved Pegboard Test 
2.7.10 Modified Rankins Scale  
This is a quick 6 point scale that assesses the level of disability (Lyden and 
Lau, 1991) (Kappetein et al., 2013). This ranges from 0 = no disability, 1=no 
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significant disability despite symptoms, 2= slight disability, 3=moderate, 4= 
moderate to severe, 5= Severe disability, 6=Death. 
2.8 Health Related Quality of Life  
Two generic questionnaires were conducted at each time point (baseline, 30 
days, 6 months and 12 months). This was performed at the same time as 
the neuropsychological assessment.  
2.8.1 EQ5D (EuroQoL)  
This covers 5 domains; mobility, self-care, usual activities, pain/discomfort 
and anxiety/depression (Szende et al., 2007). This allows calculation of a 
utility measure between 0 (death) and 1(full health). The questionnaire is 
scored using the UK population time-trade off valuation data set. A visual 
analogue score was also completed by patients indicating their health status 
as a percentage between 0 (worst imaginable) to 100 (best possible).  
2.8.2 Short Form-12  
The SF-12 survey (Short Form 12 v2, Quality Metric, Lincoln, Rhode Island, 
USA) covers 12 questions related to eight multi-item domains which 
measure: physical functioning, role limitations to physical health problems, 
bodily pain, general health, vitality, social functioning, role limitations due to 
emotional difficulties and mental health (Ware et al., 1996). The eight 
domains are combined to produce an average score related to physical 
(physical component summary PCS) and mental (mental component score 
MCS). All data are adjusted to give normalised based scores (NBS) using 
dedicated scoring software (Quality Metric Inc. Lincoln Rhode Island).  
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2.9 Hospital Anxiety and Depression Scale (HADS) 
The Hospital Anxiety and Depression Scale is a validated and reliable 
instrument to identify features of mood disorders in the general population 
(Zigmond and Snaith, 1983). There are 14 questions to address around the 
patient’s feelings which are scored 0 to 3. After completing the sheet the 
assessor adds the scores for Anxiety and Depression. A score of less than 7 
is normal, 8 to 10=mild, 11-14=moderate and 15 to 21=severe mood 
affective disorder (Bjelland et al., 2002). HADS was obtained from GL 
assessments, Swindon (www.gl-assessment.co.uk). 
2.9.1 Statistical Analysis 
Data will be presented as mean with standard deviations or median and 
interquartile ranges. Continuous variables will be compared with paired or 
unpaired t tests and for more than two groups then analysis of variance 
(ANOVA) will be used. Most of the data will be analysed by ANOVA for 
repeated measures. Discrete variables will be compared with chi squared 
test or Mann-Whitney or Wilcoxon signed rank tests.  
Further statistical methods were used depending on the individual results 
chapters such as mixed-effect modelling. 
The software packages used during the study were Microsoft Excel and 
SPSS.  
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3 Consequence of Cerebral Embolism following 
Transcatheter Aortic Valve Implantation (TAVI) 
compared to Contemporary Surgical Aortic Valve 
Replacement (SAVR): effect on Health-Related 
Quality of Life (HRQoL) and DWI 
 
3.1 ABSTRACT  
Background: The incidence of cerebral micro-infarcts is higher after 
Transcatheter Aortic Valve Implantation (TAVI) compared to surgical aortic 
valve replacement (SAVR). It is unknown whether these lesions persist and 
what direct impact they have on Health-Related Quality of Life (HRQoL). 
The objective was to identify predictors of cerebral micro-infarction and 
measure their effect on HRQoL over 6 months after TAVI compared to 
SAVR.  
 
Methods and Results: Cerebral MR imaging was conducted at baseline, 
post-procedure and 6m using diffusion weighted imaging (DWI). HRQoL was 
measured at baseline, 30d and 6m with SF12v2 and EQ5D questionnaires. 
111 patients (TAVI n=71; SAVR n=40) were studied. The incidence 
(54(77%) vs. 17(43%), p=0.001) and mean number (3.4±4.9 vs. 1.2±1.8, 
p=0.001) of new micro-infarcts was greater after TAVI compared to SAVR. 
The mean total volume per micro-infarct was smaller in TAVI compared to 
SAVR (0.230.24ml vs. 0.761.8ml, p=0.04).  The strongest associations for 
micro-infarction were: TAVI (arch atheroma grade r=0.46, p=0.0001); SAVR 
(concomitant coronary artery bypass grafting (r=-0.33, p=0.03)).  
 
- 66 - 
Physical component scores (PCS) in TAVI increased after 30d (32.1±6.6 vs. 
38.9±7.0, p<0.0001) and 6m (40.4±9.3, p<0.0001); the improvement 
occurred later in SAVR (baseline: 34.910.6, 30d: 35.910.2, 6m: 42.811.2, 
p<0.001). Following TAVI, there were no differences in the SF12v2 scores 
according to the presence or size of new cerebral infarction.  
 
Conclusion:  Cerebral micro-infarctions are more common post-TAVI 
compared to SAVR but appear to have no negative effect on early (30days) 
or medium term (6 month) HRQoL. Aortic atheroma (TAVI) and concomitant 
CABG (SAVR) are independent risk factors for cerebral micro-infarction. 
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3.2 INTRODUCTION 
Transcatheter aortic valve implantation (TAVI) in patients with symptomatic 
severe aortic stenosis (AS) is an alternative to medical therapy or surgical 
aortic valve replacement (SAVR) in those at high surgical risk (Vahanian et 
al., 2012). TAVI has been shown to reduce mortality, and improve patient 
symptoms and health related quality of life (HRQoL) (Kodali et al., 2012a, 
Fairbairn et al., 2012b). Whilst TAVI appears cost-effective compared to 
SAVR, embolic cerebral infarction remains a concern due to its frequency 
and the associated morbidity, mortality and healthcare costs (Fairbairn et al., 
2013a). This will be increasingly important if TAVI is considered for lower-
risk or younger patient populations. 
Previous work has shown that embolic cerebral infarction occurs following 
both TAVI and SAVR, with the majority remaining subclinical (Kahlert et al., 
2010, Fairbairn et al., 2012b, Kahlert et al., 2012, Ghanem et al., 2010b, 
Rodes-Cabau et al., 2011, Stolz et al., 2004). The incidence of cerebral 
emboli appears to be greater post-TAVI, with no significant difference 
between the access routes (transfemoral vs. transapical) or valve types 
(Medtronic CoreValve™ vs. Edwards Sapien™)(Rodes-Cabau et al., 2011). 
The clinical consequences of these ‘silent infarcts’ and identification of risk 
factors is yet to be fully established. Two studies have assessed basic 
cerebral function using a mini-mental state examination (MMSE) pre- and 
post-TAVI, demonstrating no significant change at 3 months (Kahlert et al., 
2010, Kahlert et al., 2012). We have previously described the early (30d) 
effect of cerebral emboli upon patient HRQoL after TAVI, and identified age 
and aortic atheroma severity as risk factors (Fairbairn et al., 2012b). 
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However, there is uncertainty regarding the long-term significance of these 
silent infarcts, whether their location determines functional status, and how 
this compares to a contemporary SAVR group. 
The principal aim of this study was to compare the incidence and natural 
history of cerebral embolization and their impact on medium-term HRQoL 
between a TAVI and SAVR group. A secondary aim was to determine 
factors associated with cerebral embolization. 
3.3 METHODS 
3.3.1 Study participants 
Patients with severe symptomatic AS were prospectively recruited if they 
were due to undergo either SAVR or TAVI at a large tertiary surgical centre. 
Severe AS was defined by transthoracic echocardiography (TTE) with an 
aortic valve area of <0.8cm2 and a peak velocity of >4ms-1. Between May 
2008 and February 2013 TAVI patients were selected by a multidisciplinary 
heart team in accordance with contemporary UK guidance (Kappetein et al., 
2012). Older, higher-risk (based on EuroSCORE) SAVR patients with one or 
more co-morbidities were identified for recruitment so that they more closely 
represented the TAVI population (complete matching was not possible due 
to the current UK TAVI guidelines). Exclusion criteria included any 
contraindication to MRI. Some study patients overlapped as they had quality 
of life assessments (Ch 3) and neurocognitive assessment (Ch 4).The study 
was approved by the institutional ethics committee and complied with the 
Declaration of Helsinki. All patients provided written informed consent. 
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3.3.2 TAVI procedure 
TAVI was performed with the Medtronic CoreValve™ prosthesis by a single 
experienced, high-volume operator as previously described (Piazza et al., 
2008). Briefly, all procedures were performed under general anaesthesia 
with X-ray fluoroscopy and transoesophageal echocardiographic (TOE) 
guidance. All patients received heparin to maintain an activated clotting time 
>200s and were treated with dual anti-platelet therapy (aspirin and 
clopidogrel) for 3 to 6 months post-procedure.  
3.3.3 SAVR operation 
Midline sternotomy was performed for all surgical patients using intra-
operative TEE guidance. Following standard heparinization the aorta was 
cross-clamped and cardiopulmonary bypass was initiated with mild 
hypothermia. The type and size of surgical prosthesis varied dependent 
upon annulus size, patient characteristics, surgical and patient preference. 
Coronary artery bypass grafting was concomitantly performed when 
indicated.  
3.3.4 Cerebral MRI 
Cerebral magnetic resonance imaging (MRI) was conducted pre- and post-
procedure (within 7d) and again at 6m using identical imaging protocols. MRI 
was performed on the same 1.5T system for all serial scans for any 
individual patient (Intera, Phillips Healthcare, Netherlands or Avanto, 
Siemens Medical Systems, Germany). The imaging protocol consisted of T2 
weighted fast field echo, T2 turbo field echo and diffusion weighted imaging 
(DWI) (22 slices, 5mm thick, 1mm gap, FOV 350, RFOV 100). Each scan 
was independently assessed by three experienced Neuroradiologists, 
blinded to clinical details. In the case of disagreement, a consensus view 
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was recorded. Cerebral embolism or micro-infarction was defined as a new 
restricted diffusion lesion on DWI. New cerebral micro-infarcts were localised 
to hemisphere and vascular territory. As previously described, infarct 
diameter was used to categorise patients into small or large lesion sub-
groups (<5mm or >5mm; in the case of multiple lesions the largest lesion 
was used to determine status). The total volume of micro-infarcts (ml) were 
measured off-line using standard post-processing software (QMass7.2, 
Medis, The Netherlands). 
 
3.3.5 Neurological assessment and status 
A detailed neurological examination was conducted prior to intervention and 
daily after the procedure by an experienced consultant physician until 
hospital discharge (typically day 7). A National Institutes of Health Stroke 
Scale (NIHSS) score was recorded. Transient ischaemic attack was defined 
as any focal neurological deficit that lasted <24h. Stroke was defined as any 
persistent focal neurological deficit lasting >24h.  
3.3.6 Health related quality of life assessment 
Health status was evaluated at baseline, 30 days(30d) and 6 months(6m) 
(Valve Academic Research Consortium recommended time-points) using 
two generic health related quality of life (HRQoL) questionnaires: short form-
12 health outcomes (SF12v2, QualityMetric, Lincoln, Rhode Island, USA) 
and EQ5D (©EuroQoL). The SF12v2 survey covers eight domains: physical 
functioning, role limitations due to physical health problems, bodily pain, 
general health, vitality, social functioning, role limitations due to emotional 
difficulties and mental health. Domains are combined to produce an average 
score related to physical (physical component summary (PCS)) and mental 
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(mental component summary (MCS)) health. Data are adjusted to give 
normalised based scores (NBS) using dedicated scoring software 
(QualityMetric Inc, Lincoln, Rhode Island, USA).  
The EQ5D questionnaire covers 5 domains; mobility, self-care, usual 
activities, pain/discomfort and anxiety/depression. This provides a utility 
measure between 0 (death) and 1(full health). The questionnaire was scored 
using the UK population time-trade off valuation data set. A visual analogue 
score was also completed by patients indicating their health as a percentage 
between 0 (worst imaginable health) and 100 (best possible health).  
3.3.7 Risk factors for embolism 
Demographic and procedural risk factors for cerebral embolization were 
recorded for all patients. The ascending, arch and descending thoracic aorta 
were imaged using TOE in order to grade severity of atheroma in 
accordance with a recognised 5-point scale (Barbut et al., 1997): 1=Normal, 
2=Severe intimal thickening without protruding atheroma, 3=Atheroma 
<5mm, 4=Atheroma >5mm, 5=Mobile atheroma of any size. In addition, 
aortic valve calcification was graded using published criteria: 1=no 
calcification, 2=mild calcification,  3=moderate calcification, 4=severe 
calcification (Rosenhek et al., 2000). All patients were having TOE as part of 
their procedures and so they data was more easily available. CT aortogram 
for TAVI assessment was not widely performed during the start of this study, 
but could have given information regarding arch atheroma. 
3.3.8 Statistical analysis 
Continuous variables are presented as mean±SD and categorical variables 
as frequency and percentage. Normality was determined by a Shapiro-Wilks 
test. Comparative statistics were performed using the Student t-test or Chi-
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squared test. Non-normal data were compared with the Mann-Whitney test 
or Wilcoxon signed rank test. HRQoL scores (baseline, 30d and 6m) were 
analysed using linear mixed-effects modelling with an unstructured 
covariance matrix and time as the fixed effect and Bonferroni post-hoc 
correction for multiple comparisons. The linear mixed-effects model was 
used instead of repeated measures ANOVA to overcome any potential 
impact of missing data and the need for a balanced design.  
Our sample size was based on published data to detect a 5 to 10 point 
difference in SF12v2 summary scores and a 0.1 point difference in EQ5D 
score. To achieve a power of 80% we needed 33 patients in each group, 
with an alpha error set at 0.05(two sided) (Ware, 2002). 
All analyses were performed using the PASW software (SPSS 19, IBM, 
Chicago, Ill). Two-sided p<0.05 was considered statistically significant. 
Univariate linear regression analysis was performed using all identified 
covariates and compared to the number of new infarcts post procedure. 
Variables with p≤0.1 were entered into a stepwise multivariable regression 
analysis. Propensity scores (predictive probability) for receiving TAVI were 
calculated using a binary logistic regression model (TAVI Yes=1, No=0) with 
confounding variables entered as co-variates (Age, sex, EuroSCORE, STS, 
BSA, NYHA class, diabetes, hypertension, hypercholesterolaemia, AF, 
stroke, prior CABG, PVD, porcelain aorta, valve calcification, aortic 
atheroma grade). Propensity score adjustment for number of new cerebral 
infarcts was performed by linear regression analysis with number of new 
cerebral infarcts as the dependent variable and the independent variables 
were TAVI (yes or no) and the propensity scores  
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3.4 RESULTS 
3.4.1 Patient and procedural factors 
One hundred and eleven consecutive patients were recruited (71 TAVI and 
40 SAVR). Baseline patient characteristics are presented in Table 3-1. The 
TAVI group were older (80±6.3 vs. 70.88.3 years, p<0.001), had higher 
logistic EuroSCORE, EuroSCORE II and STS scores, with a higher 
prevalence of AF, CABG, PVD and aortic atheroma (Table 3-1). Overall the 
two groups are markedly different which is expected given TAVI patients are 
surgical turndowns and the differences may confound subsequent 
comparisons. Procedural data for both TAVI and SAVR are detailed in Table 
3-2. No major peri-procedural complications were reported in the study 
population.  
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Table  3-1 Baseline patient characteristics 
Data are Mean±SD, n(%). TAVI=Transcatheter Aortic Valve Implantation, SAVR=Surgical Aortic Valve 
Replacement, BSA=body surface area, BMI=body mass index, NYHA=New York Heart Association, 
STS=Society of Thoracic Surgery, TIA=transient ischaemic attack, MI=myocardial infarction, 
CABG=coronary artery bypass grafting, PVD=peripheral vascular disease, COPD=chronic obstructive 
pulmonary disease, eGFR=estimated glomerular filtration rate. *Mann Whitney U test. 
 
Demographics and clinical 
characteristics 
TAVI (n=71) SAVR (n=40) p value 
Age, years 80.5±6.3 70.88.3 <0.0001 
Male, n (%) 31 (44) 27 (68) 0.02 
BSA, m
2
 1.780.2 1.90.4 0.007 
BMI, kgm
-2
 27.44.7 29.24.7 0.07 
NYHA Class, n (%) 
I 
II 
III 
IV 
 
0 
4 (6) 
47 (66) 
20 (28) 
 
1 (2) 
2 (5) 
37 (93) 
0 
 
0.002* 
EuroSCORE, (%) 18.210.9 5.92.9 <0.0001 
EuroSCORE II, (%) 6.13.6 1.50.6 <0.0001 
STS Score (%) 6.02.8 2.41.7 <0.0001 
Hypertension, n (%) 37 (52) 27 (68) 0.16 
Diabetes, n (%) 27 (38) 8 (20)  0.06 
Hypercholesterolaemia, n (%) 36 (51) 29 (73) 0.03 
Atrial fibrillation, n (%) 23 (32) 4 (10) 0.01 
Stroke/TIA, n (%) 21(30) 5 (13) 0.06 
MI, n (%) 2 (3) 5 (13) 0.10 
CABG, n (%) 15 (21) 0 0.0001 
PVD, n (%) 24 (34) 3 (8) 0.002 
COPD, n (%) 10 (14) 9 (23) 0.29 
Creatinine µmolL
-1
 12469 8518 <0.0001 
eGFR ml/min/1.73m
2
 5521 8829 <0.0001 
Porcelain Aorta, n (%) 11 (16) 0 <0.0001 
Aortic Valve Calcification grade, n (%)   
IV 
III 
II 
I  
51 (72) 
14 (20) 
5 (7) 
1 (2) 
24 (60) 
16 (40) 
0 
0 
p=0.46* 
 
Aortic Atheroma Grade, (median, Q1-Q3)   
Ascending 
Arch 
Descending 
2 (2–3) 
2 (1–3) 
2 (2–3) 
2 (1–2) 
2 (1–2) 
2 (1–2) 
<0.0001* 
0.003* 
<0.0001* 
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Table  3-2 Procedural and operative data 
  n (%) 
TAVI   
Medtronic CoreValve size 31mm 2 (3) 
 29mm 47 (66) 
 26mm 19 (27) 
 23mm 3 (4) 
Vascular access  Femoral 65 (91) 
 Subclavian 5 (7) 
 Carotid 1 (1.5) 
Procedure-time, (min)  13871 
Fluoroscopy-time, (min)  238 
Contrast volume, (ml)  15748 
SAVR   
Biological, n (%)  34 (85) 
Mechanical, n (%)  6 (15) 
Size, (mm)(median, range)  21 (18–29) 
Bypass-time, (min)(mean±SD) 
 
All  
SAVR only 
SAVR and CABG 
10948 
7246 
10023 
Cross-clamp-time,(min) (mean±SD) All  
SAVR only 
SAVR and CABG 
8241 
9247 
13932 
CABG, n (%)  13 (33) 
Abbreviations as in Table 3-1 
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3.4.2 Detection of cerebral emboli 
All 111 (TAVI=71, SAVR=40) patients completed the baseline MRI scan. 
The majority of patients 108 (97%) completed pre-and early post-procedural 
scans (2 pacemaker implantations (TAVI=1, SAVR=1) and 1 death (SAVR)). 
Six-month follow-up scans were performed in 66 (59%) patients (TAVI=32, 
SAVR=34); 38 TAVI patients could not re-attend (physically unable to attend 
the department due to frailty=19, declined a further MRI scan=3, pacemaker 
inserted in the follow up period=7) (Figure 3-1). 4 SAVR patients did not 
have the 6-month scan (death=1, unable to attend due to poor health=3). 
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Figure  3-1. Study flow-diagram of patient recruitment and the 3-
cerebral MRI and Health related Quality of Life (HRQoL) time-
points.  
(PPM=permanent pacemaker, NH=nursing home) 
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Baseline: The cerebral scan showed TAVI patients had greater pre-existing 
cerebral micro-infarction than the SAVR group (n=26(37%) vs. n=6(15%), 
p=0.012). There was no difference in the baseline distribution of infarction 
between TAVI and SAVR (anterior: 86% vs. 44%; posterior: 14% vs. 56%, 
Chi-square=2.86, p=0.09).  
Post-procedure: Figure 2 shows a typical example of new micro-infarction 
detected by DWI. The incidence of new embolic micro-infarcts on DWI-MRI 
were higher in TAVI patients compared to SAVR (54(77%) vs. 17(43%), 
p=0.001). The mean number of new cerebral micro-infarctions per patient 
was 3.4±4.9 (median=2 (Q1-Q3 14)) for TAVI and 1.2±1.8 (median=0 (Q1-
Q3 03) for SAVR (p=0.001). The mean volume per micro-infarct was 
significantly smaller in TAVI compared to SAVR (0.230.24ml vs. 
0.761.8ml, p=0.04). However, there was no difference in the mean total 
volume of new micro-infarction between TAVI (median 0.36ml, Q1-Q3 0.12–
1.93) and SAVR (median 0.24ml, Q1-Q3 0.07–1.28, p=0.48) groups. 
Patients with new micro-infarcts were categorised according to size of the 
DWI lesion: for TAVI: <5mm, n=32 (46%); >5mm, n=22 (31%); SAVR: 
<5mm, n=7 (18%); >5mm n=10 (25%). The arterial distribution of new 
cerebral infarctions post-TAVI and SAVR were similar between the groups 
(anterior 62% vs. 66%; posterior 38% vs. 34%, p=0.65). (TAVI: anterior 
cerebral artery (ACA)=17%, middle cerebral artery (MCA)=45%, posterior 
cerebral artery (PCA)=19%, vertebrobasilar artery (VB)=19%; SAVR: 
ACA=24%, MCA=42%, PCA=17%, VB= 17%). 
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Figure  3-2 DWI before and after TAVI with multiple high-intensity 
lesions seen in both hemispheres consistent with embolization 
and their subsequent resolution after 6 months. 
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6 months follow-up:  There were relatively few new micro-infarcts in both 
groups (TAVI n=2(6.3%) vs. SAVR n=2(5.8%), p=0.68). All previous DWI 
lesions had resolved in both groups, however, more TAVI patients compared 
to SAVR had evidence of gliosis (13 (40.6%) vs. 8 (23.5%) p=0.024 
respectively). Figure 3-3 shows the absolute number of cerebral micro-
infarcts across the three time points for TAVI and SAVR populations.  
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Figure  3-3 Box and whisker plots of DWI-detected cerebral infarcts 
(TAVI and SAVR) at baseline, post-procedure and at 6 months.  
(Black horizontal line is the median, boxes represent the 2nd and 3rd 
quartiles, whiskers are 1.5x interquartile range(IQR).) 
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3.4.3 Neurological assessment 
Two (2.8%) TAVI patients had early (<30d) focal and persistent neurological 
signs such that a diagnosis of minor stroke was made (NIHSS scores 2 and 
4). There was 1(2.5%) early stroke in the SAVR group (NIHSS=2). No stroke 
or TIA occurred in the 6m follow-up period in either group. 
3.4.4 Health Related Quality of Life 
HRQoL questionnaires were completed at baseline (n=111(100%); TAVI 
n=71, SAVR n=40), 30d (n=97(87%); TAVI n=59, SAVR n=38) and 6 months 
(n=96(86%); TAVI n=59, SAVR n=37).  
TAVI HRQoL: In the TAVI group, SF12v2 showed a significant improvement 
in the Physical Component Score (PCS) over the 3 time points (p<0.0001). 
PCS improved from baseline to 30d (32.1±6.6 vs. 38.9±7.0, p<0.0001) and 
6m (32.1±6.6 vs. 40.4±9.3, p<0.0001). The Mental Component Score (MCS) 
did not change from baseline after 30d (45.2±11.2 vs. 46.4±11.2, p=0.66), 
but significantly improved after 6m (baseline vs. 49.3±9.6, p=0.02). The 
component scores of Physical Functioning (PF), Bodily Pain (BP), General 
Health (GH) and Mental Health (MH) significantly increased 30d after TAVI 
(Figure 4). There was no change at 30d for Role Physical (RP), Vitality (VT), 
Social Functioning (SF) and Role Emotional (RE) (Figure 3-4). After 6m 
there was a significant improvement in all scores except for MH (Figure 3-4). 
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Figure  3-4 SF12 scores for TAVI and SAVR patients before and after 
30d and 6m.  
(Black horizontal line is the median, boxes represent the 2nd and 3rd quartiles, 
whiskers are 1.5xIQR.) P values derived from linear mixed-effects model, *p<0.05, 
**p<0.01, ***p<0.001, PF=physical function, RP=role-physical, BP=bodily pain, GH= 
general health, VT=vitality, SF=social functioning, RE=role-emotional, MH=mental 
health.) 
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The EQ5D score and visual analogue score showed a significant 
improvement over the study period (Table 3-3). There was no significant 
change in EQ5D at 30d but there was significant improvement by 6m. The 
VAS significantly improved from baseline to 30d and to 6m, without further 
significant change between the 30d and 6m time periods (Table 3-3). 
SAVR HRQoL: In the SAVR group, the PCS score of SF12v2 showed an 
improvement only after 6m (baseline, 34.4±10.6 vs. 30d, 35.9±10.2, p=0.67, 
baseline vs. 6m, 42.8±11.2 p=0.0001). There was a significant decrease in 
the MCS score at 30d (baseline, 49.7±12.0 vs. 30d, 44.6±11.5, p=0.01) after 
SAVR which returned to baseline levels at 6m (baseline vs. 6m. 51.1±9.4, 
p=0.54. At 30d post-SAVR, there was no improvement in any of the 
component scores, whilst there was a significant reduction in social 
functioning (baseline, 44.4±12.9 vs. 30d, 35.4±11.3, p=0.001) (Figure 3-4). 
Nevertheless, at 6m there were significant improvements in all component 
scores compared to baseline values (Figure 3-4). 
The EQ5D and visual analogue scores (VAS) showed a significant 
difference over the 3 time points (Table 3-3). There was no significant 
difference for the EQ5D score between baseline and either 30d or 6m; there 
was however a significant improvement between 30d and 6m. From 
baseline, the VAS did not change at 30d, but had significantly improved by 
6m (Table 3-3). 
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Table  3-3 EQ5D and VAS scores over 3 time points and US population 
Norms 
 US Norms* Baseline 30 days 6 months  p value 
TAVI  (n=71) (n=59) (n=59)  
EQ5D 0.66±0.2 0.63±0.22 0.71±0.25 0.74±0.2† 0.001 
VAS 53±7 54.7±15.6 66.1±17.7† 68.1±16.6† 0.0001 
SAVR  (n=40) (n=38) (n=38)  
EQ5D 0.66±0.2 0.69±0.23 0.66±0.25 0.79±0.22 0.002 
VAS 53±7 60.1±18.9 67.1±16.2 76.6±17.1‡ <0.00001 
*US norms are reported for a US population stratified according to age (80 to 
89 years). †p<0.001, ‡p<0.0001, p values are reported for a change in 
health for each time point compared with baseline by using linear mixed-
effects model with Bonferroni post hoc correction. VAS=visual analogue 
scale. 
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Comparison of TAVI and SAVR HRQoL Scores 
Figure 3-5 shows the differences in SF-12v2 scores from baseline to 30d 
and baseline to 6m for TAVI and SAVR. At 30d, mean TAVI scores have 
improved across all components whilst SAVR score have generally declined; 
PF and GH did improve but the change was significantly less than in TAVI 
(Figure 3-5A). At 6m there was a positive improvement in all component 
scores and there was no statistically significant difference between TAVI and 
SAVR (Figure 3-5B). The improvement in PCS score at 30d was significantly 
greater for TAVI than SAVR, whilst there was a significant reduction of MCS 
score in SAVR compared to TAVI (Figure 3-5C). At 6m there was no 
statistical difference between TAVI and SAVR (Figure 3-5D). The EQ5D and 
VAS scores increased over the three time points but there were no 
statistically significant differences between TAVI and SAVR.  
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Figure  3-5 Comparison between TAVI and SAVR SF12 questionnaires. 
 A) Difference in component score between baseline and 30d.  B) Difference 
in component score between baseline and 6m. C) Difference in summary 
scores between baseline and 30d. D) Difference in summary scores 
between baseline and 6m. (Line bars represent Standard error (SE), Paired 
t-test *p<0.05, **p<0.01, ***p<0.001, Abbreviations as in Figure 4 
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3.4.5 Influence of cerebral emboli on HRQoL scores 
The patients that had cerebral MRI and HRQoL assessment were placed 
into 3 categories: no new infarct, infarcts <5mm or infarcts >5mm (Table 3-
4A&B). In the TAVI group, there were no differences in the SF12v2 PCS, 
MCS or component scores according to the presence or size of new cerebral 
micro-infarction (Table 3-4A). However in the SAVR group, PCS and the 
component scores for physical function and bodily pain were significantly 
lower at 30d in those with smaller (<5mm) infarctions, although these scores 
had returned to baseline after 6m (Table 3-4B).   
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Table  3-4 AB SF12 scores at 30 days and 6 months according to the 
size of infarctions detected by Cerebral DWI after TAVI and SAVR 
TAVI  
(n=59) 
Time-point No infarction 
(n=13) 
<5mm 
(n=28) 
>5mm 
(n=18) 
 
p value 
PF 30d 37.2±10.7 36.0±9.6 37.7±7.6 0.81 
 6m 41.9±9.9 38.9±10.9 38.8±9.5 0.74 
RP 30d 38.8±12.9 35.6±7.9 39.9±10.1 0.30 
 6m 45.5±10.6 40.7±6.9 41.4±8.1 0.35 
BP 30d 43.7±14.2 48.1±9.5 45.8±12.6 0.54 
 6m 45.4±12.4 46.7±12.3 46.4±10.6 0.96 
GH 30d 44.7±7.2 40.7±10.9 45.4±10.3 0.26 
 6m 45.9±9.9 42.3±10.7 43.2±12.9 0.75 
VT 30d 42.0±11.7 41.0±11.2 45.1±11.2 0.48 
 6m 44.4±11.5 43.6±10.4 44.6±8.6 0.95 
SF 30d 37.3±16.3 40.7±11.9 45.0±11.2 0.27 
 6m 43.4±15.0 46.4±10.1 47.6±11.6 0.68 
RE 30d 37.5±17.8 41.7±13.1 44.0±12.9 0.51 
 6m 45.3±10.9 45.3±10.3 45.6±12.2 0.99 
MH 30d 44.6±17.2 47.9±9.3 50.6±9.9 0.39 
 6m 51.6±11.0 48.2±10.7 48.9±7.6 0.69 
PCS 30d 40.8±9.8 37.9±7.7 39.6±6.3 0.58 
 6m 42.9±9.5 40.2±9.5 39.9±9.8 0.74 
MCS 30d 41.7±18.7 46.1±10.2 49.5±10.8 0.27 
 6m 48.6±10.2 48.7±9.1 50.0±9.0 0.89 
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Table 4B 
SAVR 
(n=38) 
Time-point No infarct 
(n=20) 
<5mm 
(n=8) 
>5mm 
(n=10) 
  
p value 
PF 30d 39.1±12.1 26.2±8.9* 37.5±10.1 0.01 
 6m 41.613.1 43.99.2 47.013.4 0.42 
RP 30d 37.5±9.4 30.2±8.0 34.7±6.1 0.10 
 6m 43.710.0 42.112.1 46.812.7 0.56 
BP 30d 43.9±10.2 31.2±12.6* 44.8±8.2† 0.01 
 6m 48.010.6 41.515.3 47.914.7 0.41 
GH 30d 40.3±12.0 41.5±13.0 40.4±11.2 0.95 
 6m 45.611.1 42.011.6 46.29.9 0.67 
VT 30d 43.9±11.6 39.3±15.7 37.2±6.5 0.31 
 6m 49.97.5 46.811.3 50.513.9 0.65 
SF 30d 37.9±11.9 36.9±12.9 29.0±6.1 0.10 
 6m 48.211.1 48.413.2 43.817.4 0.61 
RE 30d 42.9±13.0 40.8±16.9 38.9±11.3 0.80 
 6m 47.811.0 46.412.6 45.310.8 0.70 
MH 30d 48.5±12.8 46.3±13.8 43.2±6.9 0.52 
 6m 52.011.6 54.711.1 49.99.7 0.69 
PCS 30d 38.2±10.5 27.3±8.9* 38.7±7.5 0.01 
 6m 42.510.6 39.511.1 47.013.2 0.45 
MCS 30d 46.4±10.8 48.0±14.6 38.7±8.8 0.25 
 6m 52.58.7 52.911.1 47.711.1 0.45 
Scores are mean±SD. *=p <0.05 for the change in scores at each time point 
compared to no infarction using linear mixed-effects model with Bonferroni 
post hoc correction. †= p <0.05 when comparing between large and small 
infarcts. PF=physical function, RP=role physical, BP=bodily pain, GH= 
general health, VT=vitality, SF=social functioning, RE=role emotional, 
MH=mental health, PCS=Physical component score, MCS=Mental 
component score. 
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Overall, there was no difference in EQ5D scores according to the presence 
or size of new cerebral micro-infarction (Table 3-5). The VAS was 
significantly decreased in the TAVI group with>5mm) infarcts at 30d (but 
returned to baseline value by 6m). 
Table  3-5 EQ5D scores at 30 days and 6 months according to the size 
of infarctions detected by Cerebral DWI after TAVI and SAVR 
 Time 
point 
No infarct < 5mm >5mm  p value 
TAVI  (n=10) (n=28) (n=18)  
EQ5D 30d 0.750.31 0.680.27 0.690.29 0.60 
 6m 0.800.19 0.760.15 0.690.27 0.29 
VAS 30d 74.017.4 65.617.4 51.816.5* 0.001 
 6m 73.314.6 67.417.4 62.316.0 0.20 
SAVR  (n=20) (n=8) (n=9)  
EQ5D 30d 0.670.28 0.670.17 0.610.25 0.90 
 6m 0.830.15 0.700.29 0.820.27 0.40 
VAS 30d 70.816.4 64.119.3 61.913.5 0.40 
 6m 79.413.9 72.816.1 77.016.7 0.70 
Scores are meanSD. *=p <0.05 for the difference in scores for each group 
compared to no infarction using linear mixed-effects model with Bonferroni 
post hoc correction. 
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3.4.6 TAVI patients without 6 month cerebral imaging 
Of the 70 TAVI patients that had a post procedure head scan only 32 had 
the 6 month follow-up scan. Excluding the 5 deaths, this left 33 patients that 
did not have a follow-up scan. To look for any potential bias due to this, the 
early DWI findings and HRQoL scores were compared to those that were 
scanned (follow-up scan vs. no follow-up scan). There was no difference in 
the number of infarcts or volumes (new infarcts 3.773.4 vs. 5.076.6, 
p=0.37; infarct volumes 0.760.8mls vs. 1.753.3mls, p=0.31). There were 
no differences in HRQoL summary scores at baseline (PCS 34.16.2 vs. 
31.06.5, p=0.11; MCS 45.010.9 vs. 45.911.4, p=0.8) or 30 d. (PCS 
41.45.5 vs. 36.58.5, p=0.08; MCS 45.913.2 vs. 47.59.0, p=0.66). 
3.4.7 Associated factors for new cerebral micro-infarction 
Univariate analysis for factors associated with new cerebral micro-infarction 
are summarised in Table 3-6. In the TAVI group, atheroma in the arch and 
descending thoracic aorta and fluoroscopic time were the significant 
univariate factors associated with new cerebral infarction (Table 3-6). In the 
multivariable analysis (including the univariate predictors (p≤0.1)), the only 
significant independent predictor was aortic arch atheroma grade (B=2.33, 
t=3.06, p=0.004)(r=0.46, p=0.0001). In the SAVR group, there were no 
baseline or procedural variables from univariate analysis that significantly 
predicted new cerebral infarction (Table 3-6). Multivariable analysis of 
univariate factors (p≤0.1) showed that concomitant CABG at the time of 
SAVR was the only statistically significant predictor of cerebral infarction 
(B=-1.67, t=2.16, p=0.04)(r=-0.33, p= 0.03).  
Propensity score adjustment for number of new cerebral infarcts showed 
that despite adjusting for potential confounders, TAVI was still significantly 
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associated with new cerebral infarction (unstandardized coefficient 
BSE=2.260.85, standardised β=0.25, p=0.009).  
- 94 - 
Table  3-6 Univariate regression analysis for the prediction of the 
number of new cerebral infarcts 
Variables TAVI  SAVR  
 R p value R p value 
Age 0.17 0.18 0.15 0.36 
EuroSCORE 0.10 0.44 0.06 0.70 
EuroSCORE II 0.24 0.05 0.13 0.42 
STS score 0.004 0.97 0.16 0.35 
BSA 0.02 0.88 0.20 0.24 
BMI 0.02 0.85 0.01 0.95 
NYHA class 0.12 0.34 0.002 0.79 
Hypertension 0.15 0.24 0.002 0.99 
Diabetes 0.13 0.30 0.12 0.48 
Hyperlipidaemia 0.21 0.09 0.10 0.54 
Atrial Fibrillation 0.07 0.57 0.12 0.94 
Previous MI 0.04 0.77 0.10 0.57 
CABG 0.07 0.59 0.08 0.64 
Previous PCI 0.05 0.72 0.11 0.51 
PVD 0.15 0.21 0.18 0.29 
TIA/Stroke 0.16 0.21 0.04 0.84 
Creatinine 0.10 0.44 0.12 0.46 
eGFR 0.07 0.55 0.12 0.47 
COPD 0.01 0.91 0.24 0.14 
Porcelain aorta 0.14 0.26   
Aortic Atheroma 
         Ascending 
         Arch 
          Descending 
 
0.18 
0.46 
0.37 
 
0.14 
0.0001 
0.002 
 
0.14 
0.18 
0.18 
 
0.40 
0.39 
0.30 
Valve Calcification 0.11 0.40 0.08 0.65 
TAVI approach 0.10 0.40   
BAV size 0.29 0.06   
CoreValve size 0.22 0.07   
Procedural-time 0.12 0.40   
Fluoroscopy-time 0.30 0.02   
Contrast volume 0.06 0.97   
Bypass-time   0.28 0.10 
Cross-clamp-time   0.32 0.07 
Valve size   0.02 0.89 
CABG performed   0.34 0.07 
Valve type   0.21 0.20 
TAVI=Transcatheter Aortic Valve Implantation, SAVR=Surgical Aortic Valve Replacement, 
BSA=body surface area, BMI=body mass index, NYHA=New York Heart Association, 
STS=Society of Thoracic Surgery, TIA=transient ischaemic attack, MI=myocardial infarction, 
CABG=coronary artery bypass grafting, PVD=peripheral vascular disease, COPD=chronic 
obstructive pulmonary disease, BAV=balloon aortic valvuloplasty, eGFR=estimated 
glomerular filtration rate. 
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3.5 DISCUSSION 
This relatively large prospective study provides evidence that compared to 
SAVR, TAVI results in a higher burden of post-procedural cerebral micro-
infarcts. Aortic atheroma and concomitant CABG were independent 
predictors of cerebral infarction for TAVI and SAVR respectively. New micro-
infarcts had no effect upon the TAVI patients’ short or medium term mental 
and physical quality of life. After SAVR, patients with micro-infarcts had an 
initial decline in physical health which recovered by 6 months. A major 
limitation is the significant differences between the baseline characteristics 
of the two cohorts. Unfortunately this is a significant limitation of early TAVI 
research as these patients are too high risk for surgery. 
The size of the TAVI micro infarcts were smaller than the SAVR micro 
infarcts mainly related to the mechanism that cause them. The total volumes 
were not different which is an interesting finding. This suggests the TAVI 
patients have a broader spread of small cerebral micro-infarcts where the 
SAVR group have larger localised cerebral infarcts. 
 
Previous studies, including our own have shown high rates (77-84%) of 
cerebral micro-infarction post-TAVI (Kahlert et al., 2010, Fairbairn et al., 
2012b). The mechanism of infarction is believed to be embolic in nature. 
Transcranial Doppler studies have shown an increase in high intensity 
transient signals (HITS) during valve alignment and deployment suggesting 
the main source of embolic material may be atheroma, calcification or even 
air embolus (Kahlert et al., 2012). We have previously shown a relationship 
between aortic atheroma and the number of peri-procedural infarcts, 
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postulating a mechanism of embolization as bulky catheters are manipulated 
around the aortic arch (Fairbairn et al., 2012b). Two studies have 
subsequently shown that the trans-femoral and trans-apical approaches 
have similar rates of embolization (Kahlert et al., 2012, Rodes-Cabau et al., 
2011). This finding does not contradict the risk associated with aortic 
atheroma as with both access techniques cardiac catheters and wires are 
passed around the aortic arch. In comparison to SAVR group, the embolism 
is more likely related to be due to thrombotic clot, perhaps even related to 
paroxysmal AF. 
Identifying risk factors for cerebral emboli is important as this may influence 
patient selection and the use of cerebral protection devices (Nietlispach et 
al., 2010). We assessed a variety of risk factors including baseline 
demographics, co-morbidity and procedural factors. Aortic atheroma, 
valvuloplasty balloon size and fluoroscopy time were key factors that 
influenced the likelihood of TAVI cerebral embolization. Aortic atheroma was 
an independent predictor of cerebral emboli. This further validates our 
previous findings and to date remains the only patient-specific risk factor 
identified for cerebral emboli (Fairbairn et al., 2012a). The use of larger 
valvuloplasty balloons could result in greater trauma to the aortic atheroma 
and hence create a substrate for embolism. Similarly, fluoroscopic time can 
be considered a surrogate marker for procedural complexity and device 
manipulation against the aortic wall. Nombela-Franco et al reported balloon 
post-dilatation to predict higher acute cerebrovascular events, whereas later 
events were best predicted from conventional risks such as new onset AF, 
PVD and cerebrovascular disease (Nombela-Franco et al., 2012).  
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SAVR is believed to result in cerebral embolization secondary to cannulation 
of the aorta and stimulation of a systemic inflammatory response induced by 
cardio-pulmonary bypass (Pugsley et al., 1994). Our results show that 
duration of cross-clamping time and concomitant CABG are associated with 
a higher rate of cerebral micro-infarction consistent with this theory. 
Differences in procedural event rates could represent the greater age and 
risk factor profile of TAVI compared to SAVR patients, as there has not been 
a study of matched patients to date. However, following propensity 
correction our data suggests the TAVI procedure is still an independent risk 
factor for cerebral emboli.  
The clinical impact of cerebral embolism is of significant concern to patients 
and physicians. TAVI has a greater risk of early stroke and TIA compared to 
surgery (Smith et al., 2011a), but by two years there appears to be no 
difference (Kodali et al., 2012b). However, silent cerebral infarcts have been 
shown to adversely affect patient memory, cognition and be associated with 
dementia (Blum et al., 2012, Arvanitakis et al., 2011). Quality of life is an 
important clinical outcome measure and is one of the main reasons that 
TAVI is conducted (Ussia et al., 2009). As such, anything negatively 
impacting upon HRQoL, such as silent cerebral emboli, would be of concern. 
This study has shown that for both TAVI and SAVR new cerebral emboli did 
not detrimentally affect patient-reported HRQoL at 6 months. Interesting 
differences occur between the two procedures from baseline to 30 days, with 
a decline in physical health in the surgical group. This appeared to be in part 
related to individuals who had developed cerebral emboli but is also likely to 
reflect the impact that major surgery (sternotomy, bypass, Intensive Care 
Unit) has upon the early physical condition of the patient thus affecting social 
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functioning. HRQoL is a global measure of health status and an important 
clinical outcome measure but is not a test of higher cognitive function; further 
research is required to identify any subtle effects that silent cerebral micro-
embolization may have on neuropsychological function following TAVI or 
SAVR. Indeed, silent cerebral infarction has been associated with global 
memory loss (Blum et al., 2012) and post-operative neurocognitive 
dysfunction following coronary artery bypass grafting(Zamvar et al., 2002) 
and cardiac procedures such as AF ablation (Medi et al., 2013). For the 
TAVI procedure, any impact on neurocognitive function will be important to 
determine if it is to be considered in lower risk and younger patients. 
Neurocognitive tests are also very specific to an area of the brain and focus 
on a particular set of functions, such as executive function and verbal 
fluency and therefore may be able to show more subtle difference that 
HRQoL may not be sensitive enough to pick up. 
3.5.1 Limitations 
Due to current TAVI implantation criteria, the groups could not be fully 
matched for age, co-morbidity or risk factor scores; our findings may be 
negatively biased against the higher risk TAVI group. Whilst the sample size 
may appear small, we had adequate power to detect measurable differences 
in health related QoL scores. Propensity matching would result in a 
significant reduction in number in each group and is ideally performed in 
larger studies with more than 1000 patients in each group. There were a 
number of TAVI patients who could not have follow up scans due to frailty or 
pacemaker insertion, which may further introduce bias. The use of MR 
compatible pacemakers would have increase the post cerebral MRI patient 
numbers. We did not assess frailty pre- and post-procedure as the study 
- 99 - 
protocol was already considered arduous for this patient group. The cerebral 
MRI scans were performed at 1.5T which reliably detects DWI infarcts, but 
higher field strengths (3.0T) may have greater sensitivity. (Medi et al., 2013)  
However, at the time of our study the CoreValve prosthesis was not 
approved for 3.0T field strength and on-going clinical trials of cerebral 
embolic protection devices are at the 1.5T field strength. The study does not 
explain the full significance of cerebral embolization on patient outcome, in 
particular the impact on neurocognitive function, and our intention is to follow 
up this work with dedicated neuropsychological testing. Finally, our study 
used CoreValve in isolation and the findings and outcomes may be different 
with other valve prostheses. 
 
3.6 CONCLUSION 
Post-procedural cerebral micro-embolic events occur more frequently after 
TAVI compared to SAVR. Aortic atheroma is the main predictor of cerebral 
emboli post-TAVI but not post-SAVR, where concomitant CABG remains the 
dominant risk factor. New cerebral micro-embolization is associated with 
reduced physical health 30 days post-SAVR, but had no detrimental effect 
on health following either procedure (TAVI or SAVR) in the medium-term (6 
months). Overall conclusions may be confounded by the marked differences 
in the baseline characteristics of the two groups. Future randomised studies 
in similar risk groups may be able to delineate in a more robust fashion. 
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4  Impact of Transcatheter Aortic Valve Implantation 
and Surgical Aortic Valve Replacement on 
neurocognitive function following the treatment of 
severe aortic stenosis 
 
4.1 ABSTRACT 
Importance: Transcatheter aortic valve implantation (TAVI) for severe aortic 
stenosis (AS) is associated with clinically silent cerebral micro-infarction. The 
medium-term consequences on neurocognitive function (NCF) are unknown. 
Objective: To assess serial change in NCF following TAVI and 
contemporary surgical aortic valve replacement (SAVR) over 12 months. 
Design: A longitudinal assessment of NCF using a two-factor mixed design, 
with treatment type as a between-subjects factor (TAVI vs. SAVR) and time 
as a within-subject factor (baseline, 30 days, 6 months and 12 months) 
Setting: Two tertiary cardiac centres in the UK. 
Participants: Ninety patients with severe AS undergoing either TAVI (n=50, 
28 males, 817 years or SAVR (n=40, 30 males, 737 years). 
Interventions: TAVI or SAVR as deemed appropriate by the 
multidisciplinary heart team.  
Main outcomes and measures: NCF assessments were conducted over 4 
time points. NCF test scores were categorised as ‘impaired’, ‘average or 
above average’ compared to published age-matched norms. Cerebral MRI 
with diffusion weighted imaging (DWI) was performed at baseline and post-
procedure. 
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Results: The incidence of cerebral micro-infarction was higher after TAVI 
compared to SAVR (30(68%) vs. 13(43%), p=0.04). TAVI patients had lower 
baseline NCF test scores compared to SAVR. At 12 months, the majority of 
NCF tests did not show a significant change in the proportion of patients 
categorised as having impaired NCF compared to baseline in the TAVI or 
SAVR groups, except for the Hopkins Verbal Learning test which showed a 
significant reduction (TAVI 32(64%) vs. 5(14%), p=0.046; SAVR 17(43%) vs. 
6(18%) p=0.019). For both TAVI and SAVR, the proportion of patients with 
impaired NCF (by any test at 30 days, 6- or 12 months) did not significantly 
change according to the presence of DWI lesions (all p>0.50) 
Conclusions: There was no evidence of short to medium-term cognitive 
decline following TAVI or SAVR. Although silent cerebral micro-infarcts were 
more common following TAVI than SAVR, they did not impact on 
neurocognitive performance.  
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4.2 INTRODUCTION 
The management of severe symptomatic aortic stenosis has changed 
dramatically with the advent of transcatheter aortic valve implantation 
(TAVI), particularly in those patients at high surgical risk, resulting in 
improved quality of life (Fairbairn et al., 2012b). Randomised controlled trials 
have shown significant survival and symptomatic benefit when compared to 
medical management, and non-inferiority to surgical valve replacement 
(Smith et al., 2011b, Makkar et al., 2012b, Adams et al., 2014). With 
improved TAVI device technology and greater operator experience there has 
been improved complication rates with a recent meta-analysis showing 
similar overall complication rates to surgical aortic valve replacement 
(SAVR) (Jilaihawi et al., 2012). However, significant concern exists relating 
to the higher incidence of stroke and silent cerebral infarction early following 
TAVI compared to SAVR (Nombela-Franco et al., 2012).  
Cerebral embolisation during device manipulation and delivery is an inherent 
risk with TAVI and several studies have confirmed a high incidence of 
cerebral infarction using diffusion-weighted magnetic resonance imaging 
(DW-MRI) (Ghanem et al., 2010a, Fairbairn et al., 2012a). The vast majority 
of these cerebral infarcts are small, producing no focal neurological signs, 
and hence are labelled as silent infarcts. The short, mid and long-term 
consequences of silent cerebral infarction following TAVI and SAVR are 
unknown, as conventional clinical and mental state examinations may not 
detect subtle neuro-functional disturbances. The concept of post-operative 
cognitive dysfunction (POCD) has been linked to early dementia (Newman 
et al., 2001) and has been reported after coronary artery bypass grafting 
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(CABG), carotid stenting and trans-septal AF ablation (Zamvar et al., 2002, 
Huang et al., 2013, Medi et al., 2013).  
In chapter 3, we showed that health related quality of life (HRQoL) improved 
in both TAVI and SAVR groups but there was no direct influence of cerebral 
micro-infarction on HRQoL scores. Perhaps as they are generic instruments 
they may not detect subtle defects. Hence neurocognitive assessment uses 
tests specifically designed to assess cognitive function. Therefore we may 
be able to link cerebral infarcts on DWI to neurocognitive function.  
Neurocognitive tests have been extensively studied, especially in traumatic 
brain injury and stroke and use reliable and validated tools.  
As the current TAVI clinical trials seek to broaden the procedural indications 
to younger, lower-risk patient groups, it will be important to understand the 
natural history of neurocognitive function (NCF) following TAVI compared to 
SAVR and whether patient or procedural factors have an impact on 
neurocognitive outcomes. The aims of this study were to 1) perform 
comprehensive, serial, neurocognitive assessments of TAVI and 
contemporary SAVR patients over a twelve month time period and identify 
evidence of short to medium term neurocognitive dysfunction; 2) relate the 
occurrence and extent of new silent cerebral infarction by DW-MRI after 
TAVI and SAVR to NCF.   
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4.3 METHODS 
4.3.1 Patient selection 
Patients with severe symptomatic aortic stenosis were prospectively 
recruited from two large UK tertiary cardiothoracic centres (Leeds and 
Leicester) with established high-volume TAVI programmes. All patients were 
assessed by the multi-disciplinary Heart team and considered suitable for 
TAVI or SAVR based on contemporary international guidelines. Older, 
higher-risk (higher EuroSCORE) SAVR patients were preferentially recruited 
wherever possible, in an attempt to have baseline demographics more 
comparable to the TAVI group. Inclusion criteria were patients with severe 
aortic stenosis as defined by echocardiography (mean gradient >40mmHg, 
peak velocity >4m/s, valve area<1cm2). Exclusion criteria included any 
contraindication to MRI or pre-existing severe cognitive impairment (MMSE 
score<10). The study was approved by the institutional ethics committee 
(08/H1307/106), complied with the Declaration of Helsinki and all patients 
provided written informed consent. 
 
4.3.2 Transcatheter Aortic Valve Implantation 
In each centre, TAVI was performed by a single experienced (>5years) 
operator with either an 18F CoreValve Revalving system (CVR, Medtronic, 
Minneapolis, Minnesota, USA) or Edwards Sapien prosthesis (Edwards 
Lifesciences Corp. Irvine, California, USA) via the femoral or subclavian 
artery under general anaesthesia with X-ray fluoroscopy and 
transoesophageal echocardiographic guidance. All patients received weight-
adjusted unfractionated heparin to maintain an activated clotting time >200s 
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and were treated with dual antiplatelet therapy (aspirin 75mg and clopidogrel 
75mg) for a minimum of 6 months. 
 
4.3.3 Surgical Aortic Valve Replacement  
SAVR was performed by standard midline sternotomy with cardiopulmonary 
bypass and mild hypothermia. Biological or mechanical prostheses of 
varying sizes were used according to surgical preference; concomitant 
coronary artery bypass grafting was performed as indicated.  
 
4.3.4 Neurological assessment and status 
A detailed neurological examination was conducted prior to intervention and 
daily after the procedure by an experienced consultant physician until 
hospital discharge. A National Institutes of Health Stroke Scale (NIHSS) 
score was recorded. Transient ischaemic attack was defined as any focal 
neurological deficit that lasted <24h. Stroke was defined as any persistent 
focal neurological deficit lasting >24h. 
 
4.3.5 Neurocognitive assessment  
The neurocognitive test battery was performed by trained assessors in a 
quiet comfortable environment at Valve Academic Research Consortium 
(VARC) recommended time points (baseline, 30 days, 6 month, 12 months). 
Training of assessors and performance validation was undertaken by an 
experienced neuropsychologist. Follow-up assessment was conducted at 
the patient home or the hospital. Total assessment time ranged between 60-
90min with appropriate rest periods. Baseline characteristics, hospital 
anxiety and depression scale (HADS), handedness and years of education 
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were recorded. The national adult reading test NART was used to calculate 
the full scale intelligent quotient (FSIQ=123.2-(1.029 x NART error score)). A 
broad battery of previously validated neurocognitive assessments were 
performed in all individuals at all time points,(Hachinski et al., 2006) and 
included: Global function: mini mental state examination (MMSE), Mnemonic 
function: Hopkins Verbal Learning Tests (HVLT), Rey-Osterrieth Complex 
Figure (ROCF), Executive function: Controlled Oral Word Association Test 
(COWAT), Letter Number Sequencing (LNS), Trail-making A and B tests; 
and psychomotor function test: Grooved Pegboard Test (Model 32025, 
Lafayette Instruments Co, IN, USA), Digit-Symbol Substitution Test (DSST). 
Scores were compared with age-matched published norms and grouped 
according to impaired, average or above average function. Cognitive decline 
was defined as a reduction of the score by 1 SD of the baseline score for all 
NCF tests (Knipp et al., 2013, Ghanem et al., 2013, Zamvar et al., 2002). 
 
4.3.6 Cerebral MRI 
Cerebral MRI was conducted pre- and post-procedure (within 7d) using 
identical imaging protocols. MRI was performed on the same 1.5T system 
for all serial scans for any individual patient (Intera, Phillips Healthcare, The 
Netherlands or Avanto, Siemens Medical Systems, Germany). The imaging 
protocol consisted of T2 weighted fast field echo, T2 turbo field echo and 
diffusion weighted imaging (DWI) (22 slices, 5mm thick, 1mm gap, FOV 350, 
RFOV 100). Each scan was independently assessed by two experienced 
Neuroradiologists, blinded to all clinical/procedural details. In the case of 
disagreement, a third blinded Neuroradiologist was consulted and a 
consensus view was recorded. Cerebral embolism or micro-infarction was 
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defined as a new restricted diffusion lesion on DWI. New cerebral micro-
infarcts were localised to hemisphere and vascular territory. Infarct diameter 
was used to categorise patients into small or large lesion sub-groups (<5mm 
or >5mm; in the case of multiple lesions the largest lesion was used to 
determine status). The total infarct volume (ml) was measured off-line using 
standard post-processing software (QMass7.2, Medis, The Netherlands) as 
previously published (Fairbairn et al., 2012a, Uddin et al., 2015). 
4.3.7 Statistical Analysis  
Data were tested for normality using the Shapiro-Wilks test. Continuous 
variables were expressed as meanSD or median (Q2-Q3 or interquartile 
range (IQR)) and discrete variables as n (%). The changes in test scores 
(baseline, 30d, 6m and 12m) were assessed using the linear mixed-effects 
model with an unstructured covariance matrix. Groups (TAVI or SAVR) and 
time-points were entered as the fixed effect and interactions between group 
x time-points were measured. Bonferroni post-hoc correction was used for 
multiple comparisons. This method was used instead of repeated measures 
ANOVA to overcome potential effects of missing data and need for a 
balanced design (West, 2009). Fishers exact test or Chi squared test was 
used for discrete variables. Univariate logistic regression was performed to 
look for predictors of cognitive impairment (average or above-average=0, 
impaired=1) at baseline and after the respective procedures. Factors with 
p<0.1 were entered into a multivariate logistic regression analysis in a 
stepwise method. Odds ratios with 95% confidence intervals were recorded. 
Sample size to detect cognitive decline (reduction in score by 1SD) was 
estimated using IBM SPSS Samplepower version 3, and using normative 
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data for the test to have 80% power (alpha 0.05), a minimum of 17 patients 
were required in each group (TAVI/SAVR). 
 
4.4 RESULTS 
4.4.1 Patient Characteristics 
A total of 90 patients with severe aortic stenosis were studied (Figure 4-1, 
Table 4-1). The TAVI group were older with higher surgical risk scores and 
there was a higher prevalence of prior CABG, PCI, PVD and COPD (Table 
4-1). The echocardiographic parameters were similar except for a smaller 
valve area and higher prevalence of left ventricular systolic dysfunction in 
the TAVI group (Table 4-1). Overall 70 (78%) of the participants completed 
the full study protocol. During the study period, 4 deaths occurred in the 
TAVI group and one in the SAVR group. There are clear and significant 
differences in the study groups given the differences in co-morbidity, which 
may confound any findings. This is an expected limitation.  
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Figure  4-1 Study flow chart  
(AS=aortic stenosis, MR=magnetic resonance, NCF=neurocognitive 
function, PPM=permanent pacemaker, SAVR=surgical aortic valve 
replacement, TAVI=transcatheter aortic valve implantation) 
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Table  4-1 Baseline patient characteristics 
 
Data are Mean±SD or n (%). BMI=body mass index, NYHA=New York Heart Association, 
STS=Society of Thoracic Surgery, TIA=transient ischaemic attack, MI=myocardial infarction, 
CABG=coronary artery bypass grafting, PVD=peripheral vascular disease, COPD=chronic 
obstructive pulmonary disease, eGFR=estimated glomerular filtration rate, AV=aortic valve. 
LVEF=left ventricular ejection fraction. *Mann Whitney test. 
Demographics and clinical 
characteristics 
TAVI (n=50) SAVR (n=40) p value 
Age, years 81.1±7.0 72.57.2 <0.0001 
Male, n (%) 28 (56) 30 (75) 0.07 
BMI, kgm
-2
 27.65.6 27.94.7 0.96 
NYHA Class, n (%) 
     I 
     II 
     III 
     IV 
 
0 
5 (10) 
38 (76) 
7 (14) 
 
2 (5) 
15 (37) 
23 (58) 
0 
0.0003* 
 
EuroSCORE, (%) 20.610.1 6.87.9 <0.0001 
EuroSCORE II, (%) 5.53.4 1.50.9 <0.0001 
STS Score, (%) 5.43.1 2.10.8 <0.0001 
STS Morbidity, (%) 23.86.6 15.44.4 <0.0001 
Hypertension, n (%) 31 (62) 25 (63) 0.42 
Diabetes, n (%) 11 (22) 6 (15) 0.61 
Hypercholesterolaemia, n (%) 26 (52) 27 (68) 0.21 
Atrial fibrillation, n (%) 12 (24) 4 (10) 0.10 
Stroke/TIA, n (%) 10 (20) 7 (18) 0.80 
MI, n (%) 7 (14) 6 (15) 0.88 
CABG, n (%) 13 (26) 0 0.0001 
PCI, n (%) 13 (26) 2 (5) 0.009 
PVD, n (%) 8 (16) 2 (5) 0.002 
COPD, n (%) 12 (24) 2 (5) 0.02 
Pulmonary Hypertension n (%) 13 (26) 5 (13) 0.18 
eGFR, ml/min/1.73m
2
 6517 7211 0.05 
 
Echocardiographic data: 
   
Peak AV velocity, ms
-1
 4.50.7 4.40.8 0.54 
Mean AV gradient, mmHg 4816 4717 0.49 
Aortic valve area, cm
2
 0.60.2 0.80.4 0.01 
LVEF, n (%) 
     Normal 
     Mild 
     Moderate 
     Severe 
 
9 (18) 
29 (58) 
5 (10) 
7 (14) 
 
20 (50) 
18 (44) 
1 (3) 
1(3) 
0.004* 
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4.4.2 Procedural characteristics 
TAVI procedural success was 100%, with Transfemoral access being the 
predominant route. The majority of SAVR patients received a biological 
valve replacement and 38% had concurrent CABG (Table 4-2). 
Table  4-2 Procedural and operative data 
  n (%) 
TAVI (n=50)   
Medtronic CoreValve, n=46 31mm 8 (16) 
 29mm 26 (52) 
 26mm 9 (18) 
 23mm 3 (6) 
Edwards Sapien, n=4 29mm 2 (4) 
 26mm 2 (4) 
Access route Femoral 42 (88) 
 Subclavian 7 (10) 
 Carotid 1 (2) 
Procedure time, (min)  14783 
Fluoroscopy time, (min)  2412 
Contrast volume, (ml)  14476 
 
SAVR (n=40) 
  
Biological, n (%)  34 (85) 
Mechanical, n (%)  6 (15) 
Size, (mm) (median, Q1-Q3)  23 (21–24) 
Bypass time, (min)  
 
All  
AVR only 
AVR and CABG 
12466 
10754 
15275 
Cross clamp time, (min)  All  
AVR only 
AVR and CABG 
9256 
8351 
10761 
CABG, n (%)  15 (38) 
Data are Mean±SD or n (%).   
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4.4.3 Baseline education and Intelligence 
The majority of patients were right handed (TAVI: 47(94%) vs. SAVR: 
38(95%))  The TAVI group had fewer years in education compared to SAVR 
group ( 10.51.5 vs.  12.23.0yrs, p=0.003), but nevertheless were similar in 
full scale IQ ( 10612 vs. 10910, respectively p=0.27). 
4.4.4 Effect of treatment on absolute neurocognitive function 
scores  
Global function (MMSE): The MMSE at baseline was statistically significantly 
lower for TAVI than SAVR ( p=0.0004), but did not change after intervention 
at 30 days, 6 months and 12m (Table 4-3). 
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Table  4-3 Summary of neurocognitive test scores at baseline, 30d, 6m, 
12m 
 
MMSE=mini mental state exam, HVLT=Hopkins Verbal Learning test, ROCF=Rey-
Osterrieth complex figure test, LNS=Letter-number sequencing, COWAT=controlled oral 
word association test, DSST=Digit-symbol substitution test, HADS=Hospital Anxiety 
Depression Scale. *p<0.05, **p<0.01 vs. baseline score by Bonferroni correction; †p<0.05, 
††p<0.01 vs. SAVR score. ‡ p<0.05 for group effect from mixed-effect model. § p values 
from mixed-effect model for effect of time. ¶p<0.05 vs. 30d 
 Group Baseline 
(mean±SD
) 
30 d 
(mean±SD) 
6 m 
(mean±SD) 
12 m 
(meanSD) 
  
p value§ 
MMSE TAVI‡ 28.4±2.2†† 28.3±2.3†† 28.4±2.2†† 27.92.6†† 0.44 
 SAVR 29.6±0.8 29.2±1.1 29.3±1.1 29.50.9 0.41 
       
LNS TAVI‡ 7.64.1 7.54.1 8.24.4 7.94.2† 0.70 
 SAVR 8.53.1 8.64.0 9.53.7 10.43.6* 0.01 
       
DSST TAVI‡ 3314†† 3514†† 3713†† 3915†† 0.12 
 SAVR 4816 5220 5218* 5217* 0.02 
HADS       
Anxiety score TAVI 53 64 44 53 0.39 
 SAVR 44 54 43 33 0.19 
Depression score TAVI 53 44 44 53 0.17 
SAVR 44 43 33 44 0.17 
       
Groove Pegboard       
Dominant time (sec) TAVI‡ 14255†† 14266†† 13759†† 15067†† 0.46 
SAVR 10033 9836 10289 9851 0.78 
Non-dominant time (sec) TAVI‡ 167124† 16461† 16978† 16280†† 0.64 
SAVR 13166 128103 130100 11971 0.42 
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Mnemonic function  
HVLT: Immediate recall of a simple list of words did not change after TAVI 
but significantly improved after 12 months in the SAVR group (Figure 4-2). 
Although the TAVI group had a lower total learning score compared to SAVR 
(p=0.002), there was no change in learning scores after TAVI or SAVR at 30 
days and 6 months but a significant increase at 12 months for SAVR only 
(Figure 4-2). Delayed recall scores improved after 6 months and 12 months 
in the SAVR group and were higher than the TAVI group at 30 days and 6 
months (Figure 4-2). The TAVI group had a lower Discrimination Index (DI) 
at baseline compared to SAVR group. The DI was worse for TAVI after 6 
months and 12 months (baseline: 103 vs. 12 months: 85, p=0.03). There 
was a significant improvement in DI between 30 days and 6 months for 
SAVR (Figure 4-2); there was no deterioration in DI in the SAVR group at 12 
months (baseline: 112 vs. 12 months: 94, p=0.14) (Figure 4-2). 
ROCF: At baseline, the TAVI group had significantly lower scores for 
copying (p=0.001), immediate (p<0.0001) and delayed recall (p<0.001) 
compared to the SAVR group (Figure 4-2). After 6 months and 12 months, 
both the TAVI and SAVR groups had significantly improved immediate and 
delayed recall scores; however the TAVI group remained lower relative to 
SAVR (Figure 4-2).  
Executive function  
Trail Making Test (TMT) A and B: The TAVI group were slower to complete 
both trails compared to SAVR (TMT-A:  p=0.001), (TMT-B: p=0.005) (Figure 
4-2). The recorded times for both tasks did not change after TAVI or SAVR 
at 30 days, 6 months and 12 months (Figure 4-2). 
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Figure  4-2 Summary of neurocognitive function test scores at baseline, 
30 d, 6 m and 12 m 
‡ p<0.05 for group effect from mixed-effect model. *p<0.05, **p<0.01 vs. baseline score by Bonferroni correction; 
†p<0.05, ††p<0.01 vs. SAVR score. HVLT=Hopkins Verbal Learning test, ROCF=Rey-Osterrieth complex figure 
test, COWAT=controlled oral word association test, TMT=Trail Making Test. Bars represent standard error. 
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Figure 4.2 (continued) Summary of neurocognitive function tests scores at 
baseline, 30 d, 6 m and 12 m. 
 
‡ p<0.05 for group effect from mixed-effect model. *p<0.05, **p<0.01 vs. baseline score by Bonferroni correction; 
†p<0.05, ††p<0.01 vs. SAVR score. HVLT=Hopkins Verbal Learning test, ROCF=Rey-Osterrieth complex figure 
test, COWAT=controlled oral word association test, TMT=Trail Making Test. Bars represent standard error. 
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Letter Number Sequencing task (LNS): TAVI patients had lower scores at 
baseline compared to SAVR (p=0.01), and did not change after 30 days, 6 
months and 12 months. However, the SAVR groups score significantly 
increased at 12 months (Table 4-3).  
Verbal fluency (COWAT): There was no effect of group (p=0.10) on verbal 
fluency at baseline. Whilst there was no significant change in verbal fluency 
scores after TAVI at 30 days, 6 months and 12 months, the SAVR group 
increased their scores significantly after 12 months (Figure 4-2). 
Semantic fluency (COWAT): The TAVI group had lower scores compared to 
SAVR at baseline (p=0.002), and the scores for both groups did not change 
after 30 days, 6 months and 12 months (Figure 4-2). 
Switching fluency (COWAT): The TAVI group had comparable baseline 
score to SAVR and there was no change in scores for either group with time 
(Figure 4-2). 
Psychomotor speed  
DSST: The TAVI group had significantly lower scores at baseline compared 
to SAVR (p<0.001) (Table 4-3), and did not change at 30 days, 6 months 
and 12 months. The SAVR scores however increased significantly after 6 
months and 12 months (Table 4-3).  
Mood  
HADS: Both TAVI and SAVR groups had normal scores (normal<8) with no 
evidence of anxiety and depression at baseline or at 30 days, 6 months and 
12 months (Table 4-3). 
Fine motor co-ordination and speed (grooved pegboard test (GPT): The 
TAVI group were consistently slower at the task with the dominant hand, 
across the 4 time points when compared to SAVR (p<0.001) (Table 4-3). 
- 118 - 
There were similar differences with the non-dominant hand (p=0.004). 
Overall there was no detectable change after TAVI or SAVR at 30 days, 6 m 
and 12 months (Table 4-3). 
4.4.5 Grade of Cognitive impairment at baseline and after TAVI 
and SAVR 
Table 4 shows the proportions of patients that were graded as “impaired” vs. 
“average or above” across the four measured time points according to 
published norms: 
Mnemonic function  
HVLT grade: For both the TAVI and SAVR groups, there was evidence of 
significant reduction in the percentage of impairment for total learning over 
12 months. The TAVI group did not change on delayed recall but in the 
SAVR group there was a significant reduction in the percentage who were 
graded impaired (Table 4-4). The percentage of patients with an impaired 
discrimination index did not change across the 12 months in either group. 
The TAVI group had higher percentage of impairment at baseline compared 
to SAVR for total learning (Table 4-4, p=0.005), but there were equivalent 
levels of impairment for delayed recall and discrimination indices.  
ROCF grade: The TAVI group had a greater proportion of patients with 
impairment of visuospatial memory at baseline compared to SAVR (p=0.01). 
For both TAVI and SAVR, there was no change in the proportion of 
impairment over 12 months for copy and recall grades, except for a 
significant reduction of impairment in delayed recall grade in the TAVI group 
only (Table 4-4). 
 
Executive function 
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TMT-A and B: For both TAVI and SAVR groups, there was no statistically 
significant change in the proportion of patients with an impaired grade after 
treatment at 30 days, 6 months and 12 m (Table 4-4). However, across the 
12 months the TAVI group had a higher proportion of impaired patients than 
SAVR (baseline, TAVI vs. SAVR: TMT-A, p=0.0001; TMT-B, p=0.006). 
For the letter number sequencing task (LNS), and verbal and semantic 
fluency (COWAT), the TAVI group compared to SAVR had similar 
proportions of impaired patients at baseline and this did not change 
significantly out to 12 months (Table 4-4). For the perceptual and motor 
speed and visual memory (DSST) and the fine motor co-ordination and 
speed (GPT), the TAVI group had a greater proportion of impaired patients 
compared to SAVR at baseline, but there was no change within groups out 
to 12 months (Table 4-4). 
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Table  4-4 Proportion of patients graded as impaired function 
according to published norms for neurocognitive tests across four 
time points: 
 (baseline, 30d, 6m and 12m). 
 Group 
 
Baseline 
TAVI n=50 
SAVR n=40 
n (%) 
30 days 
TAVI n=41 
SAVR n=36 
n (%) 
6 months 
TAVI n=38 
SAVR n=34 
n (%) 
12 months 
TAVI n=36 
SAVR n=34 
n (%) 
p value* 
HVLT        
Total learning TAVI 32(64)** 26(63) 17(45) 5(14) 0.046 
 SAVR 17(43) 19(53) 15(44) 6(18) 0.019 
Delay Recall TAVI 21(42) 20(49) 15(40) 16(44) 0.88 
 SAVR 22(55) 21(58) 12(35) 7(21) 0.005 
Discrimination Index TAVI 35(70) 25(61) 24(63) 23(64) 0.81 
 SAVR 30(75) 27(75) 30(88) 26(77) 0.44 
ROCF       
Copy TAVI 6(12) ** - 8(21) 8(22) 0.39 
 SAVR 1(2.5) - 5(15) 1(3) 0.07 
Recall TAVI 6(12) ** - 6(14) 5(13) 0.95 
 SAVR 2(5) - 1(3) 1(3) 0.85 
Delayed Recall TAVI 18(36) ** - 6(16) 4(11) 0.02 
 SAVR 4(10) - 1(3) 1(3) 0.29 
Trail Making Tests       
A  TAVI 27(54) 17(41) 18(48) 15(42) 0.59 
 SAVR 10(25) 8(22) 10(29) 6(18) 0.79 
B TAVI 24(48) 13(32) 16(42) 16(44) 0.39 
 SAVR 11(28) 10(28) 6(18) 7(21) 0.73 
LNS TAVI 22(44) 20(49) 16(42) 20(56) 0.65 
 SAVR 12(30) 15(42) 8(24) 8(24) 0.29 
COWAT       
Verbal fluency TAVI 14(28) 7(17) 10(26) 13(36) 0.38 
 SAVR 11(28) 11(30) 7(21) 9(27) 0.78 
Semantic fluency TAVI 18(36) 16(41) 13(34) 19(50) 0.55 
 SAVR 9(23) 7(19) 12(35) 7(21) 0.44 
DSST TAVI 40(80)** 33(81) 29(76) 26(72) 0.90 
 SAVR 22(55) 15(42) 14(41) 12(35) 0.36 
Grooved Pegboard       
Dominant hand TAVI 41(82)** 32(78) 29(76) 26(72) 0.74 
 SAVR 19(48) 14(39) 7(21) 10(30) 0.095 
Non-dominant hand TAVI 42(84)** 36(88) 31(82) 24(66) 0.20 
 SAVR 17(43) 13(36) 13(38) 12(35) 0.96 
 
HVLT=Hopkins Verbal Learning test, ROCF=Rey-Osterrieth complex figure test, LNS=Letter-number 
sequencing, COWAT=controlled oral word association test, DSST=Digit-symbol substitution test,*p 
values from Chi squared test, **p value form Fishers Exact test, TAVI vs. SAVR. 
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4.4.6 Cerebral MRI 
Seventy-four patients (82%) (TAVI, n=44, SAVR, n=30) completed baseline 
and post-procedure cerebral MRI. Four TAVI and one SAVR patient chose 
to have the neurocognitive assessment only (Figure 4-1).  
Baseline: There was a trend towards a higher proportion of patients in the 
TAVI group having evidence of previous stroke (TAVI: 10(23%) vs. SAVR: 
2(8%), p=0.06) and peri-ventricular ischaemia (TAVI: 16(36%) vs. SAVR: 
8(26%) p=0.16). There was evidence of recent micro-infarction on cerebral 
DWI in four (9%) TAVI patients but none in the SAVR group. The mean 
volumeSD of baseline micro-infarction in the TAVI group was 0.260.33ml. 
Post-procedure: Post-procedure time to scan was earlier for TAVI compared 
to SAVR patients (Median (Q1–Q3), TAVI: 4(4–5) vs. SAVR: 6(5–7) days, 
p=0.001). The incidence of new micro-infarction on DWI-MRI was higher 
post TAVI compared to SAVR (30(68%) vs. 13(43%), p=0.04). The number 
of new cerebral micro-infarcts per patient was higher for TAVI (meanSD; 
2.12.7 (median=1, Q1-Q3, 0–4) than SAVR (meanSD, 0.690.99 
(median=0, Q1–Q3, 0–1) (p=0.006)). The mean volume per micro-infarct 
was significantly smaller for TAVI patients compared to SAVR patients 
(0.110.08 vs. 0.941.9ml, p=0.0001). There was no difference between 
TAVI and SAVR according to the categorical size of micro-infarcts on DWI: 
(TAVI: <5mm: 14(32%), >5mm: 6(14%), both: 10(23%); SAVR: <5mm: 
5(17%), >5mm: 5(17%) both 6(20%), 2=1.32, p=0.52). The TAVI group had 
a greater number of patients with micro-infarcts in the middle cerebral artery 
(MCA) and posterior cerebral artery (PCA) territory compared to SAVR 
(MCA:TAVI 15(34%) vs. SAVR 7(23%), p=0.008; PCA: TAVI 12(27%) vs. 
SAVR 2(6%), p=0.037). There was no statistical difference between the 
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number of micro-infarcts in the anterior cerebral artery (ACA) or 
vertebrobasilar artery (VBA) (ACA: TAVI 9(20%) vs. SAVR 7(23%), p=0.75; 
VBA: TAVI 10(23%) vs. SAVR 7(23%), p=0.54). 
4.4.7 Influence of Cerebral Emboli on Neurocognitive function 
Figure 4-3 and Table 4-5 show the proportion of patients with impaired NCF 
tests, with and without evidence of cerebral embolism after TAVI and SAVR, 
over the 4 time points. For those patients that had detected cerebral 
embolism, there were no significant differences in their baseline test scores 
compared to those that had none (Figure 4-3 and Table 4-5). Overall within 
each treatment group (TAVI or SAVR) there was no difference in the 
proportion of patients with impaired NCF at 30 days, 6 months and 12 
months, whether or not they had new cerebral embolism (Figure 4-3 and 
Table 4-5). In patients with DWI lesions, there was a significantly higher 
proportion with NCF impairment in the TAVI group compared to the SAVR 
group at 30 days (according to delayed recall, discrimination index and 
semantic fluency) and at 6 months (according to DI, ROCF and semantic 
fluency), but these differences were no longer present by 12 months (Figure 
4-3 and Table 4-5). There were no significant differences between groups 
over the study period in trail making, letter number sequencing, digit symbol 
substitution tests and grooved peg board tests (Figure 4-3 and Table 4-5). 
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Figure  4-3 Proportion of patients with impaired neurocognitive function tests with 
and without cerebral embolism on DWI following TAVI and SAVR over 4 time 
points 
 
TAVI=Transcatheter aortic valve implantation, SAVR=Surgical aortic valve replacement, 
DWI=Diffusion weighted imaging, HVLT=Hopkins verbal learning test, TL=total learning, DR=delayed 
recall, DI=discrimination index, ROCF=Rey Osterrieth complex figure, COWAT=Controlled oral word 
association, VF=verbal fluency, SF=semantic fluency, P values are from 
2
 test for effect of DWI 
lesions across 4 time points. Fishers exact p<0.05: comparing groups vs lesions present *at 30d, at 
6m, at 12m. 
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Figure 4-3 (continued) Patients with impaired neurocognitive function tests with and without 
cerebral embolism on DWI following TAVI and SAVR over 4 time points 
 
TAVI=Transcatheter aortic valve implantation, SAVR=Surgical aortic valve replacement, 
DWI=Diffusion weighted imaging, HVLT=Hopkins verbal learning test, TL=total learning, DR=delayed 
recall, DI=discrimination index, ROCF=Rey Osterrieth complex figure, COWAT=Controlled oral word 
association, VF=verbal fluency, SF=semantic fluency, P values are from 
2
 test for effect of DWI 
lesions across 4 time points. Fishers exact p<0.05: comparing groups vs lesions present *at 30d, at 
6m, at 12m. 
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Table  4-5 Proportion of patients with impaired neurocognitive function tests 
with and without cerebral embolism on MRI after TAVI and SAVR over 4 
time points 
 Group Baseline 
TAVI n=44 
SAVR n=30 
n (%) 
 30 days 
TAVI n=41 
SAVR n=30 
n (%) 
 6 months 
TAVI  n=38 
SAVR n=30 
n (%) 
 12 months 
TAVI n=36 
SAVR n=30 
n (%) 
 p* 
DWI 
lesions
** 
 none ≥1 none ≥1 none ≥1 none ≥1  
           
LNS TAVI 10(23) 11(25) 11(27) 10(24) 11(29) 6(16) 14(39) 7(19) 0.54 
 SAVR 5(17) 4(13) 6(20) 5(17) 4(13) 2(7) 3(10) 3(10) 0.96 
DSST TAVI 20(46) 16(36) 18(44) 15(37) 18(47) 12(32) 17(47) 11(31) 0.97 
 SAVR 10(33) 7(23) 6(20) 5(17) 6(20) 4(13) 6(20) 3(10) 0.92 
GPT           
D TAVI 19(43) 18(41) 19(46) 14(34) 15(40) 15(40) 10(28) 16(44) 0.63 
 SAVR 10(33) 4(13) 7(23) 3(10) 3(10) 2(7) 4(13) 3(10) 0.83 
Non-D TAVI 20(46) 17(39) 20(49) 17(42) 16(42) 16(42) 12(33) 13(36) 0.99 
 SAVR 8(27) 4(13) 6(20) 4(13) 4(13) 5(17) 4(13) 4(13) 0.60 
 
TAVI=Transcatheter aortic valve implantation, SAVR=Surgical aortic valve replacement, 
DWI=Diffusion weighted imaging, LNS=Letter number sequencing, DSST=Digit symbol 
substitution test, GPT=grooved pegboard test, D=dominant hand. *P values are from 
2
 test 
for effect of DWI lesions across 4 time points. **DWI lesions on post procedure cerebral 
MRI.  
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Predictors for Cognitive Impairment 
Baseline impairment: Univariate and multivariate logistic regression analysis 
for predictors of cognitive impairment at baseline are shown in Table 4-6. 
For TAVI, significant univariate factors of AF, prior CABG, COPD and 
creatinine were entered into the multivariate analysis. Only AF (OR 8.31, 
1.1-60.9, p=0.037) and creatinine (OR 1.03, 1.0-1.05, p=0.02) were 
statistically significantly associated with impaired baseline NCF. For the 
SAVR group the predictors were hypertension and baseline creatinine but 
were not statistically significant in the multivariate analysis (Table 4-6). 
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Table  4-6 Univariate and multi-variate logistic regression analysis for predictors 
of baseline cognitive impairment 
 
BMI=body mass index, STS=Society of Thoracic Surgery, AF=atrial fibrillation, TIA=transient ischaemic attack, MI=myocardial 
infarction, CABG=coronary artery bypass grafting, PVD=peripheral vascular disease, PCI=percutaneous coronary intervention, 
COPD=chronic obstructive pulmonary disease, PHT=pulmonary hypertension, MRI=magnetic resonance imaging, 
PVI=periventricular ischaemia, DWI=diffusion weighted imaging.*Odds adjusted for TAVI (AF, CABG, COPD, creatinine) and SAVR 
(Hypertension, creatinine)  
Risk factors Unadjusted 
odds ratios 
95% CI p value Adjusted odds 
ratios* 
95% CI p value 
TAVI       
Age 0.98 0.92 to 1.05 0.63    
male 0.97 0.36 to 2.57 0.94    
BMI 0.97 0.88 to 1.07 0.56    
EuroSCORE 1.00 0.95 to 1.05 0.83    
EuroSCORE II 0.94 0.82 to 1.08 0.39    
STS Score 0.93 0.79 to 1.09 0.37    
STS Morbidity 1.02 0.95 to 1.10 0.61    
Hypertension 0.61 0.22 to 1.67 0.33    
Diabetes 2.97 0.75 to  11.7 0.12    
Hypercholesterolaemia 0.47 0.17 to 1.30 0.14    
AF 5.79 1.20 to 28.05 0.03 8.31 1.1 to 60.9 0.037 
Stroke/TIA 1.27 0.38 to 4.25 0.70    
MI 0.57 0.15 to 2.20 0.41    
CABG 0.37 0.12 to 1.10 0.07 0.29 0.08 to 1.0 0.056 
PVD 0.82 0.23 to 2.90 0.75    
PCI 0.93 0.31 to 2.82 0.90    
COPD 3.70 0.95 to 14.45 0.06 2.72 0.5 to 14.1 0.24 
Creatinine 1.02 0.99 to 1.03 0.07 1.03 1.00 to 1.05 0.02 
PHT 1.48 0.48 to 4.62 0.50    
Cerebral MRI 
      PVI 
      DWI 
 
0.68 
1.11 
 
0.20 to 2.32 
0.18 to 6.79 
 
0.54 
0.91 
   
SAVR       
Age 1.01 0.91 to 1.10 0.87    
male 1.0 0.21 to 4.77 1.0    
BMI 1.08 0.93 to 1.24 0.32    
EuroSCORE 1.17 0.91 to 1.52 0.23    
EuroSCORE II 1.99 0.50 to 7.76 0.33    
STS Score 1.57 0.59 to 4.11 0.36    
STS Morbidity 1.15 0.95 to 1.40 0.16    
Hypertension 3.43 0.79 to 14.85 0.10 3.16 0.7 to 14.6 0.14 
Diabetes 0.78 0.12 to 5.05 0.80    
Hypercholesterolaemia 2.92 0.66 to 12.99 0.16    
AF 1.06 0.1 to 1.59 0.46    
Stroke/TIA 2.86 0.30 to 27.02 0.36    
MI 0.78 0.12 to 5.05 0.79    
CABG - - -    
PVD - - -    
PCI - - -    
COPD - - -    
Creatinine 1.04 0.99 to 1.10 0.09 1.04 0.99 to 1.1 0.11 
PHT 1.82 0.18 to 18.41 0.61    
Cerebral MRI 
      PVI 
      DWI 
 
0.68 
- 
 
0.13 to 3.47 
- 
 
0.65 
- 
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Post-procedural cognitive impairment at 12 months: Univariate logistic regression 
for the associations of cognitive impairment at 12 months was conducted (Tables 4-
7). For both TAVI and SAVR, there were no major associations for the development 
of impaired NCF after considering extensive cardiovascular risk factors, co-
morbidities, surgical risk scores and procedural factors. The only exception was 
hypercholesterolaemia in the TAVI group. Importantly, there was no association 
with cerebral-DWI micro-infarcts, either by number of new lesions or total lesion 
volume (Table 4-7).  
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Table  4-7 Univariate logistic regression analysis for the associations with 
cognitive impairment at 12 months 
Risk factors Unadjusted 
odds ratios 
95% CI p values 
TAVI    
Age 0.97 0.89 to 1.06 0.54 
Male 0.97 0.12 to 1.42 0.16 
BMI 0.97 0.91 to 1.04 0.41 
EuroSCORE 0.97 0.91 to 1.04 0.41 
EuroSCORE II 0.99 0.83 to 1.18 0.92 
STS Score 0.85 0.68 to 1.07 0.17 
STS Morbidity 0.96 0.88 to 1.06 0.47 
Hypertension 1.02 0.91 to 1.14 0.70 
Diabetes 0.83 0.22 to 3.13 0.78 
Hypercholesterolaemia 0.24 0.07 to 0.84 0.026 
AF 1.6 0.43 to 5.96 0.48 
Stroke/TIA 0.84 0.21 to 3.43 0.81 
MI 0.81 0.14 to 4.54 0.81 
CABG 0.36 0.08 to 1.66 0.19 
PVD 0.85 0.18 to 3.92 0.85 
PCI 1.42 0.34 to 5.91 0.63 
COPD 1.60 0.43 to 5.95 0.48 
Creatinine 1.00 0.98 to 1.01 0.97 
PHT 3.05 0.67 to 13.77 0.15 
Number of DWI lesions 
Volume of lesions 
1.19 
2.07 
0.86 to 1.63 
0.26 to 16.52 
0.29 
0.49 
TAVI size 1.16 0.86 to 1.56 0.80 
Femoral access 0.82 0.10 to 6.40 0.84 
Procedure Time 1.00 0.99 to 1.01 0.38 
Fluoroscopic time 1.03 0.97 to 1.08 0.35 
Contrast volume 0.99 0.99 to 1.00 0.88 
    
SAVR    
Age 1.01 0.90 to 1.20 0.78 
Male 0.84 0.79 to 8.88 0.88 
BMI 0.88 0.62 to 1.25 0.48 
EuroSCORE 0.88 0.62 to 125 0.49 
EuroSCORE II 0.47 0.56 to 3.99 0.49 
STS Score 1.68 0.51 to 5.53 0.39 
STS Morbidity 0.98 0.78 to 1.23 0.85 
Hypertension 0.71 0.10 to 4.59 0.71 
Diabetes 0.83 0.22 to 3.13 0.78 
Hypercholesterolaemia 0.49 0.05 to 4.95 0.54 
AF 0.46 0.03 to 6.06 0.55 
Stroke/TIA 1.00 0.09o 11.02 1.00 
MI 1.00 0.09 to 11.03 1.0 
Creatinine 0.99 0.93 to 1.04 0.99 
No of DWI lesions 
Volume of lesions 
1.15 
1.37 
0.44 to 3.04 
0.91 to 2.06 
0.77 
0.13 
Bypass time 0.99 0.97 to 1.01 0.43 
Cross clamp time 0.98 0.96 to 1.02 0.38 
Valve size 1.0 0.61 to 1.64 1.00 
CABG performed 1.6 0.27 to 9.53 0.60 
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4.5 DISCUSSION 
This study shows that TAVI and SAVR have no significant detrimental effect on 
neurocognitive function in the short to medium-term. New silent cerebral micro-
infarction, which was more frequent after TAVI had no relationship neurocognitive 
function at 12 months. However, unfortunately the baseline characteristics are 
significantly different and therefore may well confound the differences observed.  
Using a comprehensive battery of validated tests to cover a wide variety of 
important higher neurocognitive faculties across 4 defined time points, there was a 
steady improvement in absolute test scores and a quicker performance in timed 
tasks. The SAVR group showed improvement in immediate memory recall and 
delayed memory recall over 12 months. Both the TAVI and SAVR groups showed 
improvement in delayed visual recall and drawing tasks over 12 months. The TAVI 
and SAVR groups had similar levels of IQ and therefore cognitively would be 
expected to perform in a similar fashion. However, the TAVI group were impaired in 
several areas at baseline, such as MMSE, but this did not deteriorate further post-
TAVI. The greater prevalence of baseline NCF impairment in the TAVI group likely 
reflects their advanced age and significant comorbidities. Thus in the TAVI group 
cognitive function might be expected to decline with time, as in the general 
population, but this was not seen in our study.  
Both TAVI and SAVR groups improved in visuospatial memory tasks indicating 
genuine improved cognitive performance rather than a learning effect, as the tests 
were 12 months apart. In the trail making and grooved pegboard tasks the TAVI 
group was significantly slower, but this may have been related to visual impairment 
or manual dexterity being limited by age related frailty.  
When categorising the patients into “impaired” and “average or above” according to 
published norms for age and levels of education, the TAVI group overall had higher 
percentages of “impaired” patients. This again may be related to other significant 
co-morbidities contributing negatively to cognitive function. However, in our study 
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there was no evidence following TAVI or SAVR that more patients became 
neurocognitively impaired out to 12 months. 
In the previous chapter we observed significant improvements in health-related 
quality of life (HRQoL) parameters across time, however, during neurocognitive 
assessment, this was not seen. This is because HRQoL looks at global health 
status and well-being, whereas neurocognitive assessment is looking for 
deteriorations in memory function. Therefore, given the cerebral insults by micro-
infarction, we would be concerned with a decline. Also, cognitive function does tend 
to decline gradually with time especially in the elderly, which we did not observe in 
our study, suggesting a beneficial effect of intervention. 
Both TAVI and SAVR are significant life changing events that patients may find 
difficulty adjusting to. However, in our study there was no evidence of pre-existing 
anxiety or depression. Moreover, our two groups of patients were routinely 
assessed using HADS and did not develop any evidence of psychological 
disturbance, which undetected can affect neurocognitive function.  
Several studies have confirmed a higher incidence of new cerebral micro-infarction 
after TAVI compared to SAVR(Uddin et al., 2015, Fairbairn et al., 2012a, Kahlert et 
al., 2010, Ghanem et al., 2010a, Stolz et al., 2004). However, the incidence of 
micro-infarction was marginally lower in comparison to the findings in chapter 3 ; 
68% vs 77% in the TAVI arm and 43% vs 43% for SAVR. The potential 
mechanisms are related to device manipulation around atheromatous aortas, as 
well as embolisation of valvular or atheromatous material during balloon aortic 
valvuloplasty and prosthesis deployment (Kahlert et al., 2012). The TAVI technique 
is newer than established SAVR and so there is an operator experiential effect 
which may be observed in the difference in the two chapters, as Chapter three was 
studied first and this chapter was a differing cohort. Although there were frequent 
new cerebral micro-infarctions detected in our study, there was no significant 
impact on NCF in the TAVI patients out to 12 months, as evidenced by the absence 
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of change in the proportion of patients being graded as ‘impaired’ over time. 
However, we did see an early (30 days and 6 months) transient decline in verbal 
memory recall and executive function in TAVI patients with new silent micro-
infarction when compared to SAVR patients. This may be due to transient neuronal 
dysfunction post-procedure directly related to the higher numbers of DWI lesions in 
the TAVI group, which recovered with time. A degree of neuronal remodelling may 
occur following an ischaemic insult, there may be gradual neuronal cell death and 
areas of oedema that recovery by forming new neuronal network connections. 
In our study, we identified AF and renal function to be predictors of baseline 
cognitive impairment, which may both be associated with embolic and diffuse 
cerebrovascular disease. Interestingly, new silent cerebral micro-infarction and 
operative (TAVI and SAVR) procedural factors were not significantly associated 
with impaired NCF, suggesting that the invasive insult does not have a negative 
impact on short to medium-term cognitive function. Whilst vascular dementia is a 
significant cause of cognitive disability worldwide, its cause is multifactorial. Prior 
studies have not shown a direct negative effect on cognition after TAVI although the 
consequences of silent cerebral infarction remain a concern (Ghanem et al., 2013). 
Knipp et al studied transapical TAVI and SAVR patients and showed early decline 
in the surgical patients but no association with cerebral emboli or ischaemia (Knipp 
et al., 2013). However, this study only looked at follow up to 3 months and did not 
perform any pencil and paper tests which could have provided additional 
information for comprehensive neuropsychological evaluation. The differences seen 
between patients could be related to “cognitive reserve”; which is the ability to 
maintain cognitive function by making new neuronal connections following a 
neurotoxic insult. 
Embolic protection devices to reduce post-procedure stroke may have an important 
role and have also been shown to reduce the number of silent cerebral micro-
infarcts, with a high procedural success rate and safety profile (Baumbach et al., 
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2015). The direct effect on neurocognitive function will be difficult to assess, 
however early results from DEFLECT III have shown an improvement in delayed 
recall and overall improvement in cognition using the Montreal Cognitive 
assessment (Lansky et al., 2015). As TAVI is now being evaluated in randomised 
trials against SAVR in patients with moderate to high surgical risk, our findings 
suggest that the higher rate of silent cerebral micro-infarcts after TAVI may not 
have an observable negative effect on short-medium term NCF.  
4.5.1 Limitations 
The study groups could not be completely matched due to current international 
guidelines reserving TAVI for patients that are inoperable or deemed to be at high 
surgical risk; this is a limitation of all current non-randomised studies in this disease 
area (Joint Task Force on the Management of Valvular Heart Disease of the 
European Society of et al., 2012). Therefore the differences that we have 
demonstrated could be influenced by bias related to differences in baseline 
characteristics. The TAVI group were older and may have had more limited 
cognitive reserve in comparison to the SAVR group, who were younger and with 
less medical co-morbidity. Although the study was prospectively powered with an 
appropriate sample size, a larger study population would allow greater confidence 
in the findings. Complete follow up and evaluation to 12 months was not possible in 
all patients, which again may have introduced bias. The TAVI group in particular are 
elderly and frail, with a high annual mortality rate, making this population 
exceptionally hard to study in the medium term (Nielsen et al., 2012). 
The study was limited to two high-volume TAVI centres which may not be sufficient 
to overcome centre selection bias for TAVI or SAVR treatment, and trans-apical 
TAVI was not evaluated. Neurocognitive function was assessed at the four VARC 
recommended time points, but we are unable to comment on the longer-term 
consequences on NCF beyond 12 months. This may be especially important if TAVI 
is to be considered in younger lower-risk patients, who have a longer life 
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expectancy. The cerebral MRI scans were performed at 1.5T whereas higher field 
strengths may have detected more subtle embolic events. However, at the time of 
our study the CoreValve prosthesis was not approved for 3.0T field strength and 
on-going clinical trials of cerebral embolic protection devices are at the 1.5T field 
strength. Nevertheless we were unable to demonstrate an association between new 
cerebral micro-infarction and a decline in cognitive performance.  
4.6 CONCLUSION 
There was no evidence of short to medium-term cognitive decline following TAVI or 
SAVR for severe aortic stenosis. Although silent cerebral micro-infarcts were more 
common following TAVI than SAVR, there was no impact on neurocognitive 
performance. 
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5 Extracellular Volume (ECV) in health: 
Reproducibility of myocardial T1 values and 
estimation of ECV fraction in healthy adult 
volunteers using the Modified Look-Locker 
Inversion recovery (MOLLI) method 
5.1 ABSTRACT 
Objective: To establish the reproducibility of T1 mapping and ECV calculation in 
healthy adults. 
Methods: Twenty healthy volunteers underwent CMR studies at 1.5T using the 
identical MOLLI (3,3,5) method with acquisition in 3 short axis slices and 4 chamber. 10 
of the volunteers were restudied. Native and post-contrast (0.2mmol/kg of gadoteric 
acid contrast (Dotarem®) T1 values were obtained for myocardium and blood pool, and 
ECV calculated. T1 maps were generated offline using MR Maps software.  
Results: Mean age 20.61.5 years (9(45%) male; BSA 1.860.2m
2
; Haematocrit 
0.440.03). All cardiac volumetric measurements were in the normal range (ejection 
fraction 605%; LV mass index 324g/m
2
). A total of 320 T1 maps (3 slices, 16 
segments) were produced from 20 volunteers and graded according to image quality 
(unusable n=4(1%); poor n=50(16%); adequate n=93(29%); excellent n=174(54%)). 
There was no statistical difference in pre-contrast myocardial T1 values between, apex, 
mid-, base or 4 chamber slices (70173ms vs. 73977ms vs. 70175ms vs. 72256 
ms; ANOVA, p=0.29). Post-contrast myocardial T1 values were also consistent across 
the slices (apex 42251ms, mid- 44641ms, base 43147ms, 4Ch 43959ms; ANOVA, 
p=0.51). Mean ECV values were: apex 22.36%, mid- 23.93%, base 22.16% and 
4Ch 23.47% (ANOVA F=0.72, p=0.55). 
The intra-observer, inter-observer and inter-study variability was fair to good for native 
myocardial T1. The intra-, inter-observer and inter-study agreement was fair to excellent 
(inter-class correlation co-efficient ranges (R (0.52 to 0.80), R (0.51 to 0.77) and R (0.52 
to 0.81). ECV measurement had variability but excellent agreement (R (0.73 to 0.84). 
Conclusions: In healthy young volunteers at 1.5T, native and post-contrast T1 
mapping using MOLLI and ECV fraction show good agreement across the myocardium 
and fair observer and inter-study reproducibility. 
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5.2 INTRODUCTION 
Cardiovascular magnetic resonance imaging has provided a deeper insight 
into the understanding of various cardiomyopathic processes such as 
genetic, ischaemic, inflammatory and infiltrative causes (Kuruvilla et al., 
2014, Motwani et al., 2014).  The advantages of CMR are in the high spatial 
resolution and multi-planar imaging, as well as contrast enhanced imaging. 
Late gadolinium enhanced imaging is widely used in clinical practice to 
investigate cardiomyopathy and detects specific patterns related to disease 
processes, such as sub-endocardial LGE in myocardial infarction or mid wall 
enhancement in Dilated cardiomyopathy (DCM) (Kim et al., 2009). LGE 
imaging is excellent for focal fibrosis or scar but does not highlight diffuse 
cardiomyopathic processes as well. T1 mapping involves measuring the T1 
value (ms) of each voxel within the myocardium (and blood pool) and 
subsequently generating a parametric map from which regional variations in 
the T1 relaxation time can be visualised.  T1 mapping techniques have 
developed following investigations of diffuse processes that can occur in 
infiltrative or valvular heart disease, such as aortic stenosis (Mewton et al., 
2011). Various methods of T1 mapping have been developed, but are based 
around an inversion recovery sequence (Wacker et al., 1999, Flacke et al., 
2001). Messroghli et al developed the modified Look-locker inversion 
recovery method to provided estimations of tissue t1 values (Messroghli et 
al., 2004). This technique was developed in Leeds on the Phillips 1.5T 
scanner. MOLLI has been widely studied and published in aortic 
regurgitation, acute MI, stable CAD and valvular disease(Sparrow et al., 
2006). Modifications of the MOLLI method include shortened MOLLI 
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(ShMOLLI) (Piechnik et al., 2013). We decided to use the original MOLLI as 
this was only available on our scanner and this had already been validated. 
This study aimed to use the original MOLLI sequence using 3,3,5 readout at 
1.5T in healthy adult volunteers and confirm reproducibility before using this 
in patients with severe aortic stenosis. 
5.3 METHOD 
5.3.1 Study participants 
We recruited 20 healthy volunteers who had CMR studies using an identical 
protocol, 10 of these were randomly selected to have repeat study. Inclusion 
criteria: age > 18 years. Exclusion criteria: History of any medical problem, 
recent cold or flu, contra-indication for MRI, claustrophobia, pregnancy. 
Informed written consent was obtained and this study was approved by the 
Local ethic committee. An intravenous 20-gauge cannula was placed in the 
antecubital fossa vein. A full blood count by venesection was obtained for 
haematocrit. 
5.3.2 Scan protocol 
The study was performed on 1.5 Tesla (Intera, Philips Healthcare, Best, 
Netherlands) with Master gradients (30mT/m, 150[mT.m-1]/msec) and a five-
element cardiac phased array receiver coil with vector cardiogram. Localiser 
images were obtained using cine steady state free precession for the vertical 
long axis (VLA), horizontal long axis (HLA) and short axis (SA) of the left 
ventricle (SSFP, TR 3.0ms, TE 1.5ms, Slice thickness 8mm, FOV 400, 
RFOV 80, 30 phases). The LV volumes were acquired in the short axis 
plane using multi-slice and multi-phase cine imaging. Typically 10 to 12 
contiguous slices were acquired covering from the mitral valve plane to 
- 138 - 
beyond the apex (Slice thickness 10mm, 0 gap, 30 phases, FOV 380, RFOV 
100). The “3 of 5” technique was used to identify basal, mid- ventricular and 
apical slices as this has been shown to be reproducible (Messroghli et al., 
2005).  This is performed by planning 5 parallel short axis slices from the 
outmost aspect of mitral annulus and LV apex, with the ventricle in systole. 
The centre 3 slices are used to acquire cine images and later plan MOLLI 
sequences.  
T1 mapping was performed with the MOLLI pulse sequence which was 
described by Messroghli (Messroghli et al., 2004). For each individual slice 
(base, mid, apex, 4Ch), there were 3 successive Look-Locker acquisitions 
(trains). Each of these trains, starts with a specific inversion time (100ms, 
200ms and 350ms) after which multiple single shot images are acquired 
over consecutive heart beats in end-diastole. The 3 trains produce 3, 3 and 
5 images (3,3,5 MOLLI).  MOLLI was performed pre-contrast (twice), and 5 
and 15 minutes after intravenous administration of 0.2mmol/kg of gadoteric 
acid contrast (Dotarem®, Guerbet, Villepinte). The contrast was followed by 
a 20mls saline flush.  
5.3.3 Image analysis 
Left ventricular volumes using the summation of discs method were 
calculated by manually contouring the endocardial and epicardial borders at 
end-diastole and again at end-systole in commercially available software 
(Qmass 6.0, Medis, Netherlands). Mass = epicardial volume – endocardial 
volume multiplied by the myocardial density (1.05g/cm3) (Gaasch and Zile, 
2011).  
- 139 - 
T1 maps were generated off-line from source MOLLI data images using 
published software MR Maps (Messroghli et al., 2010). In the software the 
images are manually checked and corrected for significant motion before 
map generation. The software sorts the images in order of effective inversion 
time (TI) and uses three-parameter non-linear curve fitting using a 
Levenberg-Marquardt algorithm. A T1 map is generated as a DICOM file 
which is stored. This T1 map is analysed in Qmass 6.0 (Medis, The 
Netherlands). A small region of interest is drawn in the myocardial mid 
septum and mid ventricular blood pool to measure mean signal intensity for 
the T1 value. A conservative septal ROI has been shown to provided good 
reproducibility (Rogers et al., 2013). Image quality was assessed by two 
independent observers and were graded using a Likhart scale (1=unusable, 
2=poor, 3=adequate, 4=excellent). 
5.3.4 Extra cellular volume (ECV) calculation 
The myocardial partition coefficient was calculated using the following 
equation: 
 𝜆 =
∆𝑅1 𝑚𝑦𝑜𝑐𝑎𝑟𝑑𝑖𝑢𝑚
∆𝑅1 𝑏𝑙𝑜𝑜𝑑 𝑝𝑜𝑜𝑙
 where 1 =
1
𝑇1
 . The 𝐸𝐶𝑉 = (1 − ℎ𝑎𝑒𝑚𝑎𝑡𝑜𝑐𝑟𝑖𝑡) ×  𝜆  
The haematocrit is measured from the full blood count sample. The 15 min 
post contrast values were used for ECV. 
5.3.5 Statistical analysis 
Data are presented as meanSD or median (IQR). Normality of the 
continuous data were checked for using the Shapiro-Wilks test and 
comparisons were made using un-paired or paired Student’s t-test or the 
non-parametric equivalent.  
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Reproducibility analysis was performed for intra-observer, inter-observer and 
inter study, using coefficients of variation (CoV) and calculating intra-class 
correlation coefficients (ICC). Coefficients of variation were calculated by 
dividing the standard deviations of the differences between two 
measurements over the mean of the groups. Agreement was considered as 
follows: Excellent:R≥0.75, Good: R=0.60 to 0.74, Fair:=0.40 to 0.59, Poor 
R0.40 (Oppo et al., 1998). Data were analysed using Microsoft Excel 2010 
or in SPSS (version 22, IBM, USA) as appropriate. 
5.4 RESULTS 
 All twenty volunteers completed the study protocol along with ten who were 
re-studied at a median 90 days. The age was 20.61.5 years, 9 (45%) 
males, with a BSA 1.860.2. Mean Haematocrit was 0.440.03. 
5.4.1 LV volumes 
All volumetric measurements were in the normal range(Alfakih et al., 2003); 
Indexed End-diastolic volume=8915ms/m2, indexed end-systolic volume= 
369.8ml/m2, stroke volume 53ml9.8ml/m2, ejection fraction 605%, 
indexed LV mass 324g/m2. 
5.4.2 Image quality  
A total of 320 T1 maps (3 slices, 16 segments) were produced from 20 
volunteers (Grade: unusable n=4(1%), poor n=50 (16%), adequate n=93 
(29%), excellent n=174 (54%). The median grade was 4 (IQR 1) for all 
(apex, mid, base, 4Ch) slices Kruskal Wallis test p=0.96) 
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5.4.3 T1 measurements and extracellular volume (ECV) 
estimations 
Table 5-1 shows the T1 values of myocardium and blood pool obtained from 
the 20 healthy volunteers. There was no statistical difference in myocardial 
T1 value between apex, mid- or base for the first and second pre-contrast 
measures (pre-contrast 1) (ANOVA F=1.26, p=0.29) & (pre-contrast 
2)(F=0.88 p=0.45), 5 mins (F=0.15 p=0.92) or 15 mins (F=0.77 p=0.51) after 
contrast (Table 5-1). The calculated mean ECV were: Apex 22.36%, Mid- 
23.93, Base 22.16 and 4Ch 23.47 (ANOVA F=0.72, p=0.55). 
Table  5-1 T1 measurements of myocardium and blood pool for 20 
volunteers 
 
 
Myocardium Apex Mid Base 4 Ch 
 T1 (ms) T1 (ms) T1 (ms) T1 (ms) 
Pre-contrast 1 
 
70173 73977 70175 72256 
Pre-contrast 2 
 
71384 73493 70089 74174 
5 mins 
 
38884 38744 39648 39965 
15 mins 
 
42251 44641 43147 43959 
Blood Pool Apex 
 
Mid Base 4 Ch 
Pre-contrast 1 
 
1597225 1677257 1664233 1619193 
Pre-contrast 2 
 
1648222 1673258 1678233 1580246 
5 mins 
 
26229 28146 291355 29542 
15 mins 
 
32944 36246 35545 36655 
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5.4.4 Reproducibility and agreement 
Reproducibility of T1 measurements was assessed for intra-, inter-observer 
(two observers) and inter-study variation (two studies) (Table 5-2). The intra-
observer for T1 measurement was fair to good for pre-contrast T1 
measurements but the post contrast measurements had higher coefficients 
of variation.  The CoV for ECV was  high over 10%. The inter-observer 
variability also had similar coefficient of variation values with lower values for 
pre-contrast. The inter-study variability was fair but had high coefficients for 
post contrast T1 measurements. Overall, there was consistency of T1 
measurements across ventricular slices (apex, mid-, base and 4 chamber) 
(Table 5-2). The intra-class correlation coefficients for intra-, inter-observer 
and inter-study are shown in table 5-3. There was evidence of good to 
excellent agreement on T1 measurement for intra-, inter-observer and inter-
study (Table 5-3). The ECV measurement had excellent agreement for intra-
, inter-observer and inter-study.   
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Table  5-2 Intra-, inter observer and inter study reproducibility of T1 
measurements in 10 healthy volunteers 
 Apex  Mid  Base  4 Ch  
 Mean 
diffSD 
CoV Mean 
diffSD 
CoV Mean 
diffSD 
CoV Mean 
diffSD 
CoV 
Intra-observer         
Pre contrast 1 -1.440 6.5 2.735 5.4 3.130 5.8 2.854 7.4 
Pre contrast 2 -2.445 8.8 4.560 8.3 4.657 8.3 5.935 6.6 
Post contrast         
5 min  -4.650 13.1 1.258 15.1 1.457 14.3 7.944 11.0 
15 min -1.749 10.4 5.040 10.3 4.250 11.6 8.339 8.9 
ECV(%) -0.12 14.9 -0.33 13.5 0.32 12.1 0.12 11.2 
Inter-observer         
Pre contrast 1 -3.445 6.3 4.740 5.4 6.140 5.7 -1.854 7.4 
Pre contrast 2 -3.463 8.6 9.960 8.2 -9.658 8.1 4.949 6.6 
Post contrast         
5 min  -9.650 13.4 -0.258 15.1 0.457 14.3 -3.944 11.0 
15 min  -1.644 10.3 -4.546 10.5 4.150 11.6 6.339 8.8 
ECV(%) -0.14 17.1 -1.84 17 -0.34 16.0 -0.53 14.3 
Inter-study         
Pre contrast 1 -13.624 3.6 -11.180 11.9 -12.898 14.3 -8.784 11.3 
Pre contrast 2 0.450 7.2 -1.873 10.5 -11.763 9.2 -12.764 8.8 
Post contrast         
5 min  -7.551 13.7 2.849 12.8 -3.769 17.3 -8.463 15.3 
15 min -11.359 14.2 -5.333 7.8 -8.784 12.4 -9.678 18.0 
ECV(%) 0.83 11.8 1.83 12.1 0.82 9.6 0.52 9.0 
All values show mean differenceSD in T1 (ms). ECV=extracellular volume. 4Ch= 4 chamber slice 
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Table  5-3 Intraclass correlation coefficient for Intra-, inter-observer and 
inter-study reproducibility of T1 measurements in 10 healthy 
volunteers 
 
 Apex  Mid  Base  4 Ch  
 ICC CI ICC CI ICC CI ICC CI 
Intra-observer         
Pre contrast 1 0.70 (0.60–0.80) 0.68  (0.60–0.79) 0.67 (0.57–0.77) 0.59 (0.21–0.87) 
Pre contrast 2 0.73 (0.65–0.79) 0.69 (0.35–0.80) 0.70 (0.64–0.80) 0.55 (0.47–0.85) 
Post contrast         
5 min  0.75 (0.60–0.90) 0.76 (0.61–0.90) 0.61 (0.56–0.80) 0.58 (0.39–0.82) 
15 min  0.80 (0.60–0.96) 0.81 (0.51–0.89) 0.69 (0.32–0.80) 0.52 (0.40–0.69) 
ECV 0.73 (0.66–0.86) 0.77 (0.61–0.80) 0.77 (0.61–0.83) 0.77 (0.50–0.88) 
Inter-observer         
Pre contrast 1 0.66 (0.61–0.72) 0.64  (0.60–0.71) 0.63 (0.58–0.76) 0.59 (-0.11–0.87) 
Pre contrast 2 0.71 (0.65–0.75) 0.59 (0.15–0.84) 0.72 (0.65–0.79) 0.54 (0.47–0.85) 
Post-contrast         
5 min  0.64 (0.62–0.77) 0.72 (0.61–0.79) 0.61 (0.56–0.80) 0.51 (-0.50–0.84) 
15 min  0.77 (0.61–0.87) 0.64 (0.51–0.82) 0.69 (0.36–0.80) 0.52 (0.40–0.69) 
ECV 0.70 (0.66–0.76) 0.76 (0.63–0.79) 0.77 (0.60–0.81) 0.76 (0.49–0.89) 
Inter-study         
Pre contrast 1 0.67 (0.63–0.71) 0.66 (0.60–0.81) 0.68 (0.60–0.80) 0.69 (0.24–0.90) 
Pre contrast 2 0.60 (0.58–0.68) 0.72 (0.48–0.83) 0.71 (0.49–0.79) 0.71 (0.40–0.89) 
Post contrast         
5 min  0.64 (0.63–0.69) 0.79 (0.50–0.85) 0.70 (0.63–0.76) 0.53 (0.43–0.63) 
15 min  0.81 (0.78–0.86) 0.75 (0.63–0.81) 0.70 (0.62–0.75) 0.52 (0.42–0.79) 
ECV 0.79 (0.62–0.89) 0.84 (0.65–0.93) 0.72 (0.22–0.90) 0.79 (0.61–0.86) 
ICC=intraclass correlation coefficient, CI=95% confidence intervals for ICC, ECV=extracellular volume 
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5.5 DISCUSSION 
This study showed that T1 mapping using MOLLI at 1.5T produced good 
quality T1 maps. The T1 maps of the apex, mid, basal and 4 chamber 
ventricular slice provided consistent T1 values with fairly acceptable 
coefficients of variation. Intra-, inter-observer and inter-study reproducibility 
was good to excellent. The calculation of extracellular volume was 
consistent across the slices and had fair intra-, inter-study and inter-study 
reproducibility.  
Unfortunately, 16% of the maps generated were of poor quality, which was 
specifically related to the apical slices and in volunteers with poorly timed 
breath hold. The need for manual motion correction also added another 
potential source of error. 
These findings are consistent with Messroghli et al at 1.5T who showed 
good image quality and excellent reproducibility although reproducibility was 
only assessed in the mid-cavity slice (Messroghli et al., 2006). In addition 
our study looked at 4 chamber slice and quantified extra-cellular volume. 
Chin et al performed a similar study but at 3 Tesla with 20 volunteers and 
reported longer pre-contrast T1 times (approx. 120040) but similar 
ECV(Chin et al., 2014). Also, the normal volunteers were compared with 
patients with asymptomatic aortic stenosis, but a difference in T1 times nor 
ECV could be identified.  
Equilibrium contrast cardiovascular magnetic resonance (EQ-CMR) is a 
method to estimate diffuse myocardial fibrosis which uses an infusion of 
gadolinium contrast to reach steady state. Flett et al reported 13.4% diffuse 
myocardial fibrosis in healthy volunteers which was lower than the ECV 
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percentage in our data (Flett et al., 2012). This may be because the EQ-
CMR method is validated against patients that underwent myocardial biopsy 
in order to measure collagen volume fractions (Flett et al., 2010). 
Shortened MOLLI (ShMOLLI) acquires the readout over 5,5,1 as opposed to 
3,3,5 by MOLLI. Therefore the subject has a shorter breath hold and less 
likely to experience artefact with the advantage of speedier image 
acquisition (Piechnik et al., 2010). However, although a robust and 
reproducible variation to MOLLI, there is a consistent underestimation of T1 
by 4%.  
T1 mapping using this MOLLI sequence is reproducible but some errors can 
occur during acquisition due to altered breath holding or poor triggering 
which can affect the subsequent map generation. For each ventricular slice, 
the map required 3 separate breath-holds which may slightly alter the 
position of acquisition. All readout images were manually motion corrected in 
the MR Maps software. The need for motion correction can introduce error 
and automated and semi-automated methods of motion correction have 
been shown to improve T1 mapping (Kellman et al., 2012). The 
improvements have reduced variability in the T1 value. Off resonance 
artefact can affect the regional T1 measurement but is more significant at 3T 
rather than 1.5T (Kellman et al., 2013).  
The coefficients of variation for ECV were high and this may be because of 
existing variability in the measurement of pre- and post-contrast myocardial 
T1 values combined with the variability of blood pool measurements. A 
single breath hold MOLLI which was not available on our scanner at the time 
of study may overcome this potential problems.  
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Other limitations of this study are that we have studied healthy volunteers 
with a mean age of 20 years and therefore the normal values obtained may 
not reflect or represent a control group for older patients.  Ideally, a larger 
sample with a wide stratified age range would be helpful. This study was 
only performed on 1.5T which has a longer T1 value compared to 3T, 
nevertheless, T1 mapping is favourably a 1.5T based technique given 
problems with mapping at 3T.   
There are a variety of T1 mapping techniques available which have been 
studied in normal and diseased states, however, there is a very wide range 
of normal T1 values which often overlap with ranges quoted for disease 
processes. Currently this makes it very challenging to differentiate between 
true normal and a true disease processes. 
Also, the post-processing time is long with multiple stages and therefore may 
not be immediately or easily applicable to clinical patients.  
5.6 CONCLUSION 
This small study of healthy volunteers showed T1 mapping and ECV 
calculation to be feasible and reproducible at 1.5T. The intra-, inter-observer 
and inter-study agreement was fair for both T1 measurement and 
extracellular volume estimation. However, further studies in diffuse 
myocardial fibrosis of patients are necessary. 
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6 Left Ventricular Reverse Remodelling and Changes 
in Diffuse Myocardial Fibrosis in Severe Aortic 
Stenosis after treatment with Transcatheter Aortic 
Valve Implantation and Contemporary Surgical 
Aortic Valve Replacement 
 
6.1 ABSTRACT  
Background: TAVI for severe aortic stenosis has been effective in treating 
high risk patients with improvement in symptoms and quality of life. There is 
an improvement in cardiac function through reverse remodelling in 
Transcatheter Aortic Valve Intervention (TAVI) and Surgical Aortic Valve 
Replacement (SAVR). 
Aim: To determine if 1) extracellular volume (ECV), a measure of diffuse 
fibrosis, changes after treatment of severe aortic stenosis by TAVI or SAVR; 
2) is baseline ECV related to reverse remodelling.  
Methods: Cardiovascular MRI was conducted at baseline and 6 months 
after intervention. Left ventricular volumes, masses and aortic flows were 
measured. Changes in ECV were measured using T1 mapping using 
modified Look-Locker inversion recovery (MOLLI).  
Results: Seventy patients with severe aortic stenosis were studied (TAVI 
n=39, SAVR n=31, Age: 80.17yrs vs. 73.17yrs, p<0.0001, EuroSCORE: 
20.67 vs. 7.18.2, p<0.0001). After 6 months, there were significant 
improvements in indexed end-diastolic volumes (TAVI: 10025mls vs. 
8726mls, p<0.001; SAVR 9128mls vs. 8217mls, p<0.05) and reduction in 
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mass for both TAVI (7516g vs. 5517g, p<0.001) and SAVR (7524g vs. 
595915g, p<0.001) patients. Only TAVI patients showed a significant 
reduction in end-systolic volume (4826mls vs. 4019mls, p<0.05). 
Extracellular volumes were similar for both groups at baseline (range 22.8 to 
24.6%). There was no significant change in ECV after 6 months (TAVI, 
24.09% vs. 29.311%, SAVR, 23.87 vs. 23.59, p= 0.76). In multivariate 
logistic regression only AF and baseline LV mass were significant for cardiac 
reverse remodelling (Adjusted odds ratio (OR) and confidence intervals (CI), 
AF: OR, 2.06, CI 1.2 to.3.7, p=0.04; LV mass OR 1.08, CI 1.008 to 1.147, 
p=0.03) 
Conclusion: Significant cardiac reverse remodelling takes place by 6 
months after TAVI and SAVR due to cellular changes. ECV does not change 
after TAVI or SAVR and is not independently associated with LV reverse 
remodelling.  
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6.2 INTRODUCTION 
Severe aortic stenosis is a progressive disease with associated risk of death 
from heart failure. This is prevalent in the elderly population who often are 
deemed unsuitable to receive surgical aortic valve replacement (SAVR) due 
to high operative risk. Recent large randomised controlled trials and 
subsequent follow-up studies to 3 to 6 years have shown that Transcatheter 
Aortic Valve Implantation (TAVI) has survival benefit and is associated with 
significant improvement in symptoms and quality of life (Leon et al., 2010b, 
Kodali et al., 2012c, Fairbairn et al., 2012b). UK TAVI six year follow-up 
showed survival at one year to be 81.7% falling to 37.3% at six years 
(Ludman et al., 2015). The benefits are possibly due to the obliteration of the 
valvular obstruction and subsequent improvement in ventricular function 
through reverse remodelling which has been shown by echocardiography 
and CMR (Fairbairn et al., 2013b). A possible contributing pathological 
process is myocardial interstitial fibrosis that is associated with severe aortic 
stenosis and the related left ventricular hypertrophy (Rudolph et al., 2009). In 
aortic stenosis there is predominantly a reactive form of interstitial fibrosis 
which is diffuse and not readily detectable, but can also be focal scar, which 
can be seen on CMR late gadolinium imaging (Flett et al., 2011, Fairbairn et 
al., 2013b). The degree of diffuse fibrosis and focal fibrosis (scar) may 
influence subsequent reverse remodelling after valve surgery or intervention. 
Fairbairn et al showed focal myocardial fibrosis to be a predictor for reverse 
re-modelling because the presence of scar was associated with poor 
baseline volumes and ejection fraction which in turn determined post 
intervention volumes and function (Fairbairn et al., 2013b). Although TAVI 
and SAVR are different approaches, both have been shown to improve 
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ventricular function early as 14 days (Crouch et al., 2015). Studies have 
shown the increasing importance of patient selection for high risk expensive 
procedures and there is a need to identify predictors for beneficial outcomes 
that the Heart MDT may use to influence management decisions (Ludman et 
al., 2015). The aim of the study was to see if there was a change in diffuse 
interstitial fibrosis after TAVI and whether it was similar in patients receiving 
SAVR. Secondly, is diffuse myocardial fibrosis associated with LV reverse 
remodelling? 
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6.3 METHODS 
6.3.1 Study Participants 
Between March 2012 to October 2013, patients with symptomatic severe 
aortic stenosis were prospectively and consecutively recruited from two large 
tertiary (Leeds & Leicester) TAVI centres. Severe aortic stenosis was 
defined by transthoracic echocardiography with a peak aortic velocity of 
>4ms-1 , mean gradient >40 mmHg and a valve area <1.0cm2.  All patients 
were assessed by the multi-disciplinary Heart team and considered suitable 
for SAVR or TAVI according to contemporary guidance. Complete matching 
was not possible because of current UK TAVI guidelines, however, Older, 
higher risk based on the logistic EuroSCORE (European System for Cardiac 
Operative Risk Evaluation) SAVR patients with ≥1 comorbidities were 
identified for recruitment. Exclusion criteria were: any contraindication to 
MRI, such as cardiac pacemaker and claustrophobia, end stage renal 
failure. The study was approved by the Institutional Ethics Committee and 
complied with the Declaration of Helsinki. All patients provided written 
informed consent.  
6.3.2 TAVI procedure 
TAVI was performed by highly experienced consultant interventional 
cardiologists (>5 years TAVI experience) with the Medtronic CoreValve or 
Edward Sapien prosthesis according to institutional preference, as 
previously described (Piazza et al., 2008). In brief, all procedures were 
performed under general anaesthesia with X-ray fluoroscopy and 
transoesophageal echocardiographic guidance in the cardiac catheter 
laboratory. At the time of study conscious sedation was not widely practiced 
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in the UK. All patients received weight-adjusted unfractionated heparin to 
maintain an activated clotting time >200secs and were treated with dual 
antiplatelet (aspirin and clopidogrel) for 6 months post procedure. 
6.3.3 SAVR operation 
All patients under went general anaesthesia and midline sternotomy with 
cardiopulmonary bypass and mild hypothermia. The surgical valve 
prosthesis varied according to annular size, patient characteristics and 
surgeon/patient preference. Coronary artery bypass grafting was 
concomitantly performed if indicated.  
6.3.4 Scan protocol 
Each participant was imaged on the same vendor platform with an identical 
protocol. The study was performed on 1.5 Tesla (Intera, Philips Healthcare, 
Best, Netherlands) with Master gradients (30mT/m, 150[mT.m-1]/msec) and 
a five-element cardiac phased array receiver coil with vector cardiogram. 
Localiser images were obtained using cine steady state free precession for 
the vertical long axis (VLA), horizontal long axis (HLA) and short axis (SA) of 
the left ventricle (SSFP, TR 3.0ms, TE 1.5ms, Slice thickness 8mm, FOV 
400, RFOV 80, 30 phases). The LV volumes were acquired in the short axis 
plane using multi-slice and multi-phase cine imaging. Typically 10 to 12 
contiguous slices were acquired covering from the mitral valve plane to 
beyond the apex (Slice thickness 10mm, 0 gap, 30 phases, FOV 380, RFOV 
100).  The “3 of 5” technique was used to identify basal, mid- ventricular and 
apical slices as this has been shown to be reproducible (Messroghli et al., 
2005). This is performed by planning 5 parallel short axis slices from the 
outmost aspect of mitral annulus and LV apex, with the ventricle in systole. 
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The centre 3 slices are used to acquire cine images and later plan MOLLI 
sequences.  
T1 mapping was performed with the MOLLI pulse sequence which was 
described by Messroghli (Messroghli et al., 2004). For each individual slice 
(base, mid, apex), there were 3 successive Look-Locker acquisitions (trains). 
Each of these trains, starts with a specific inversion time (100ms, 200ms and 
350ms) after which multiple single shot images are acquired over 
consecutive heart beats in end-diastole. The 3 trains produce 3, 3 and 5 
images (3,3,5 MOLLI).  MOLLI was performed pre-contrast, and 5 and 15 
minutes after intravenous administration of 0.2mmol/kg of gadoteric acid 
contrast (Dotarem®, Guerbet, Villepinte). The contrast was followed by a 
20mls saline flush.  
6.3.5 Image analysis 
Left ventricular volumes using the summation of discs method were 
calculated by manually contouring the endocardial and epicardial borders at 
end-diastole and again at end-systole in commercially available software 
(Qmass 6.0, Medis, Netherlands) (Mass = epicardial volume – endocardial 
volume multiplied by the myocardial density (1.05g/cm3)). (Gaasch and Zile, 
2011). 
T1 maps were generated off-line from source MOLLI data images using 
published software MR Maps (Messroghli et al., 2010). In the software the 
images are manually checked and corrected for significant motion before 
map generation. The software sorts the images in order of effective inversion 
time (TI) and uses three-parameter non-linear curve fitting using a 
Levenberg-Marquardt algorithm. A T1 map is generated as a DICOM file 
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which is stored. This T1 map is analysed in Qmass 6.0 (Medis, 
Netherlands). A region of interest (ROI) is drawn in the myocardial septum 
and blood pool to measure T1. A conservative septal ROI has been shown 
to provide good reproducibility (Rogers et al., 2013). Image quality was 
assessed by two independent observers and were graded Likhart scale 
(1=unusable, 2=poor, 3=adequate, 4=excellent). 
6.3.6 LGE Analysis 
Focal areas of hyperenhancement were described according to their number 
and location and specific pattern (mid wall fibrosis or sub-endocardial infarct 
type) by three independent observers. Quantitative analysis was performed 
by semi-automated signal intensity analysis according to the full width half 
maximum method which has been previously published in severe aortic 
stenosis (CVI42, Circle Cardiovascular Imaging, Calgary, Alberta, Canada) 
(Fairbairn et al., 2013b). 
6.3.7 ECV calculation 
The myocardial partition coefficient was calculated using the following 
equation: 
 𝜆 =
∆𝑅1 𝑚𝑦𝑜𝑐𝑎𝑟𝑑𝑖𝑢𝑚
∆𝑅1 𝑏𝑙𝑜𝑜𝑑 𝑝𝑜𝑜𝑙
 where 1 =
1
𝑇1
 . The 𝐸𝐶𝑉 = (1 − ℎ𝑎𝑒𝑚𝑎𝑡𝑜𝑐𝑟𝑖𝑡) ×  𝜆  
The haematocrit is measured from the full blood count sample. 
 
6.3.8 Statistical analysis  
Data were tested for normality with the Shapiro-Wilks test. Continuous 
variables were expressed as meansSD or medians (Q1-Q3) and discrete 
variables as n (%). Continuous variables were compared with ANOVA for 
repeated measures with Bonferroni correction or independent T tests. The 
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between subjects’ factor was treatment group (TAVI vs. SAVR). Age and sex 
were entered as co-variates when necessary. Fishers exact or Chi squared 
was used for comparison of discrete variables. Wilcoxon signed rank test 
and Mann-Whitney test was used for non-parametric testing. 
Univariate linear regression analysis was conducted using clinical and CMR 
fibrosis variables and compared with the change in LV mass. Variables with 
p≤0.10 were entered into a stepwise multivariable regression analysis. 
Univariate logistic regression analysis was performed for overall LV 
remodelling (yes=1 or no=0) (LV remodelling=reduction in EDV and ESV by 
10mls and reduction in mass by 10g). 
Previous CMR studies have shown that to detect a 10ml change in LV 
volumes then a sample size of n=10-12 would be sufficient and 3% change 
in EF, n=15 (Bellenger et al., 2000b). To detect a 0.038 change in ECV 
(Equivalent to 3% histological fibrosis) the sample of n=27 in each group 
would be necessary for power of 80% and alpha error on 0.05 (Liu et al., 
2012). 
- 157 - 
6.4 RESULTS 
6.4.1 Patient characteristics 
Seventy patients with severe aortic stenosis were recruited (Figure 6-1). 
Expectedly, the TAVI group were older with higher surgical risk scores and a 
higher prevalence of prior CABG, PCI and COPD (Table 6-1). Both groups 
have similar prevalence of hypertension, diabetes, AF, prior stroke and 
hypercholesterolaemia. The echocardiographic parameters are shown in 
table 6-1. The peak velocities were similar but calculated valve areas were 
significantly smaller in TAVI group and there were also higher proportion of 
LV impairment (table 6-1). There was a higher dropout in the TAVI group 
compared to SAVR as they were elderly and had greater co-morbidities.  
Figure  6-1 Study Flow Chart 
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Table  6-1 Patient characteristics  
Data are Mean±SD or n (%). BMI=body mass index, NYHA=New York Heart Association, 
STS=Society of Thoracic Surgery, TIA=transient ischaemic attack, MI=myocardial infarction, 
CABG=coronary artery bypass grafting, PVD=peripheral vascular disease, COPD=chronic 
obstructive pulmonary disease, eGFR=estimated glomerular filtration rate, AV=aortic valve. 
LVEF=left ventricular ejection fraction. *Mann Whitney test. 
Clinical characteristics TAVI (n=39) SAVR (n=31) p value 
Age, years 80.16.9 73.17.2 <0.0001 
Male, n (%) 20 (51) 23 (74) 0.04 
BSA, m2 1.820.2 1.970.2 0.008 
BMI, kgm-2 27.94.6 28.44.7 0.66 
NYHA Class, n (%) 
     I 
     II 
     III 
     IV 
 
0 
3 (8) 
30 (77) 
6 (15) 
 
2 (7) 
12 (39) 
17 (55) 
0 
0.0001* 
 
EuroSCORE, (%) 20.67.1 7.18.2 <0.0001 
EuroSCORE II, (%) 5.43.9 1.50.9 <0.0001 
STS Score, (%) 5.33.4 2.20.7 <0.0001 
STS Morbidity, (%) 24.07.2 15.93.7 <0.0001 
Hypertension, n (%) 21 (53.8) 21 (67) 0.18 
Diabetes, n (%) 8 (21) 6 (19) 0.57 
Hypercholesterolaemia, n (%) 22 (56) 24 (77) 0.08 
Atrial fibrillation, n (%) 11 (28) 3 (10) 0.07 
Stroke/TIA, n (%) 6 (15) 5 (16) 0.99 
MI, n (%) 5 (13) 5 (16) 0.75 
CABG, n (%) 10 (26) 0 0.002 
PCI, n (%) 10 (26) 2 (7) 0.03 
PVD, n (%) 8 (21) 2 (7) 0.17 
COPD, n (%) 12 (31) 2 (7) 0.02 
Pulmonary Hypertension n (%) 8 (23) 4 (13) 0.35 
eGFR, ml/min/1.73m2 6717 7512 0.03 
 
Echocardiographic data: 
   
Peak AV velocity, ms-1 4.50.6 4.51.4 0.88 
Mean AV gradient, mmHg 4914 4513 0.18 
Aortic valve area, cm2 0.60.2 0.80.5 0.04 
LVEF, n (%) 
     Normal 
     Mild 
     Moderate 
     Severe 
 
18 (46) 
16 (41) 
3 (8) 
2 (5) 
 
24 (78) 
6 (19) 
0 (0) 
1(3) 
0.03* 
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6.4.2 Procedural characteristics 
TAVI was successful in all cases with predominant femoral access. Most 
SAVR patients received biological valves and 14(35%) had concomitant 
CABG which prolonged bypass time (Table 6-2). 
Table  6-2 Procedural details 
  n (%) 
TAVI (n=39)   
Medtronic CoreValve, n=29 31mm 4 (10) 
 29mm 19 (49) 
 26mm 3 (8) 
 23mm 3 (8) 
Boston LOTUS, n=10 27mm 8 (21) 
 23mm 2 (5) 
Access route Femoral 38 (97) 
 Carotid 1 (3) 
Procedure time, (min)  16076 
Fluoroscopy time, (min)  2613 
Contrast volume, (ml)  13869 
SAVR (n=31)   
Biological, n (%)  26 (84) 
Mechanical, n (%)  5 (16) 
Size, (mm) (median, Q1-Q3)  23 (21–25) 
Bypass time, (min)  
 
All  
AVR only 
AVR and CABG 
13372 
11365 
15874 
Cross clamp time, (min)  All  
AVR only 
AVR and CABG 
9961 
8961 
11161 
CABG, n (%)  14 (35) 
Data are Mean±SD or n (%). CABG=coronary artery bypass grafting 
- 160 - 
6.4.3 Cardiovascular MRI findings 
Volumes, mass and flow analysis  
Cardiovascular MR volumetric analysis is shown in Table 6-3. There were 
significant improvements in indexed end-diastolic volumes and reduction in 
mass for both TAVI and SAVR patients. This was reflected in a statistically 
significant reduction in mass to volume ratio (LVM/LVEDV) Table 6-3. Only 
TAVI patients showed statistically significant reduction in end-systolic 
volumes and stroke volumes (Table 6-3). There was no significant change in 
ejection fraction for TAVI and SAVR patients. Both treatments resulted in 
significant reductions in mean aortic pressure gradients and there was no 
significant post procedural aortic regurgitation (Table 6-3).  
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Table  6-3 Cardiovascular magnetic resonance volumetric, flow and late 
gadolinium enhancement findings at baseline and after 6 months. 
 TAVI  SAVR   
 Baseline 
n=39 
6m 
n=30 
Baseline 
n=31 
6m 
n=27 
p value† 
Left ventricle      
LVEDVI (ml/m2) 10025 8726*** 9128 8217* 0.002 
LVESVI (ml/m2) 4826 4019* 3922 3414 0.006 
LVSV (ml/m2) 529 4713* 5212 488 0.005 
LVEF (%) 5413 5315 6012 6010 0.54 
LVM (g) 7516 5517*** 7524 5915*** 0.001 
LVM/LVEDV (g/ml) 0.760.3 0.620.18** 0.850.2 0.730.2*** 0.04 
      
Aortic valve      
Mean PG (mmHg) 3516 1712*** 4421 2110*** 0.0001 
AR fraction 1610 66*** 1513 88* 0.001 
      
Late gadolinium enhancement      
Mass (g) 4.84.7 5.55.7 7.26.5 6.38.3 0.60 
Percentage myocardium 3.23.1 7.77.8** 4.43.9 5.35.9 0.001 
      
T1 mapping      
Pre-contrast myocardial T1 (ms)      
Base 76192 76070 76083 74077 0.22 
Mid 75282 76786 75990 75570 0.49 
Apex 73277 76478 75484 73073 0.31 
      
Post-contrast T1 (ms)      
Base 45080 42662 44778 42655 0.38 
Mid 44786 41878 45177 43878 0.42 
Apex 45350 41467 43160 41056 0.35 
Extracellular Volume (%)      
Base 23.59 27.310 24.67 23.78 0.38 
Mid 24.09 29.311 23.87 23.59 0.76 
Apex 22.88 26.110 21.97 22.88 0.08 
      
 
Values are meansSD.  †Repeated measures ANOVA with treatment group as between 
subjects’ factor. Paired t test vs baseline: *p<0.05, **<0.01, ***p<0.001. For T1 mapping 
analysis, age was entered as a co-variate in ANOVA. AR=aortic regurgitation, EDVI=end diastolic 
volume indexed to body surface area, ESVI= end-systolic volume indexed, SV=stroke volume, 
LV= Left ventricular, EF=ejection fraction, M=mass, PG= peak gradient, SAVR= surgical aortic 
valve replacement, TAVI=transcatheter aortic valve implantation. 
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Late gadolinium findings 
Sixteen (41%) TAVI and 14 (45%) SAVR patients had evidence of LGE at 
baseline (p=0.81). There was no statistically significant difference in fibrosis 
mass at baseline between the two groups (TAVI vs. SAVR, 4.84.7g vs. 
7.26.5g, p=0.20).  
At baseline, the basal and mid ventricle had higher proportions of 
enhancement, but there were no statistically significant differences between 
TAVI and SAVR (TAVI vs. SAVR; Base, 16/16 (100%) vs. 13/14(93%) 
(p=0.47), mid 15/16(94%) vs. 10/14(71%) (p=0.16) and apex 8/16(50%) vs. 
3/14(21%) (p=0.14). There was also higher proportion of septal wall 
enhancement at each ventricular level but no difference between TAVI vs. 
SAVR, (basal septum 10/16 (62%) vs 7/13(54%) (p=0.71), mid septum 9/15 
(60%) vs 6/10(60%) (p=0.13) apical septum 3/8(38%0 vs 2/3 (66%). (p=0.9))  
There was no change in mean mass of fibrosis 6 months after TAVI and 
SAVR (Table 6-3). However, the percentage myocardium with scar after 
TAVI was significantly higher (Table 6-3). 
T1 mapping and extracellular volume analysis 
There was no difference between baseline pre-contrast T1 measurements 
between TAVI and SAVR (base, mid and apex all p>0.05) (Table 6-3). 
Similarly, there were no statistical differences in post contrast measurements 
(Table 6-3). After 6 months, the T1 measurements did not change for either 
group (Table 6-3).  
The extracellular volumes were similar at baseline for both TAVI and SAVR 
(range 22.8 to 24.6%) across the base, mid and apex. After 6 months, there 
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were no statistically significant reductions in ECV for either TAVI or SAVR 
(Table 6-3) over the 3 slices.  
6.4.4 Predictors of LV mass regression and LV reverse remodelling 
Clinical variables and baseline cardiovascular MR measures of diffuse and 
focal fibrosis were analysed using univariate and multivariate regression to 
detect change in LV mass indexed by BSA (Table 6-4). The significant 
univariate predictors were gender, PVD and mass of fibrosis on late 
gadolinium but not diffuse fibrosis as measured by extracellular volume. 
However, in multivariate analysis these variables did not reach significance 
(Gender: β=0.05, p=0.78, PVD β=0.24, p=0.16, LGE fibrosis, β=0.24, 
p=0.18). 
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Table  6-4 Univariate regression analysis of clinical and CMR variables for 
prediction of LV mass regression 
variables R P value 
TAVI 0.01 0.98 
Age 0.07 0.59 
Male 0.28 0.04 
BSA 0.19 0.16 
NYHA class 0.18 0.18 
EuroSCORE 0.02 0.89 
EuroSCORE II 0.12 0.38 
STS score 0.01 0.98 
Hypertension 0.04 0.76 
Diabetes 0.08 0.56 
Hyperlipidaemia 0.16 0.23 
Atrial Fibrillation 0.16 0.23 
TIA/Stroke 0.01 0.96 
Previous MI 0.21 0.13 
CABG 0.09 0.52 
Previous PCI 0.06 0.64 
PVD 0.26 0.05 
COPD 0.05 0.71 
PHT 0.17 0.21 
GFR 0.11 0.40 
LGE fibrosis 0.27 0.10 
ECV (mid) 0.09 0.56 
T1 (mid) 0.03 0.80 
 - - 
TAVI=Transcatheter Aortic Valve Implantation, SAVR=Surgical Aortic Valve Replacement, 
BSA=body surface area, BMI=body mass index, NYHA=New York Heart Association, 
STS=Society of Thoracic Surgery, TIA=transient ischaemic attack, MI=myocardial infarction, 
CABG=coronary artery bypass grafting, PVD=peripheral vascular disease, COPD=chronic 
obstructive pulmonary disease, BAV=balloon aortic valvuloplasty, eGFR=estimated 
glomerular filtration rate. 
- 165 - 
LV reverse remodelling was defined by a reduction in LVEDV and LVESV by 
10mls and reduction in LV mass by 10g. Predictors of reverse remodelling 
were analysed using a logistic regression analysis (Remodelling; yes=1, 
no=0) (Table 6-5). AF, PVD and baseline CMR volumes and mass were 
predictors of cardiac reverse remodelling but not late gadolinium 
enhancement fibrosis or extracellular volume. In multivariate logistic 
regression only AF and baseline LV mass remained significant factors 
(Adjusted odds ratio (OR) and confidence intervals (CI), AF: OR, 2.06, CI 1.2 
to.3.7, p=0.04; LV mass OR 1.08, CI 1.008 to 1.147, p=0.03). 
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Table  6-5 Univariate logistic regression analysis of clinical and CMR 
variables for predictors of left ventricular reverse remodelling 
Abbreviations as in table 4. 
Risk factors Unadjusted 
odds ratios 
95% CI p values 
TAVI 1.66 0.58 to 4.75 0.34 
Age 1.00 0.95 to 1.05 0.87 
Male 2.08 0.70 to 6.2 0.19 
BSA 1.60 0.17 to 16.1 0.41 
NYHA 1.04 0.46 to 2.36 0.93 
EuroSCORE 1.0 0.96 to 1.06 0.73 
EuroSCORE II 0.96 0.82 to 1.12 0.57 
STS Score 1.02 0.82 to 1.25 0.88 
Hypertension 0.67 0.23 to 1.94 0.46 
Diabetes 2.00 0.45 to 8.91 0.36 
Hypercholesterolaemia 0.63 0.21 to 1.9 0.41 
AF 3.1 1.54 to 11 0.02 
Stroke/TIA 0.54 0.13 to 2.12 0.38 
MI 1.67 0.36 to 7.77 0.55 
CABG 2.5 0.44 to 14.1 0.30 
PCI 1.44 0.36 to 5.77 0.61 
PVD 0.10 0.01 to 0.86 0.04 
COPD 1.1 0.29 to 4.12 0.89 
PHT 2.40 0.53 to 10.83 0.26 
Creatinine 0.99 0.98 to 1.01 0.93 
LV EDVi 1.05 1.02 to 1.08 0.001 
LV ESVi 1.03 1.01 to 1.06 0.02 
LVSV 1.13 1.05 to 1.21 0.002 
EF 0.97 0.92 to 1.01 0.14 
LV mass 1.08 1.04 to 1.13 0.001 
LGE mass 1.10 0.94 to 1.27 0.22 
ECV 0.13 0 to 13.9 0.57 
T1 1.01 0.99 to 1.00 0.72 
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DISCUSSION 
This study showed that reverse remodelling occurs within 6 months of 
intervention with both TAVI and SAVR. We showed that both groups had a 
reduction in end diastolic volumes and LV mass regression, but the TAVI 
group also had a reduction in end systolic volumes. The latter difference 
may be related to the differences between the TAVI device and the surgical 
prosthesis, suggesting TAVI may achieve a greater effective orifice area and 
hence a lower final end systolic volume. With late gadolinium imaging we 
showed the presence of scar was similar in both TAVI and SAVR.  This  
study used T1 mapping in patients with severe aortic stenosis who either 
received TAVI or SAVR dependent on their surgical risk. We showed similar 
levels of extracellular volumes in both patient groups but there was no 
significant change after six months. However, a change may not have been 
detected because of the wide standard deviations. Also, there has been 
reported overlaps between the ranges of normal T1 values and pathological 
states. Therefore, larger sized samples may be necessary to detect 
significant differences. In addition, key factors for predicting mass regression 
were gender, peripheral vascular disease and fibrosis mass on late 
gadolinium imaging. When defining revere cardiac remodelling as a 
reduction in EDV, ESV and mass, we found that the presence of AF and the 
baseline LV mass were important factors.  
The groups are significantly different with regard to their baseline 
characteristics as we have seen in the earlier chapters. The TAVI group had 
a smaller aortic valve area which may imply that they had a more severe 
form of aortic stenosis and thus the results could be confounded. 
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Focal fibrosis as detected by LGE may not be fixed and can undergo 
remodelling with time and the patterns can be mid wall or sub endocardial as 
in myocardial infraction. Previous studies have shown that there was a 
quantitative reduction after TAVI but not SAVR in myocardial fibrosis 
(Fairbairn et al., 2013b). 
Flett et al showed that diffuse myocardial fibrosis was associated with 
severe aortic stenosis using the equilibrium contrast CMR method, and 
fibrosis correlated with functional status. However, the fibrosis volume did 
not alter after surgical valve replacement but LV hypertrophy receded(Flett 
et al., 2012). This suggested that cell volume reduction was the key 
component and interstitial fibrosis is fixed and not dynamic. Similar findings 
occurred in our study with TAVI patients having a higher fibrosis burden 
relative to the overall LV mass (% myocardium). This can again be a 
reflection on the frailer TAVI patient. 
Weidemann et al showed that late gadolinium enhanced fibrosis was 
associated with higher NYHA class in patients undergoing SAVR. 
Nevertheless, they did not detect a change in this form of fibrosis (scar or 
replacement fibrosis) when CMR was repeated 9 months later (Weidemann 
et al., 2009). 
The benefits of using CMR with T1 mapping and late gadolinium imaging 
are: 1) accurate changes in left ventricular volumes and aortic flow 
measurements can be detected 2) diffuse myocardial fibrosis changes can 
be identified compared after treatment and 3) fixed irreversible scarring can 
be highlighted and silent myocardial infarction can be documented.  
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6.4.5 Limitations 
There are several limitations in our study due to technical or practical 
restrictions. This study was not matched for age, sex or surgical risk due to 
restrictions and recommendations according to current international 
guidelines; however future studies may be able to overcome this when TAVI 
is being considered in a traditionally lower surgical risk setting. Therefore the 
findings are confounded by the differences in the groups. 
Histological myocardial samples were not obtained in this study, however, 
this has been extensively studied and correlated with CMR fibrosis imaging 
(Azevedo et al., 2010, Flett et al., 2012). In addition myocardial biopsy 
during TAVI may pose an additional risk to patients who are already 
vulnerable to myocardial insults.  
Unfortunately some patients would have been excluded from follow up CMR 
due to pacemaker implantation which is an inherent complication for both 
TAVI and SAVR, but the study was powered to detect sufficient change in 
ECV and thus was not influenced by exclusions.  
There are a variety of T1 mapping techniques available such as MOLLI and 
ScMOLLI, but we only had MOLLI available on the study scanner and 
therefore could not use any other sequence. Perhaps a shortened 
acquisition would reduce artefact and reduce the amount of motion 
correction necessary. This would improve the accuracy of the obtained T1 
values and subsequent ECV estimations. 
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6.5 CONCLUSIONS 
This study showed that cardiac reverse remodelling after TAVI is similar to 
contemporary surgical aortic valve replacement, with the additional reduction 
in end systolic volumes. Although the quantity of diffuse fibrosis as estimated 
with T1 mapping techniques is similar between TAVI and SAVR patients at 
baseline, we could not demonstrate a reduction in this after 6 months.  
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7  Overall Conclusions and Future directions 
The advancement of medical therapy has facilitated the prolongation of life 
and improved the quality of life over the last 100 years. A direct 
consequence of early achievements has led to the increased prevalence of 
degenerative conditions affecting various organs and systems. The 
cardiovascular system is an essential part of the body which influences other 
organs. With the aging population the diagnosis of calcific aortic stenosis 
would be such a condition. We know that as life expectancy increases the 
population will exhibit a significant proportion of patients with this condition. 
Currently it is estimated that in the over 65 years age range the prevalence 
of calcific aortic stenosis is between 2 to 7 % (Nkomo et al., 2006, Stewart et 
al., 1997). Nevertheless a recent Swedish registry highlighted that the 
prevalence of aortic stenosis may be declining and that there was a gender 
difference (Martinsson et al., 2015). There was a decline in the age-adjusted 
incidence from 15.0 to 11.4 per 100000 in men over 10 years and 9.8 to 7.1 
for women respectively. These changes may be additional evidence towards 
general improvement in healthcare and the wider use of risk factor 
modifications. 
 
Severe aortic stenosis is a progressive degenerative condition which occurs 
as a result of valve leaflet restriction. There is a reduction in aortic valve area 
which initiates changes in left ventricular performance and the myocytes 
undergo remodelling in a pressure overloaded state. The myocardium at the 
cellular level causes cellular hypertrophy and the mass of the ventricular 
increases. The patient develops symptoms of exertional dyspnoea, angina 
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pectoris, syncope and heart failure; the latter being characterised by 
oedema.  
 
The option of medical therapy is palliative as severe aortic stenosis is a 
mechanically obstructed condition and drug therapy has limited roles. The 
patient may be treated with diuretics for symptomatic improvement but other 
therapies such as beta blockers, statins and ACE inhibition have limited 
benefit. 
 
The current recommendation for from the American and European 
cardiovascular societies are that surgical aortic valve replacement should be 
offered to patients that have symptomatic aortic stenosis (Nishimura, 2014 
#923). The difficulty arises when the Heart MDT deems the patient 
unsuitable for surgical intervention due to high operative risk. The 
EuroSCORE and STS scores are used to help surgeons risk stratify such 
patients although the presence of significant medical and surgical co-
morbidity may potentiate risk. There is growing evidence that surgery in the 
elderly can be performed safely and with minimal complication (Jansen 
Klomp et al., 2016, Kolh et al., 2007). Studies of octogenarians and 
nonagenarians have reported supporting data, such as similar operative 
mortality of 2.9% in octogenarians and 1.9% in the younger cohort. The 
incidence of post-operative delirium in the elderly was high at 11% (Jansen 
Klomp et al., 2016). However, often the success is limited around specific 
surgical centres. 
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Percutaneous aortic valve implantation has been a major advance in 
cardiology for the 21st century. The procedure is now widely accepted as 
Transcatheter aortic valve implantation (TAVI). This procedure evolved from 
palliative balloon aortic valvuloplasty (BAV) which only used a balloon 
inflation to increase the aortic valve area, however was complicated by 
severe aortic incompetence or aortic rupture leading to tamponade and 
death (Dauterman et al., 2003). The other important limitation of BAV was 
the high six month restenosis rate that was observed.  
 
The initial percutaneous aortic valve prosthesis were either mounted on a 
balloon known as balloon expandable prosthesis (Edwards Lifesciences). 
The other prosthesis was on a self-expanding nitinol frame that was 
released in position after initial BAV (Medtronic CoreValve). The PARTNER 
trials or Placement of Aortic Transcatheter Valves studies were major 
randomised control studies that showed significant benefits in the TAVI arm. 
Firstly those who received TAVI reported reduced symptoms of heart failure 
and mortality was superior to medical therapy alone. In comparison the high 
risk SAVR, TAVI exhibited similar 30-day mortality but higher stroke rates. 
Overall the PARTNER studies supported the use of TAVI devices in this high 
risk frail group of patients that would die without intervention. The major risks 
in TAVI were associated with bleeding and post-procedure stroke and post 
implantation regurgitation. The complication of bleeding has reduced with 
evolution in vascular access and closure methods. The size of the sheaths 
has decreased from 24F down to 18F and improvement in suture based 
closure devices have reduced vascular complications.  
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The studies in this thesis focussed on the cerebral embolisation that occurs 
during TAVI and SAVR and the consequence of the cerebral micro-
infarctions on the patients with emphasis on the effect on their quality of life 
and changes in the neurocognitive performance. The implantation or 
replacement of the aortic valve changes the cardiac function and 
cardiovascular MRI was used to observe the changes between the diseased 
state and 6 months after intervention. Particular focus was placed on the 
process of diffuse fibrosis and the influence it may have on reverse LV 
remodelling as the ventricle adapts from a pressure overloaded state to a 
pressure free state. 
 
In Chapter 3 the study found that TAVI resulted in significantly higher 
number of cerebral micro-infarcts in comparison to the SAVR patients. This 
used a highly sensitive technique of cerebral MRI and diffusion weighted 
imaging (DWI). Clearly, the implantation of the TAVI prosthesis generates 
showers of micro-embolisation which can seed to any organ, but in the brain 
cause micro-infarction. The DWI lesion did not appear in the follow up scans 
as they would have resolved by then. The predictors of cerebral micro-
infarcts for TAVI was aortic atheroma and for SAVR the co-existing 
significant coronary artery disease. This suggests that the embolic material 
is atheromatous in origin in both groups.  
 
Health related quality of life improved earlier at 30 days in TAVI group 
supported by improvement in the physical scores. There was a lag in 
improvements in the HRQoL scores in the SAVR group which may be 
related to the longer recovery period which is associated with this group. 
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There was no negative effect of cerebral micro-infarction on the HRQoL, 
even the TAVI mental component scores improved. Interestingly, SAVR 
patients with micro-infarcts had a lower physical component score at 30 
days suggesting a greater influence on physical function. This may be due to 
additional effects of cardio-pulmonary bypass on neuronal function and 
perhaps an impaired response to injury. Therefore, although not causing a 
definite clinical stroke, the embolic event causes an effect on general 
physical well-being. 
Following the finding of this chapter, we wanted to shift the focus of the 
potential effects of cerebral micro-infarction from overall multi-factorial 
general health to more specific cerebral functions. In Chapter 4 the focus 
moved to the effect on neurocognitive function following the treatment of 
aortic stenosis with either percutaneous valve implantation(TAVI) or open 
surgical valve replacement (SAVR). Here we used specific tools designed to 
detect and grade cognitive function over a wide range of areas. The TAVI 
group had a lower level of neurocognitive function at baseline compared to 
the SAVR group which is likely to be related to the differences in baseline 
characteristics and risk factor profile. The neurocognitive functional testing 
was broad and comprehensive covering areas of global, mnemonic and 
executive functions as well as psychomotor and dexterity. There was an 
improvement in neurocognitive function in both TAVI and SAVR groups 
supporting the beneficial effects of treatment. Although the cerebral micro-
infarction was again higher in the TAVI group, the findings suggest that the 
was no detrimental effect of embolism on neurocognitive function. In 
addition, patients did not fall into the impaired neurocognitive function group 
over the 4 assessment points. The predictors of neurocognitive impairment 
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at baseline were atrial fibrillation, prior CABG and renal function suggesting 
that chronic disease processes may influence cognitive decline rather than a 
one off cerebral insult. The findings based on the serial neurocognitive 
functional testing suggests that TAVI and related cerebral embolisation does 
not have a negative effect on overall higher cerebral function.  
 
In the thesis there is evidence that the treatment of aortic stenosis with TAVI 
or SAVR improves heath related quality of life and neurocognitive function. 
However, the were significant differences in the baseline characteristics of 
the TAVI group and SAVR group. Overall, the TAVI group as expected given 
their high surgical risk had greater co-morbidities, were older and more frail. 
Thus comparisons were confounded by these differences which were 
unavoidable as the studies were not randomised control trails.  
The common but important intervention to both TAVI and SAVR groups was 
the removal of the obstruction caused by the diseased aortic valve. 
Therefore it was important to understand the changes in cardiac reverse 
remodelling that occured after both interventions. In the introduction the 
superiority of Cardiovascular magnetic resonance (CMR) to 
echocardiography was highlighted and how it is useful and accurate at 
assessing ventricular function. CMR allows comprehensive assessment by 
volumetric analysis, aortic flow measurements and tissue characterisation. 
Most processes in cardiomyopathy involve fibrosis which can be focal or 
diffuse. In chapter 5 and 6 the focus was placed on measuring myocardial 
extra cellular volume (ECV) as a measure of diffuse fibrosis. 
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In Chapter 5, T1 mapping was conducted in healthy volunteers using the 
Modified Look-Locker Inversion(MOLLI) method. The study showed that the 
T1 value was similar across the 3 slices of the left ventricle. In addition the 
ECV was similar across the 3 slices. The MOLLI method was reproducible 
with good intra- and inter observer and inter study reproducibility. There 
were limitations in this study as MOLLI was the only T1 mapping sequence 
available to the study scanners. However, this MOLLI method had been 
used before and studied in aortic regurgitation and myocardial infarction 
within the department. This gave confidence in using this method in the 
patients with severe aortic stenosis. 
In chapter 6 CMR was conducted before and 6 months after TAVI and 
SAVR. The key findings were that LV mass regression occurred in both 
groups supporting reverse myocardial remodelling. In addition the End-
diastolic volumes decreased. There was no difference in T1 at baseline or 
after TAVI/SAVR and the ECV did not significantly change. This suggests 
that reverse remodelling was occurring due to changes in myocyte 
hypertrophy and rather that the diffuse fibrosis process was fixed or takes 
longer than 6 months to change. This chapter also highlighted the limitations 
with current T1 mapping techniques.   
The predictors of reverse remodelling were the presence of atrial fibrillation 
and LV mass. Therefore, patients with aortic stenosis undergo adaptive 
processes in response to high LV pressures such as higher end-diastolic 
volumes and higher left atrial pressures. The presences of high LA 
pressures can lead to atrial dilatation and subsequent AF. The reverse 
remodelling process relies on intra-cellular adaptation and perhaps the 
extra-cellular fibrosis causing scarring is irreversible or fixed. 
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The thesis has contributed towards the treatment of severe aortic stenosis, 
especially in the recently adopted transcatheter aortic valve implantation 
population. TAVI improves health related quality of life and does not 
precipitate neurocognitive dysfunction and the detected cerebral micro-
infarction does not bear adverse outcomes. The left ventricle adapts by 
reverse remodelling and is not limited by diffuse fibrosis. The above findings 
support the continued expansion of TAVI programme. Currently TAVI is 
indicated for patients not suitable for SAVR but studies are under way 
looking at moderate to high surgical risk groups. Also, randomised control 
trials are recruiting comparing TAVI and SAVR. In the future, TAVI may be 
equal to SAVR and become available to a wider population. There are 
already advances in TAVI device technology to reduce vascular access 
sizes and valve designs to eliminate para valvular regurgitation. The peri-
procedural risks are also being reduced by performing implantation under 
local (regional) anaesthesia with light sedation.  
Further research is need in the treatment of aortic stenosis with TAVI. 
Relative to other cardiovascular interventions TAVI is still new and long term 
follow up studies about TAVI prosthesis function would be useful.  
Cerebral embolisation does occur and strategies to prevent this can be 
explored. There are devices available that provide embolic protection in the 
aortic arch at the origins of the carotids. Cerebral MRI studies could be 
conducted to confirm a reduction in embolic load. In addition, a higher field 
strength (3T) may further detect DWI lesions not seen at 1.5T. An area not 
explored in cerebral MRI could involve function MR (fMR) of patients 
undergoing TAVI and SAVR. The domains assessed in this thesis could be 
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repeated which may provide fMR data of the consequences of micro-
infarction. 
CMR continues to evolve with newer scanners and faster processing times. 
The key properties of CMR are in volumetric analysis and flow 
measurements through phase contrast imaging. Future work should study 
new valve designs such as the Boston Lotus and CoreValve Evolut R which 
have additional material known as ‘skirts’ to reduce para valvular 
regurgitation. The assessment of regurgitation after TAVI remains 
challenging and CMR may be able to quantify regurgitant volumes soon after 
implantation. Further study is required in diffuse fibrosis and other T1 
mapping techniques can be explored such as ScMOLLI.  
Other techniques that may provide insight in valvular disease may involve 
“4D flow”. This is 3-dimensional phase contrast imaging that allows 
acquisition of 3D morphology and time-resolved blood flow velocities in the 
x-, y- and z axes. These special sequences allow the acquisition of 
anatomical and directional velocities for each voxel in a 3D volume across 
the cardiac cycle. 
 
In conclusion, the thesis has explored the aims set out in the earlier 
chapters. Aortic stenosis is an important degenerative cardiovascular 
disease that can be treated successfully with surgery or in those with high 
surgical risk with percutaneous means. Health related quality of life improves 
for the better and neurocognitive function benefits from intervention. Overall, 
cerebral micro-infarction does not have any early negative impact on health-
related quality of life or neurocognitive function. Following TAVI and SAVR 
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the left ventricle undergoes reverse remodelling with no detectable change 
in diffuse fibrosis as estimated by measuring extracellular volumes.  
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9 List of Abbreviations 
 
ACE  Angiotensin Converting Enzyme 
AF  Atrial Fibrillation 
AR  Aortic Regurgitation 
AS  Aortic stenosis 
ANOVA Analysis of Variance 
AV  Aortic Valve 
BAV  Balloon Aortic Valvuloplasty 
BMI  Body Mass Index 
BP  Bodily Pain 
BSA  Body Surface Area 
CABG  Coronary Artery Bypass Grafting 
CAD  Coronary Artery Disease 
CFA  Common Femoral Artery 
CI  Confidence Intervals 
CMR  Cardiovascular Magnetic Resonance 
COPD  Chronic Obstructive Pulmonary Disease 
CoV  Coefficient of Variation 
CT  Computerised Tomography 
DI  Discrimination Index 
DR  Delayed Recall 
DSST  Digit-symbol substitution test 
DWI  Diffusion Weighted Imaging 
ECG  Electrocardiogram 
ECV  Extracellular Volume 
EF  Ejection Fraction 
EDV  End-diastolic Volume 
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ESV  End-systolic Volume 
EOA  Effective Orifice Area 
FFE  Fast Field Echo 
FID  Free Induction Decay 
FOV  Field of View 
GE  Gradient Echo 
Gf  Gradient frequency echo 
GH  General Health 
GPT  Grooved Pegboard test 
HADS  Hospital Anxiety Depression Scale 
HLA  Horizontal Long axis 
HRQoL Health Related Quality of life 
HVLT  Hopkins Verbal Learning Test 
ICC  Interclass Correlation Coefficient 
IHD  Ischaemic Heart Disease 
IQ  Intelligent Quotient 
IQR  Interquartile Range 
IR  Inversion Recovery 
LA  Left Atrium 
LGE  Late Gadolinium Enhancement 
LNS  Letter Number Sequencing 
LV  Left Ventricle 
LVM  Left Ventricular Mass 
LVOT  Left Ventricular Outflow tract 
MCS  Mental Component Score 
MDT  Multi-Disciplinary Team 
MI  Myocardial Infarction 
MH  Mental Health 
MMSE Mini-Mental State Examination 
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MOLLI Modified Look-Locker Inversion recovery  
MRI   Magnetic Resonance Imaging 
NART  National Abbreviated Reading test 
NCF  Neurocognitive Function 
NYHA  New York Heart Association 
OR  Odds Ratio 
PCI  Percutaneous Coronary Intervention  
PCS  Physical Component Score 
PF  Physical Functioning 
POCD  Post-operative Cognitive Dysfunction 
PPM  Permanent Pacemaker 
PVD  Peripheral Vascular Disease 
RE   Role Emotional 
ROCF  Rey-Osterrieth Complex Figure test 
ROI  Region of Interest 
RP  Role Physical 
RV  Right ventricle 
SA  Short Axis 
SAVR  Surgical Aortic Valve Replacement 
SD  Standard Deviation 
SE  Spin Echo or Standard Error 
SF  Social functioning or Semantic Fluency  
SSFP  Steady State Free Precession 
STS  Society of Thoracic Surgeons 
SV  Stroke volume 
TAVI  Transcatheter Aortic Valve Implantation 
TD  Delay time 
TE  Echo time 
TFE  Turbo Fast Echo 
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TI  Inversion time 
TIA  Transient Ischaemic Attack 
TOE  Transoesophageal Echocardiography 
TTE  Transthoracic Echocardiography 
TMT  Trail Making Test 
TR  Repetition time 
VAS  Visual Analogue Scale 
VENC  Velocity Encoding 
VF  Verbal Fluency 
VLA  Vertical Long Axis 
VT  Vitality 
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10.1 Appendix B Patient information Leaflet 
 
 
MRI evaluation of Transcatheter and Surgical Aortic Valve Implantation  
 
Version 1.3 November 30 2012 
 
Chief  Investigator: Prof John Greenwood 
 
Dear patient, 
 
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss 
it with friends, relatives and your GP if you wish. Ask us if there is anything that 
is not clear or if you would like more information. Take time to decide whether or 
not you wish to take part. 
 
WHY HAVE I BEEN CHOSEN? 
This study is looking at people like you, who are scheduled by their consultant 
for replacement of their aortic valve. We are looking at two groups of patients in 
this study: patients who are going to have a surgical valve replacement (done 
by a heart surgeon), and patients who are going to have a transcatheter valve 
replacement, a procedure which replaces the valve without the need for surgery 
(done by a cardiologist). This second technique is newer and we still need to 
find out more about the long term results for patients.  
How your valve is going to be replaced has been decided by your doctor and is 
based purely on your health and symptoms. This study is completely separate 
from the decision of how your valve is going to be replaced. 
 
WHAT IS THE PURPOSE OF THE STUDY? 
Patients have their aortic valve replaced because their own valve does not work 
properly, which causes problems with the function of the heart and with the 
circulation. After the valve has been replaced the heart function and the 
circulation will normally improve. In this study we want to compare that 
improvement in the two groups of patients. 
We also like to study the blood vessels in the head. As your doctor will have told 
you one of the risks of valve replacement is small clots travelling from the heart 
to the head. It is important for us to find out how often this happens with surgery 
and with non-surgical replacement, and compare the results. 
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We want to use Magnetic Resonance Imaging (MRI) in this study to look at the 
head and the heart. MRI does not involve radiation and is therefore very safe. It 
gives us very good images of the blood vessels and can tell how well the heart 
is pumping. 
DO I HAVE TO TAKE PART? 
It is up to you to decide whether or not to take part.  You do not have to decide 
straightaway; and you may discuss the study further with a member of the 
research team over the telephone, or once you come into hospital.  If you do 
decide to take part you will be given this information sheet to keep and be asked 
to sign a consent form. If you decide to take part you are still free to withdraw at 
any time and without giving a reason. This will not affect the standard of care 
you receive. Information collected up to the point of your withdrawal may still be 
used. In the unlikely event of you losing capacity (being unable to make 
decisions for yourself) you will be withdrawn from the study by us, but 
information already collected will be kept and used for the purposes of the 
study. 
 
WHAT WILL HAPPEN TO ME IF I TAKE PART? 
All patients in this study will have MRI scans of their head and heart before and 
after the valve replacement procedure. Before the valve replacement we will 
scan your head and heart during one visit to the MRI department, this visit can 
take place before your admission, or whilst you are already an in-patient in the 
hospital. This scan will take approximately 60 minutes to complete. After the 
valve replacement, and before you go home, if you have had a surgical valve 
replacement (AVR) we will scan your head only, which takes about 10 minutes. 
If you have had a transcatheter replacement (TAVI), we would like to scan your 
head (10 minutes) and do a shortened version of the heart scan (15 minutes). 
Approximately 4-6 months later we will ask you to return to the MRI department 
so we can scan you heart and your head, which takes about 60 minutes.  The 
reason why we want to do this scan later is that your heart’s function may 
continue to improve for some time after the valve replacement.  
During each scan you lie in a short 'tunnel', which holds a large magnet. Short 
bursts of radio waves from the MRI scanner allow images to be created. You will 
hear periodical loud “banging” noises while we are acquiring the images. We will 
remain in communication with you throughout the scan. If you have normal kidney 
function then once during each heart scan, we will inject an MRI contrast 
medication into a vein in your arm. The needle used for this will feel like a sharp 
scratch. Usually people are not aware of the contrast dye injection. Should your 
kidneys be impaired then the injection will not be given 
 
 
As part of the study we will ask you to fill out 2 questionnaires which will ask 
questions about how you feel the quality of your life is. A member of the 
research team can help you with this if you need assistance. We will ask you to 
complete these again after 1 month, 6 months, and 1 year. At the same time 
points we will also ask you to do a number of tests which look at memory and 
other functions of the brain. These tests will take about an hour on each 
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occasion. If you feel too tired or unwell to come to the hospital we may ask if we 
can visit you in your own home to do these tests.  
 
WHAT ARE THE RISKS AND DISCOMFORTS? 
Magnetic Resonance Imaging (MRI) is safe and no X-rays or radiation are 
used for this scan. There are no known risks from this technique. Some 
patients may experience claustrophobia. The staff will provide every possible 
means to reduce this sensation. The scan will be stopped immediately if you 
do not wish to carry on with it.  The contrast medication which we use is very 
safe but, as with any injection, reactions may occur. These include a warm 
sensation at the injection site, nausea or vomiting and transient skin rash. 
These effects usually only last for a few minutes. People with a history of 
allergy are more likely to suffer a more severe reaction, but this is rare (less 
than 1 in 3000). The department is equipped to cope with allergic reactions if 
they happen and medical staff will be on hand to deal with any unforeseen 
circumstances or problems.  
BENEFITS TO YOU 
There are no particular benefits to you from taking part in this study. 
 
EXPENSES 
We are able to meet reasonable expenses for costs of travel to and from the 
hospital for the scans and tests after you have left hospital. Alternatively we can 
arrange transport by pre-paid taxi for you. 
 
WILL MY TAKING PART BE KEPT CONFIDENTIAL? 
All information, which is collected about you during the course of the research 
will be kept strictly confidential. This information will be securely stored at the 
Cardiac MRI Unit at Leeds General Infirmary on paper and electronically, under 
the provisions of the 1998 Data Protection Act. You will not be identified in any 
publication that may result from this research. All data will be anonymised so 
that your identity will not be revealed to anybody outside the Cardiac MRI Unit 
at Leeds General Infirmary.  
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With your permission, we will inform your General Practitioner (GP) of your 
participation in this study as well as in the event of an unexpected abnormality 
on the scan.  
 
 
WHAT WILL HAPPEN TO THE RESULTS OF THE RESEARCH STUDY? 
When the study is complete the results will be published in a medical journal, 
but no individual patients will be identified. If you would like a copy of the 
published results, please ask your doctor. 
 
INDEMNITY/COMPENSATION 
If you are harmed as a direct result of taking part in this study, there are no special 
compensation arrangements. If you are harmed due to someone’s negligence, 
then you may have grounds to a legal action. Regardless of this, if you have any 
cause to complain about any aspect of the way you have been approached or 
treated during the course of this study, the normal National Health Service 
complaints mechanisms are available to you. 
 
If you have a private medical insurance please ensure that participation in the 
study does not affect your cover. 
WHO IS ORGANISING AND FUNDING THE STUDY? 
This is a research project of the Cardiac MRI department at Leeds General 
Infirmary.  
 
WHO HAS REVIEWED THE STUDY? 
The study has been reviewed and approved by the Leeds West Local Research 
Ethics Committee. 
 
For further information please contact: 
Dr Akhlaque Uddin 
Cardiac MRI department 
B Floor, Clarendon Wing 
Leeds General Infirmary 
LS1 3EX Tel: 0113 392 5224 / 0113 392 5481 
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Patient Study Number: ……………….. Date of Birth: ………………… 
 
Hospital Number: ……………………. Initials: ……………………….. 
 
CONSENT FORM – Version 1.3 November 30 2012 
MRI evaluation of Transcatheter and Surgical Aortic Valve Implantation 
 Name of Researcher: Prof John Greenwood                                                Please initial box 
1. I confirm that I have read and understood the information sheet (version 1.3 
November 30 2012) for the above study and have had the opportunity to ask 
questions. 
 
 
2. I understand that sections of any of my medical notes may be looked at by 
members of the research team and authorised personnel within the Leeds 
Teaching Hospitals NHS Trust and the University of Leeds, where it is relevant to 
the research or to assess that appropriate research standards are being 
maintained within the study. I give permission for these individuals to have 
access to my records. I understand that the information about me will be held in 
the strictest confidence and that my results will not be available to a third party. 
 
 
3. I give my consent for my General Practitioner to be informed of my participation in 
the study. 
 
 
4. I understand that images collected will be stored on a computer system, and, 
after my name and address have been removed, may be available to researchers 
at other institutions 
 
 
5. I understand that my participation is voluntary; and that I am free to withdraw at 
anytime, without giving any reason, without my medical care or legal rights being 
affected. 
 
 
6. I agree to take part in the study and that the general results of the study will be 
made available to medical community most likely through publication in a 
reputable medical journal 
 
   
7. If I were to lose capacity, I understand that data already collected will be kept and 
used for the purposes of the study. 
 
 
 
Signature.............................................................. 
 
 
Name (block 
capitals)..........................................Date………………………………………. 
 
 
Signature of witness............................................. 
 
 
Name (block 
capitals)..........................................Date………………………………………. 
 
 
 
 
 
 
 
